ESOT Congress 2023 ScientificProgramme

Scientific Programme
Saturday, 16 September 2023
ESOT SCIENCE DAY

09:00 - 10:30 ESOT Science Day: Translational and clinical cell therapy
MC 2 Chairs: Nina Pilat - Vienna Austria
Klearchos Papas - Tucson United States
In this session, the latest insight into clinical cell therapy in solid organ
transplantation is discussed. What do we learn from the clinical studies on cellular
therapy, how do we monitor our patients and what are the obstacles and
opportunities to move this field?
In addition, we will focus on monitoring aspects, how can we identify tolerant
patients?
09:00 ILC cell therapyAlternative: Translational and clinical cell therapy in solid organ
transplantation
Katja Kotsch – Berlin, Germany
09:20 Translational and clinical cell therapy in VCA

Fadi Issa – Oxford, United Kingdom
09:40 Monitoring: How can we identify tolerant patients?

Sophie Brouard – Nantes, France
10:00 Panel discussion
11:00 - 12:30 ESOT Science Day: Cheating death

MC 2
Chairs: Fadi Issa – Oxford, United Kingdom
Marlies Reinders – Rotterdam, The Netherlands
In this session, participants will learn about the most novel and exciting
approaches to organ transplantation. Supercooling of organs could revolutionize
organ allocation, the use of extracellular vesicles could overcome some hurdles
of cellular therapy and we learn about the role of mitochondria could be the key
to preventing ischemia-reperfusion injury.
11:00 Supercooling / hybernation

Gerald Brandacher – Baltimore, United States
11:20 Cell derived EV as a replacement of living cell therapy

Marcella Franquesa – Badalona, Spain
11:40 Mitochondria in the spotlight

Andras Meszaros – Innsbruck, Austria
Update 04|08|2023 1
13:30 - 15:00 ESOT Science Day: Spatial Omics

MC 2
Chairs: Annemarie Weissenbacher – Innsbruck, Austria
Sandra Lindstedt – Lund, Sweden
Spatial Omics is an exciting new field, technical advances allow for the
simultaneous assessment of multiple modalities as well as spatial organization,
providing new opportunities in the discovery of new cell types, cellular
differentiation trajectories and communication networks across cells and tissues.
This session is designed to provide an overview of how spatial omics can be
implemented in your research and will guide the discovery of novel biomarkers
and a better understanding of rejection and tolerance mechanisms.
13:30 A practical guide to start tomorrow

Benedikt Kessler – Oxford, United Kingdom
14:00 t-SNE and clustering for starters
Sören Lukassen – Berlin, Germany
14:30 Uncharting the hidden dimensions of transplantation with single cell and spatial
omics
Jasper Callemeyn - Korbeek-Lo, Belgium
15:30 - 17:10 ESOT Science Day: Organ Manipulation and bioengineering: Repair or
MC 2 replace?
Chairs: Cees van Kooten – Leiden, The Netherlands
Jan Czogalla – Hamburg, Germany
Franka Messner – Innsbruck, Austria
Organ manipulation and bioengineering are exciting fields in transplantation. We
will focus on bile duct repair on the pump and generating bile ducts from stem cells.
What is the current state of these innovations and should we repair or replace
organs? The pros and cons will be discussed in a lively discussion.
The session will end with an exciting scientific pub quiz organized by BSC,
ECTORS and VCA. Who knows the most about these fields and will win the
trophy?
15:30 Bile duct repair (on the pump)

Stuart Forbes – Edinburgh, United Kingdom
15:50 Bile duct generation from stem cells
Fotios Sampaziotis – Cambridge, United Kingdom
16:10 Pro-con discussion: Repair or replace?
Stuart Forbes – Edinburgh, United Kingdom
16:40 Quiz
Jan Czogalla – Hamburg, Germany; Franka Messner – Innsbruck, Austria
; Cees van Kooten – Leiden, The Netherlands
Update 04|08|2023 2
ESOT EDUCATION COURSE

Saturday, 16 September 2023
09:20 - 10:30 ESOT Education Course: Immunosuppression: a critical step in the

MC 3 transplantation journey - Session 1: The fundamentals of
immunosuppression (part I) - Transplant immunology
Chairs: Maria Kaisar - Oxford, United Kingdom
Luca Toti – Rome, Italy
In the area of Immunosuppression, we identified five hot topics that will be at the
centre of this one-day course:
• Transplant immunology: gain insights into the fascinating field of
transplant immunology, understanding the intricate mechanisms behind
immune responses in transplantation
• IS management: learn about the latest advances in immunosuppressive
therapy and discover effective strategies to optimise patient outcomes
• Post-transplant infections: explore the challenges posed by post-
transplant infections, including prevention, diagnosis, and treatment
approaches, ensuring comprehensive care for transplant recipients
• The patient experience: understand the transplant journey from the
perspective of patients, emphasising the importance of patient-centred
care and enhancing patient outcomes
• Tolerance: explore emerging concepts and research on tolerance
induction in transplantation, paving the way for future breakthroughs in
the field
The course combines dynamic lectures, interactive group discussions, and
engaging roundtables to foster a collaborative and enriching learning
environment. By actively participating, you can exchange ideas, learn from
leading experts, and network with peers who share a passion for improving
transplant outcomes.
09:20 Welcome and Introduction

09:30 A refresher on the basic mechanisms underlying rejection(s)

Sushma Shankar – Oxford, United Kingdom
09:45 Pharmacodynamic of the main immunosuppressive drugs

Pierre Marquet – Limoges, France
10:00 Emerging concepts in transplant immunology: innate rejection

Olivier Thaunat – Lyon, France
10:15 Q&A

MC 3 transplantation journey - Session 1: The fundamentals of
immunosuppression (part II) - The management of immunosuppression
Chairs: Jelena Stojanovic – London, United Kingdom
11:00 Kidney and pancreas

Raj Thuraisingham – London, United Kingdom
Update 04|08|2023 3
11:15 Heart and lung

Luciano Potena – Bologna, Italy
11:30 Liver and intestine

Tommaso Manzia – Rome, Italy
11:45 Management of immunosuppression in paediatric patients

Jelena Stojanovic – London, United Kingdom
12:00 Q&A and guided group discussion "Managing the side effects of
immunosuppression"
Luciano Potena - Bologna, Italy; Jelena Stojanovic - London, United Kingdom;
Raj Thuraisingham - London, United Kingdom; Luca Toti - Rome, Italy

MC 3 transplantation journey - Session 2: Living with immunosuppression: clinical
practice (part I) - Balancing the risk of rejection: infections et al.
Chairs: Luciano Potena – Bologna, Italy
13:30 Prophylaxis and treatment of post-transplant infections: CMV and other

opportunistic bugs Prophylaxis and treatment of post-transplant infections: CMV
and other opportunistic bugs
Paolo Grossi – Varese, Italy
13:45 Prevention and management of anti-microbial resistance

Sophie Alain – Limoges, France
14:00 Long-term adverse effects of immunosuppression: renal insufficiency and

malignancies
Martijn van den Hoogen – Rotterdam, The Netherlands
14:15 Infections and immune monitoring: quantiferon, TTV et al.

Gregor Bond – Vienna, Austria
14:30 Q&A and group discussion

MC 3 transplantation journey - Session 2: Living with immunosuppression: clinical
practice (part II) - Centering the patient perspective
Chairs: Anna Forsberg - Lund Sweden
Luca Toti - Rome Italy
15:30 Risk management of peculiar immunological conditions

Martijn van den Hoogen – Rotterdam, The Netherlands
15:45 Fertility and pregnancy while on immunosuppression

Marleen van Buren – Rotterdam, The Netherlands
16:00 The person with an organ - not the organ in the person. What matters to the
organ recipient and how it can be evaluated
Anna Forsberg – Lund, Sweden
Update 04|08|2023 4
16:15 Q&A
16:30 Integrating the patient perspective: patient-reported outcomes

Pisana Ferrari - Udine, Italy; Anna Forsberg – Lund, Sweden; Marleen van Buren -
Rotterdam, The Netherlands; Martijn van den Hoogen - Rotterdam, The
Netherlands; Luca Toti - Rome, Italy

MC 3 transplantation journey - Session 3: Future perspectives of
immunosuppression
Chairs: Nina Pilat - Vienna Austria
17:10 Tolerance in solid organ transplantation: the holy grail or a foreseeable reality?
Nina Pilat - Vienna Austria
17:25 Round table: Tolerance in solid organ transplantation - can we get rid of
immunosuppressive drugs in all solid organ transplant?
Sophie Brouard - Nantes, France; Olivier Thaunat - Lyon, France; Nina Pilat -
Vienna, Austria
17:55 Wrap up and conclusion
Update 04|08|2023 5
Sunday, 17 September 2023
SPECIALTY UPDATE SYMPOSIA

09:00 - 10:30 EKITA SUS: Reaching consensus among experts when evidence lacks
Trianti Chairs: David Cucchiari – Barcelona, Spain
Lorna Marson – Edinburgh, United Kingdom
The session has been envisioned to report on and to disseminate the activities in
which EKITA contributed during TLJ 3.0 and the consensus/guideline development
in the field of kidney transplantation.
09:00 ENGAGE Consensus project: European guidelines for the management of Graft
Recipients
Lucrezia Furian – Padua, Italy
09:20 The value of monitoring (subclinical) DSAs for kidney transplant outcomes
Aiko De Vries – Amsterdam, The Netherlands
09:40 Histopathological analysis of pre-implantation donor kidney biopsy: Redefining

the Role in the Process of Graft Assessment
Gianluigi Zaza – Verona, Italy
10:00 Novel antidiabetic treatments in kidney transplant recipients

Adnan Sharif – Birmingham, United Kingdom
10:20 Discussion
11:00 - 12:30 EKITA SUS: Comorbidities management post- kidney transplantation:

Trianti specialists in the arena:
Chairs: Robert Langer – Vienna, Austria
Dimitrios Moutzouris – London, United Kingdom
The second part of the session has been designed to address the topic of long-
term management of kidney transplant recipients including not only transplant
specialists but also vascular surgeons and endocrinologist and paediatricians. In
this latter part there will be a pros and cons discussion and a “talk show” format,
where different point of views in the treatment of bone disease post-transplantation
will be presented by four speakers
11:00 Pros and Cons: Management of vascular access after kidney transplantation
Emin Baris Akin - Istanbul Turkey; Joris Rotmans - Leiden, The Netherlands
11:30 Renal bone disease in kidney transplant recipients: are we speaking the same
language?
Dimitrios Moutzouris - London United Kingdom; Hanne Skou Jorgensen -
Skoedstrup, Denmark; Marc Vervloet - Amsterdam, The Netherlands
Update 04|08|2023 6
11:55 Complexities of pediatric kidney transplantation in the 21st century

12:20 Discussion
09:00 - 10:30 ELITA SUS: Non-tumoral portal vein thrombosis in liver transplant candidates
Banquet Hall Chairs: Constantino Fondevila – Madrid, Spain
Hermien Hartog – Groningen, The Netherlands
Once a contraindication to liver transplantation, now even candidates with

extensive portal vein thrombosis are increasingly undergoing the procedure. This
SUS updates the classification of PVT and optimal strategies for its management
at different stages and highlights the results of recent collaborative studies.
09:00 New insights of Pathophysiology of Portal Vein Thrombosis (PVT)

Ton Lisman – Groningen, The Netherlands
09:10 Evaluation and classification of PVT in Liver Transplant (LT) candidates

Prashant Bhangui - Gurgaon Haryana, India
09:20 Discussion
09:25 Update on medical management of PVT on cirrhotics and LT candidates

Sarwa Darwish Murad – Rotterdam, The Netherlands
09:35 Outcomes and limitations of TIPS and portal recanalization in LT candidates

Marco Senzolo – Padua, Italy
09:45 Surgical Treatment before LT: still a place for shunt surgery?
Pal-Dag Line – Asker, Norway
09:55 Discussion
10:00 Management of complex PVT: technical considerations during LT

Daniel Azoulay – Villejuif, France
10:10 Management of complex PVT: when to consider multivisceral transplantation?

Jacques Pirenne – Leuven, Belgium
10:20 Update on RP4LT Collaborative Study

Amelia Hessheimer – Madrid, Spain
10:25 Discussion
11:00 - 12:30 ELITA: Controversies and emerging issues in liver transplant candidates
Banquet Hall Chairs: Marina Berenguer – Valencia, Spain
Giacomo Germani – Padua, Italy
Update 04|08|2023 7
11:00 Active drinkers in urgent need of a liver transplant

Luca Belli – Milan, Italy
11:15 The stigma of alcohol-related liver disease and its impact on liver transplantation
Patrizia Burra – Padua, Italy
11:30 Discussion
11:45 Cardiovascular risk assessment of liver transplant candidates

Gonzalo Crespo – Barcelona, Spain
12:00 Frailty and liver transplantation: a practical approach

Matthew Armstrong – Birmingham, United Kingdom
12:15 Discussion and wrap-up
09:00 - 10:30 ELPAT,ETAHP, EDTCO in conjunction with ETPO: Patient Pioneers – Those
Skalkotas who dare to go first
Chairs: Nichon Jansen – Leiden, The Netherlands
Hannah Maple – London, United Kingdom
The aim of this Speciality Update Symposium is to discuss the vital role of patients
and their loved ones in the progression of transplantation. We will hear from
‘patient pioneers’ - those who are brave enough to pursue new treatments and
techniques as part of their transplant journey. We will discuss the ethical, legal and
psychosocial aspects of establishing new practices, and the role of patients and
the transplant multidisciplinary team. This collaborative symposium will unite
ELPAT, ETAHP, EDTCO and ETPO, enabling a fruitful conversation between a
wide group of transplant professionals and persons with transplants. Attendees
can expect to hear inspirational stories and interesting perspectives and will have
the opportunity to actively engage in what will undoubtedly be a forum for
fascinating discussion.
09:00 Welcome and introduction

09:05 My journey to new hands

Corinne Hutton – Paisley, United Kingdom; Simon Kay – Leeds, United Kingdom
09:20 Early days of Unspecified Kidney Donation in the UK

Kay Mason – Hertfordshire, United Kingdom; Jan Shorrock – Lancaster, United
Kingdom
09:35 DCD Heart Transplantation in Children

TBC
09:50 Deceased Donor family experience

Alison Moore – Huntingdon, United Kingdom
Update 04|08|2023 8

Anna Forsberg - Lund, Sweden; Nichon Jansen - Leiden, The Netherlands; Hannah
Maple – London, United Kingdom
10:25 Closing remarks for Part I
Nichon Jansen – Leiden, The Netherlands
11:00 - 12:30 ELPAT,ETAHP, EDTCO in conjunction with ETPO: Patient Pioneers – Those
Skalkotas who dare to go first
Chairs: Anna Forsberg – Lund, Sweden
11:00 Welcome and introduction to part 2 Patient Pioneers – advocacy and the role of
the Multi Disciplinary Team
11:05 What does a successful transplant look like to you? The importance of patient
expectations in pre-transplant decision making
Christian Falck, Sweden ; Guðmundur Felix Grétarsson - Lyon, France
11:25 Group discussion with the audience
Anna Forsberg - Lund, Sweden
11:40 Shared decision making, what is the team approach? Special focus on the role of
the patient, nurses, and allied healthcare professionals
Chiara Cavalli - Padua, Italy; Christian Falck, Sweden; Guðmundur Felix
Grétarsson – Lyon, France; Asia Imedi - London, United Kingdom; Yvette
Meuleman - Leiden, The Netherlands
12:00 Group discussion with the audience
Coby Annema - Groningen, The Netherlands
12:15 Transplant Care Management Award
Anna Forsberg - Lund Sweden; Marleen van Buren - Rotterdam, The Netherlands
12:25 Closing remarks
Christina Papachristou – Thessaloniki, Greece
09:00 - 10:30 ECTTA: Pushing the boundaries of heart and lung donation and preservation
MC 3 Chairs: Irene Bello – Barcelona, Spain
Stephan Ensminger – Lübeck, Germany
The session will deal with the realistic possibilities of expanding the donor pool of
thoracic donors with new innovative solutions. The envision of reshaping the field
of organ donation moving from the centre’s direct retrieval toward organ banks
will be explored and discussed. The final objective is to enlarge the
armamentarium of each transplant centre with different solutions aimed at
improving the extraction of organs and reducing the incidence of primary graft
failure
09:00 Some like it hot: Normothermic, Subnormothermic or Cold?

Marius Berman – Cambridge, United Kingdom
09:15 In-situ evaluation of DCD heart donors: the value of NRP

Elena Sandoval – Barcelona, Spain
Update 04|08|2023 9
09:30 The road from direct retrieval toward organ repair centres and organ banks.
Where are we now?
Marcelo Cypel – Toronto, Canada
09:45 Darwin and transplants: the Australian experience with Non-Ischemic Heart
Preservation
David McGiffin – Melbourne, Australia
10:00 Preserving without freezing the lung: working for a standard of care in organ
preservation.
Laurens Ceulemans – Tremelo, Belgium
10:15 DCD heart with 20 minutes of no-touch, is it feasible?

Massimo Boffini – Turin, Italy
10:20 Open discussion
11:00 - 12:30 ECTTA: Preserving the organs and the recipients in the long-term
MC 3 Chairs: David Gomez-de-Antonio – Majadahonda, Spain
Martin Schweiger – Zurich, Switzerland
The session will deal with the realistic possibilities of improving QOL and long term
survival after thoracic transplantation. Multiple and different dimensions of the
problem will be highlighted to clarify the need for multidisciplinary teams to provide
extended survival to recipients. Questions and answers with patients’
representatives will be welcome
11:00 ERAS in thoracic transplantation.

Irene Bello – Barcelona, Spain
11:15 Prehabilitation and rehabilitation in thoracic transplantation

Maria Simonenko - Saint-Petersburg, Russian Federation
11:30 Novel biomarkers to evaluate organ preservation and rejection in thoracic

transplantation(focus on dd-cfDNA)
11:45 Management of thoracic transplant candidates with preformed DSA antibodies

Antoine Roux – Suresnes, France
12:00 Prevention and treatment of chronic lung allograft dysfunction: new kids on the
block?
Robin Vos – Leuven, Belgium
12:15 Cardiac allograft vasculopathy: what’s new?

Andreas Zuckermann – Vienna, Austria
Update 04|08|2023 10
09:00 - 10:30 EPITA SUS: Predicting success of beta cell replacement therapy
MC 2
Chair: Andrew Sutherland – Edinburgh, United Kingdom
09:00 Welcome and Introductions

Julie Kerr-Conte – Lille, France
09:05 Update in perfusion technology do we have a consensus?

Joana Ferrer-Fàbrega – Barcelona, Spain
09:20 Donor factors predicting success after pancreas transplantation

Fabio Vistoli – Pisa, Italy
09:35 Pancreas and islet allocation scores-any room for improvement

Steve White - Newcastle upon Tyne, United Kingdom
09:50 Does donor HbA1C matter for islet transplantation

Julie Kerr-Conte – Lille, France
10:05 Factors predicting success during islet isolation

Paul Johnson – Oxford, United Kingdom
11:00 - 12:30 EPITA: Alternatives to simultaneous transplants

MC 2 Chairs: Ekaterine Berishvili – Geneva, Switzerland
Peter Girman – Prague, Czech Republic
11:00 Pancreas after kidney or islet after kidney: who should get what?
Michiel Nijhoff – Leiden, The Netherlands
11:15 Top scoring abstract EPITA: Islet after kidney vs kidney Transplant alone: A
French nationwide study on behalf of the TREPID group
Mehdi Maanaoui – Lille, France
11:30 Hypoimmune stem cell derived islets for transplantation without

immunosuppression.
Valeria Sordi – Milan, Italy
11:45 Conclusions
TV-STUDIO
10:30 - 11:00 The small print: update on Science and Education

Muses Foyer Host: Jacqui Thornton – Winchester, United Kingdom
Guests: Nina Pilat – Vienna, Austria, Marlies Reinders – Rotterdam, The

Netherlands; Raj Thuraisingham – London, United Kingdom; Luca
Toti – Rome, Italy; Annemarie Weissenbacher – Innsbruck, Austria
Update 04|08|2023 11
STORYTELLING
11:00 - 12:45 Diversity, inclusion and equality in medical training

MC 3.2 Chairs: Stan Benjamens – Groningen, The Netherlands
Caroline Dudreuilh – London, United Kingdom
11:00 Introduction & welcome

Caroline Dudreuilh – London, United Kingdom
11:05 DIE (diversity, inclusion, equality) in medical training

Ginny Bowbrick – Dartford, United Kingdom
11:50 The untrainable trainee- unconscious bias

Gillian Hardman – Bristol, United Kingdom
12:15 Discussion
Dilan Dabare - Birmingham, United Kingdom ; Hannah Esser – Innsbruck, Austria
GENERAL ASSEMBLY
12:30 - 14:00 ESOT General Assembly

Mitropoulos
ESOT General Assembly is reserved exclusively for ESOT members in good
standing.
SOLUTION ROOM
14:00 - 15:30 What if we make regenerative medicine available for everyone

Mitropoulos Chairs: Pedro Miguel Baptista – Zaragoza, Spain
Ekaterine Berishvili – Geneva, Switzerland
This session will bring together ethicists and regulators to discuss challenges that
lie ahead for the progression of regenerative medicine therapy products toward
the clinic.
14:00 Introduction
Pedro Miguel Baptista - Zaragoza, Spain; Ekaterine Berishvili – Geneva,
Switzerland
Update 04|08|2023 12
14:05 How can we avoid the ‘valley of death’ between first-in-human advanced therapy
trials and adopted standard of care, equitably available to all
James Shaw - Newcastle upon Tyne, United Kingdom
14:15 Navigating an ATMP through the Regulatory Maze to the Clinic

Antonia Cronin – London, United Kingdom
14:25 Impediments and Ethical-Legal Challenges on the Road of Clinical Translation

Timothy Caulfield – Edmonton, Canada
14:35 Discussion Panel with audience

Fiona Loud - Alton, United Kingdom
FISHBOWL
14:00 - 15:30 How far can we really push the envelope in organ donation
Conference Suite 1 Chairs: Chloe Balleste – Barcelona, Spain
Frank Dor – London, United Kingdom
During this session we intend for the participants to understand the current
challenges regarding organ donation in Europe and the main measures to improve
the situation; the need of improving organ quality during maintenance, the use of
normothermic regional perfusion techniques in DCD, the indications for ex-situ
perfusion machines, and strategies for cold ischemia time’s shortening from
professionals and patient’s perspectives. The session will be conducted by a
moderator that will present a clinic case and in each phase, the speakers related
to the procedure will debate with the participants the options and decisions that
can be taken based on evidence and experiences.
14:00 The safe haven of DBD

Julien Charpentier – Paris, France
14:15 The ying & yang of DCD

Beatriz Dominguez-Gil – Madrid, Spain
14:30 Fighting the ischemic clock: virtual cross match

Corinne Antoine - Paris, France
14:45 Who can they be? The donors

David Paredes-Zapata – Barcelona, Spain
15:00 Audience debate and discussion

Chloe Balleste – Barcelona, Spain; Frank Dor - London, United Kingdom
Update 04|08|2023 13
STORYTELLING
14:00 - 15:30 Future Leaders on Stage

MC 3.2 Chairs: Luca Toti – Rome, Italy
Liset Pengel – Rotterdam, The Netherlands
14:00 ESOT Grants programme 2024 launch

Umberto Cillo – Padua, Italy
14:02 Introduction
Liset Pengel- Rotterdam The Netherlands; Luca Toti - Rome, Italy
14:05 Anders Andreasson (ESOT Transplant Fellowship recipient 2021)

Anders Andreasson - Newcastle upon Tyne, United Kingdom
14:17 Emilio Canovai (ESOT Transplant Fellowship recipient 2021)

Emilio Canovai – Oxford, United Kingdom
14:29 Tess Van Meerhaeghe (ESOT Transplant Fellowship recipient 2022)

Tess Van Meerhaeghe – Brussels, Belgium
14:41 Daniele Pievani (ESOT Transplant Fellowship recipient 2022)

Daniele Pievani – Paris, France
14:53 ECP Immunomodulation award (Mallinckrodt) ceremony

14:56 Introduction to the ESOT mentorship programme

14:58 Our mentorship experience: lessons learned from mentors and mentees: Part I
Mentee: Mindaugas Kvietkauskas - Vilnus Lithuania
Mentor: Stephen Clark - Newcastle upon Tyne, United Kingdom
15:06 Our mentorship experience: lessons learned from mentors and mentees: Part II
Mentee: Lucia Ramona - Barcelona Spain
Mentor: Lorna Marson - Edinburgh, United Kingdom
15:14 Discussion with all mentors and mentees
15:26 Launch of the 2024 ESOT Mentorship programme and concluding remarks
FOCUS GROUP
14:00 - 15:30 Do we need incompatible kidney transplant
Update 04|08|2023 14
MC 3.4 Chairs: Lucrezia Furian – Padua, Italy

Oriol Bestard – Barcelona, Spain
14:00 IS UNSPECIFIED (NON-DIRECTED) KIDNEY DONATION JUSTIFIED?

RESULTS FROM A PROSPECTIVE STUDY OF 837 DONORS
14:10 THE IMPACT OF NON-DIRECTED ALTRUISTIC DONORS (NDAD) IN LIVING

KIDNEY EXCHANGE IN THE UK
L Matthew Robb – Bristol, United Kingdom
14:20 COMPARING OUTCOMES OF KIDNEY EXCHANGE PROGRAMMES WITH

DIRECT LIVING DONOR KIDNEY TRANSPLANTATION IN A COUNTRY WITH
HIGH LIVING DONATION RATES
Stijn van de Laar – Rotterdam, The Netherlands
14:30 EARLY OUTCOMES OF A MULTIMODALITY DESENSITIZATION-INDUCTION

SCHEME WITH ECULIZUMAB AND OBINUTUZUMAB IN HIGH-RISK
DECEASED-DONOR KIDNEY TRANSPLANTATION
Evaldo Favi – Milan, Italy
14:40 DESENSITIZATION AND IMMUNOMODULATION IN SENSITIZED KIDNEY

TRANSPLANT RECIPIENTS: A DELPHI METHOD CONSENSUS FROM THE
ENGAGE WORKING GROUP OF ESOT
14:50 CLINICAL OUTCOMES OF ABO- AND HLA-INCOMPATIBLE LIVING DONOR

KIDNEY TRANSPLANTATION: A NATIONWIDE STUDY
Ara Cho - Seoul, Republic of South Korea
15:00 CLINICAL OUTCOMES IN ABO MISMATCHING KIDNEY TRANSPLANTATION

IN PATIENTS WITH HIGH BASELINE ANTI-A/B ANTIBODY TITER
Seok Joon Shin - Seoul, Republic of South Korea
15:10 ENZYMATIC CONVERSION OF HUMAN BLOOD GROUP A KIDNEYS TO

UNIVERSAL BLOOD GROUP O
Serena MacMillan – Cambridge, United Kingdom
TV-STUDIO
14:00 - 14:30 The next step: Moving forward now with patient inclusion
Guests: Pisana Ferrari – Udine, Italy

Update 04|08|2023 15
FULL ORAL
14:00 - 15:30 Kidney medical complications

Trianti Chairs: Eleni Kapsia – Athens, Greece
Fernanda Ortiz – Helsinki, Finland
14:00 AUSTRALIAN AND NEW ZEALAND CANCER RELATIVE SURVIVAL IN END-

STAGE RENAL KIDNEY PATIENTS: A RETROSPECTIVE COHORT STUDY
Laia Oliveras - L'Hospitalet de Llobregat, Spain
14:10 SHIGATOXIN-PRODUCING ESCHERICHIA COLI-ASSOCIATED HEMOLYTIC

UREMIC SYNDROME IN ADULT KIDNEY TRANSPLANT RECIPIENTS
Manal Mazloum – Paris, France
14:20 CAUSES OF DEATH IN KIDNEY TRANSPLANTATION, A PARADIGM SHIFT?

Thomas Beaudrey – Strasbourg, France
14:30 CURRENT STATUS OF PREGNANCY AND DELIVERY AFTER RENAL

TRANSPLANTATION IN JAPAN
Yuki Nakagawa – Tokyo, Japan
14:40 CANCER INCIDENCE AMONG ITALIAN KIDNEY TRANSPLANT RECIPIENTS

OVER A 25-YEAR PERIOD
Pierluca Piselli – Rome, Italy
14:50 VOLUMETRIC BONE MINERAL DENSITY, BONE MICRO-ARCHITECTURE

EVOLUTION AFTER KIDNEY TRANSPLANTATION: A 1-YEAR RESULTS OF A
PROSPECTIVE COHORT STUDY
Antoine Bouquegneau – Liège, Belgium
15:00 ALLOGENEIC IMMUNITY HELPS SUSTAIN EFFECTIVE BK-VIRUS IMMUNE

RESPONSES AND PREVENTS BK VIRUS-ASSOCIATED NEPHROPATHY
Manon Dekeyser – Villejuif, France
15:10 TIME-DEPENDENT VARIATIONS IN BK POLYOMAVIRUS GENOME FROM

KIDNEY TRANSPLANT RECIPIENTS WITH PERSISTENT VIREMIA
Olga Mineeva-Sangwo – Leuven, Belgium
FULL ORAL
Update 04|08|2023 16
14:00 - 15:30 Biomarkers in Liver transplantation

Banquet Hall Chairs: Ina Jochmans – Leuven, Belgium
Paulo Martins - Boston, United States
14:00 LIVER IMMUNOSUPPRESSION FREE TRIAL (LIFT): OUTCOMES OF THE

FIRST BIOMARKER-GUIDED IMMUNOSUPPRESSION WITHDRAWAL TRIAL
IN LIVER TRANSPLANT RECIPIENTS
Julien Vionnet – Lausanne, Switzerland
14:10 MOLECULAR SIGNATURES OF REJECTION IN LIVER TRANSPLANT

BIOPSIES USING THE BANFF HUMAN ORGAN TRANSPLANT GENE PANEL
Zeynep Demir – Paris, France
14:20 EX SITU REPERFUSION INJURY/INFLAMMATION: IMMUNO-MOLECULAR

PROFILING OF HUMAN LIVERS DURING NORMOTHERMIC MACHINE
PERFUSION.
Fungai Dengu – Oxford, United Kingdom
14:30 BILE PROTEOME REVEALS BILIARY REGENERATION DURING

NORMOTHERMIC PRESERVATION OF HUMAN LIVERS
Adam M. Thorne – Groningen, The Netherlands
14:40 MMP9 CORRELATES TO WORSE ISCHEMIA REPERFUSION INJURY AND IS

PARTIALLY AMELIORATED BY NORMOTHERMIC MACHINE PERFUSION IN
LIVER TRANSPLANTATION
Abraham Den Dekker – Leiden, The Netherlands
14:50 GRAFT-DERIVED CFDNA MONITORING IN PLASMA & BILE DURING EX-

VIVO NORMOTHERMIC MACHINE PERFUSION IN LIVER
TRANSPLANTATION: A PROMISING OBJECTIVE TOOL
Daniel Cox – Melbourne, Australia
15:00 BILE ACID ANALYSIS DURING NORMOTHERMIC MACHINE PERFUSION

CAN REFINE LIVER GRAFT ASSESSMENT PRIOR TO TRANSPLANTATION:
A PROOF-OF-CONCEPT STUDY
Guillaume Rossignol – Lyon, France
15:10 ANALYSIS OF THE BILE METABOLOME TO SEARCH FOR POTENTIAL

BIOMARKERS OF QUALITY OF THE LIVER WITH PARTICULAR EMPHASIS
ON BILE ACIDS
Kamil Łuczykowski – Bydgoszcz, Poland
FULL ORAL
14:00 - 15:30 Translational immunology of rejection
Update 04|08|2023 17
Skalkotas Chairs: William E Scott III - Newcastle upon Tyne, United Kingdom
Nina Pilat – Vienna, Austria
14:00 TOWARDS DECIPHERING HLA IMMUNOGENICITY - ONE STEP FORWARD

Anat Tambur – Chicago, United States
14:10 SOLVENT-ACCESSIBLE AMINO ACID MISMATCHES ON DONOR HLA ARE

ASSOCIATED WITH KIDNEY GRAFT OUTCOMES; A STEP TOWARDS
PERSONALIZING POST-TRANSPLANT CARE?
Soufian Meziyerh – Leiden, The Netherlands
14:20 DIRECT PROFILING OF CLINICALLY RELEVANT HUMORAL IMMUNITY IN

TRANSPLANTATION AND BEYOND
Ashley Priddey – Cambridge, United Kingdom
14:30 ADOPTIVE CELLULAR IMMUNOTHERAPY FOR THE CONTROL OF HLA

CLASS II ANTIBODY- MEDIATED REJECTION IN TRANSPLANTATION
Carolt Arana – Barcelona, Spain
14:40 TCL1A PROTEIN INVOLVEMENT IN B CELLS AND TOLERANCE IN KYDNEY

TRANSPLANTATION
François Brinas – Nantes, France
14:50 CHARACTERIZATION OF EXTRACELLULAR VESICLES PRODUCED BY

REGULATORY B CELLS IN KIDNEY TRANSPLANTATION
Amandine Dupuy – Nantes, France
15:00 CHARACTERISTICS AND FUNCTION OF DONOR AND RECIPIENT TISSUE

RESIDENT LYMPHOCYTES IN KIDNEY TRANSPLANTS
Daphne Hullegie-Peelen – Rotterdam, The Netherlands
15:10 TARGETING INTRAGRAFT CELL-CELL COMMUNICATIONS DURING KIDNEY

TRANSPLANT REJECTION
Baptiste Lamarthée – Leuven, Belgium
FULL ORAL
14:00 - 15:30 Molecular monitoring of lung allograft rejection

MC 3 Chairs: Robin Vos – Leuven, Belgium
Saskia Bos - Newcastle upon Tyne, United Kingdom
14:00 UTILITY OF THE BANFF HUMAN ORGAN TRANSPLANT PANEL IN

DIAGNOSING ANTIBODY-MEDIATED REJECTION IN LUNG TRANSPLANT
BIOPSIES
Marta Sablik – Paris, France
Update 04|08|2023 18
14:10 USING PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES TO

INVESTIGATE FORMATION OF DE NOVO DONOR-SPECIFIC HLA-
ANTIBODIES AFTER LUNG TRANSPLANTATION
Maximilian Vorstandlechner – Munich, Germany
14:20 TRANSCRIPTIONAL CO-ACTIVATOR BOB1 AS THE KEY REGULATOR OF

PATHOGENIC LYMPHOCYTIC RESPONSES IN CHRONIC LUNG
ALLOGRAFT DYSFUNCTION
Nataliya Yeremenko – Nantes, France
14:30 VALIDATION OF A BLOOD GENE SIGNATURE TO PREDICT CHRONIC

ALLOGRAFT DYSFUNCTION IN LUNG TRANSPLANTATION
Richard Danger – Nantes, France
14:40 UNSUPERVISED ANALYSIS OF LUNG TRANSPLANT PHENOTYPES USING

GENE EXPRESSION DATA
Marta Sablik – Paris, France
14:50 ROLE OF DONOR-DERIVED CELL-FREE DNA IN CHRONIC LUNG

ALLOGRAFT DYSFUNCTION. A LONGITUDINAL STUDY.
Susana Gomez-Olles – Barcelona, Spain
15:00 DONOR-DERIVED CELL-FREE DNA AND CELL-FREE RNA LEVELS USING A

COST-EFFECTIVE LIQUID BIOPSY TECHNIQUE MONITORING LUNG
ALLOGRAFT REJECTION.
Owais Tisekar – Secunderabad, India
15:10 INDUCTION EXTRACORPOREAL PHOTOPHERESIS STIMULATES

BENEFICIAL IMMUNE MODULATION IN CYSTIC FIBROSIS PATIENTS
UNDERGOING LUNG TRANSPLANTATION
Ilaria Righi – Paullo, Italy
BRIEF ORAL
14:00 - 15:30 Safety and quality at the core of donation and transplantation
MC 2 Chairs: Frederike Ambagtsheer - Rotterdam, The Netherlands
Régis Bronchard - Saint Denis, France
14:00 SETTING EUROPEAN QUALITY AND SAFETY STANDARDS FOR ORGAN

DONATION AND TRANSPLANTATION
Jaime Marco de Tena – Strasbourg, France
14:06 SAFETY OF ORGAN TRANSPLANTATION FROM DONORS WITH PRIMARY

MALIGNANCY OF THE CENTRAL NERVOUS SYSTEM
Clara Manso Murcia – Murcia, Spain
Update 04|08|2023 19
14:12 DONOR-TRANSMITTED CANCER IN ORGAN DONATION AND SOLID ORGAN

TRANSPLANTATION IN GERMANY FROM 2016-2022.
Axel Rahmel – Frankfurt, Germany
14:18 NO SURVIVAL BENEFIT IN KIDNEY TRANSPLANT RECIPIENTS IN THE

EUROPEAN SENIOR PROGRAM
Marcel Naik – Berlin, Germany
14:24 DONATION AFTER MEDICAL ASSISTANCE IN DYING IN QUÉBEC – THE

FIRST FIVE YEARS
Matthew Weiss – Montrea,l Canada
14:30 THE SCARCITY OF ORGAN DONORS IN CHILE IS NOT EXPLAINED BY

FAMILIAL REFUSAL, BUT BY UNPREPARED ER AND ICU PROFESSIONALS
Francisca Gonzalez Cohens – Santiago, Chile
14:36 CITIZENSHIP STATUS AND KIDNEY FUNCTION OF LIVING KIDNEY

DONORS IN THE UNITED STATES
Voramol Rochanaroon – Rayong, Thailand
14:42 KIDNEY FUNCTION DECLINE PREDICTING FACTORS IN LIVING KIDNEY

TRANSPLANTATION DONORS
Lada Trajceska – Skopje, North Macedonia
14:48 OUTCOMES FOR KIDNEY TRANSPLANT CANDIDATES WITH DECLINED

DECEASED DONOR KIDNEY OFFERS: A RETROSPECTIVE SINGLE-
CENTRE ANALYSIS
Anna Brotherton - Birmingham United Kingdom
14:54 CHARACTERISTICS OF PROSPECTIVE AND EFFECTIVE LIVING DONORS

FOR RENAL TRANSPLANTATION: A CROSS-SECTIONAL STUDY.
Fernando Girón Luque - Bogotá Colombia
15:00 AI MEASURED PREOPERATIVE RENAL VOLUME AND RISK FACTORS

ASSOCIATED WITH CHRONIC KIDNEY DISEASE POST DONOR
NEPHRECTOMY IN THE ELDERLY
EunAh Jo - Seoul, Republic of South Korea
15:06 HIGHER ABDOMINAL FAT AREA ASSOCIATES WITH LOWER RENAL

FUNCTION BEFORE AND AFTER LIVING KIDNEY DONATION
LB Lisa Westenberg - Groningen The Netherlands
15:12 BODY MASS INDEX (BMI), OBESITY AND URIC ACID: PRIOR TO DONOR
NEPHRECTOMY AND OVER A 15-YEAR FOLLOW-UP PERIOD, EXPERIENCE
OF OUR CENTER
Jelena Tadic - Belgrade Serbia
15:18 THE CRITICAL PATHWAY FOR DECEASED DONATION: AN ANALYSIS IN

THREE REGIONS OF COLOMBIA
William Cruz Mususú – Bogota, Colombia
Update 04|08|2023 20
BRIEF ORAL
14:00 - 15:30 Progress and challenges in Pancreas and Islet transplantation

Library
Chairs: Paul Johnson – Oxford, United Kingdom
Hanne Scholz – Oslo, Norway
14:00 ISLET TRANSPLANTATION VERSUS INSULIN ALONE IN TYPE 1 DIABETIC

KIDNEY TRANSPLANT RECIPIENTS: A FRENCH NATIONWIDE STUDY ON
BEHALF OF THE TREPID GROUP.
14:06 RELATION BETWEEN PRIMARY GRAFT FUNCTION AND 5-YEAR

OUTCOMES OF ISLET TRANSPLANTATION: A RETROSPECTIVE STUDY IN
1210 PARTICIPANTS
Mikael Chetboun – Lille, France
14:12 SIMULTANEOUS ISLET KIDNEY TRANSPLANT – OUTCOMES FROM 2 UK

TRANSPLANT CENTRES
Andrew Sutherland – Edinburgh, United Kingdom
14:18 EXPLORING PRESERVATION MODALITIES IN A SPLIT HUMAN PANCREAS

MODEL TO INVESTIGATE THE EFFECT ON THE ISLET ISOLATION
OUTCOMES.
Antoine Buemi – Brussels, Belgium
14:24 RE-ANIMATING PANCREATIC GRAFTS SUBJECTED TO PROLONGED COLD

ISCHEMIA IN A PORCINE MODEL USING NORMOTHERMIC EX VIVO
PERFUSION: A FEASIBILITY STUDY
Samrat Ray – Toronto, Canada
14:30 SINGLE-CENTER INITIAL EXPERIENCE OF DUODENODUODENOSTOMY

FOR EXOCRINE DRAINAGE IN PANCREAS TRANSPLANTATION.
14:36 HEALTH RELATED QUALITY OF LIFE AFTER SIMULTANEOUS PANCREAS

KIDNEY TRANSPLANTATION: HOW GOOD DOES IT GET?
Irene Mosca – Oxford, United Kingdom
14:42 HYPERTENSION IN THE DONOR IS ASSOCIATED WITH AN INCREASED

RISK OF EARLY PANCREAS ALLOGRAFT FAILURE
Christophe Masset – Nantes, France
14:48 NORMOTHERMIC EX VIVO MACHINE PERFUSION OF THE PANCREAS IS

SAFE AND FEASIBLE IN A PORCINE MODEL OF PANCREAS
TRANSPLANTATION.
Catherine Parmentier – Toronto, Canada
Update 04|08|2023 21
14:54 ISLET ISOLATION AND TRANSPLANTATION OUTCOMES FOLLOWING

DONATION AFTER CIRCULATORY DEATH - A COMPARISON WITH
DONATION AFTER BRAIN DEATH
Paul Johnson – Oxford, United Kingdom
15:00 DIFFERENCES IN GLUCOSE HOMEOSTASIS BETWEEN TYPE 1 VS. TYPE 2

DIABETES AFTER PANCREAS TRANSPLANTATION
Richard Knight – Houston, United States
15:06 RISK FACTORS FOR GREATER THAN 10 YEARS PANCREAS GRAFT

SURVIVAL IN THE UK; SHORT TERM RISK FACTORS ARE NOT ALWAYS
THE BEST GUIDE FOR LONG TERM SURVIVAL
Argiris Asderakis – Cardiff, United Kingdom
15:12 OUTCOMES OF PANCREAS TRANSPLANTATION ALONE FROM

DONATION AFTER CIRCULATORY DEATH
Irene Mosca – Oxford, United Kingdom
15:18 IMPACT OF NORMOTHERMIC REGIONAL PERFUSION ON OUTCOMES

AFTER SPK TRANSPLANTATION – A UK ANALYSIS FROM THE NHSBT
PANCREAS ADVISORY GROUP
Ruth Owen - Newcastle upon Tyne, United Kingdom
TV-STUDIO
15:30 - 16:00 How registries will transform transplant data and care
Guests: Umberto Cillo – Padua, Italy

Penilla Gunther – Stockholm, Sweden
PLENARY
16:00 - 17:30 Opening Plenary: Transplantation at crossroads

Lambrakis Chairs: Gabriel Oniscu – Stockholm, Sweden
John Boletis – Athens, Greece
During the Covid pandemic technology was a key asset for the delivery of care and
collaboration was how we accelerated the implementation of change and achieved
successful therapies. As we are emerging on the other side of the pandemic, we
are witnessing a game-changing explosion of disruptive technologies such as AI,
digitalization and virtual reality that hold immense potential but also bring new
Update 04|08|2023 22
challenges. This session will explore how transplant care could look in a
technology-driven world. Is technology going to enhance the delivery of trusted
transplant care? What is the impact for patients and how can they benefit from this
technological revolution? We will then learn why we should sustain and expand the
level of collaboration achieved during the pandemic to further accelerate the
technological redesign of transplant care with examples from the world of Nobel
prize winners.
16:00 Introduction
Pisana Ferrari – Udine, Italy; Vassilios Papalois, London, United Kingdom
16:20 Digital transformation – make or break for transplant care

John Nosta – Mendham, United States
16:40 Realistic care and shared decision making – aspiration or reality?

Donna Cryer – Washington, United States
17:00 Deconstructing Creativity - Collaboration and it’s contribution to success

Tobias Degsell – Stockholm, Sweden
17:20 Discussion & wrap-up
JOINT SESSION
17:30 - 18:30 ESOT – ISOT joint session: Expanding living donor pool in kidney transplant
MC 2 Chairs: Sandeep Guleria – New Delhi, India
17:30 ABO Incompatible Kidney Transplant

Deepak Shankar Ray - West Bengal, India
17:45 Kidney Paired Exchange - India

Vivek Kute – Ahmedabad, India

Chloe Balleste - Barcelona, Spain; Shyam Bihari Bansal – Haryana, India; Sandeep
Guleria – New Delhi, India; Hannah Maple - London, United Kingdom; Ashish
Sharma - Chandigarh, India; Pukar Shrestha - Bhaktapur, Nepal
ASSEMBLY
17:45 - 18:45 ELITA Assembly

Library
ELITA Assembly is reserved exclusively for ELITA affiliates in good standing.
Update 04|08|2023 23
TV-STUDIO
17:45 - 18:15 President’s focus: Accelerating Away from the Crossroads

Guests: Gabriel Oniscu – Stockholm, Sweden
Update 04|08|2023 24
Monday, 18 September 2023
FULL ORAL
08:00 - 09:30 Kidney allocation to improve outcomes

Lambrakis Chairs: Nichon Jansen - Leiden, The Netherlands
Rainer Oberbauer - Vienna, Austria
08:00 KIDNEY TRANSPLANTATION FROM UNCONTROLLED DONATION AFTER

CARDIAC DEATH, AN OPTION WITH EXCELLENT RESULTS IN THE LONG
TIME.
Maria Molina – Badalona, Spain
08:10 IS THERE A DIFFERENCE IN SURVIVAL OUTCOMES OF DUAL KIDNEY

TRANSPLANTS OF DCD V/S DBD ALLOGRAFTS IN ABSENCE OF
NATIONAL PATHOLOGY SERVICE?
Abdullah Khawaja – Liverpool, United Kingdom
08:20 ALL ECD KIDNEYS ARE EQUAL BUT ARE SOME MORE EQUAL THAN
OTHERS? A POPULATION-COHORT ANALYSIS OF UK TRANSPLANT
REGISTRY DATA
Kamlesh Patel – Morden, United Kingdom
08:30 IMPACT OF DECEASED DONOR ACUTE KIDNEY INJURY (AKI) ON RENAL

TRANSPLANT OUTCOMES.
Mikhail Nozdrin – London, United Kingdom
08:40 DO WAITLISTED KIDNEY TRANSPLANT CANDIDATES AGED ≥70 YEARS

HAVE A SURVIVAL BENEFIT POST-TRANSPLANTATION?
Benjamin Anderson – Birmingham, United Kingdom
08:50 GRAFT-RELATED OUTCOMES COMPARING LEFT VERSUS RIGHT

KIDNEYS: A POPULATION COHORT ANALYSIS
Raja Rashid – Birmingham, United Kingdom
09:00 DECISION MAKING ABOUT LIVING DONOR KIDNEY TRANSPLANTATION: IN

A MULTI-ETHNIC PATIENT POPULATION
Ahmed Ahmed – Leeds, United Kingdom
09:10 THE UK LIVING KIDNEY EXCHANGE PROGRAMME – PUSHING

BOUNDARIES TO OPTIMISE TRANSPLANT POSSIBILITIES
L Matthew Robb – Bristol, United Kingdom
Update 04|08|2023 25
FULL ORAL
08:00 - 09:30 AI & Digital Health: from donation to the outcome

Trianti
Chairs: Carmen Lefaucheur – Paris, France
Michelle Willicombe – London, United Kingdom
08:00 INCREASING ORGAN DONORS AND TRANSPLANTS VIA

INTEROPERABILITY
John Piano - Los Angeles, United States
08:10 THERMODYNAMIC CHARACTERIZATION OF ORGANS PRESERVED ON ICE

– INVESTIGATING THE ASSUMPTION THAT ICE IS 4°C
Pratik Patel – Cambridge, United States
08:20 NEXT GENERATION SEQUENCING: FROM BANFF SCORE MOLECULAR

SIGNATURES AND CLASSIFIERS TO HISTOLOGICAL ARCHETYPES OF
KIDNEY BIOPSIES
Esteban Cortes Garcia – Paris, France
08:30 DEVELOPMENT, APPLICATION, AND VALIDATION OF A HISTOLOGICAL

CLASSIFICATION AUTOMATION SYSTEM FOR KIDNEY ALLOGRAFT
PRECISION DIAGNOSTICS
Valentin Goutaudier – Paris, France
08:40 DEVELOPMENT, VALIDATION, AND AUTOMATED REPORTING OF GENE

EXPRESSION-BASED DIAGNOSIS OF RENAL ALLOGRAFT REJECTION
BASED ON THE B-HOT GENE PANEL
Olivier Aubert – Paris, France
08:50 EXTENDED VALIDATION OF THE IBOX IN REAL LIFE SETTING, DIFFERENT

TRANSPLANT SYSTEMS AND CLINICAL TRIALS: THE IBOX EXTENDED
TRIAL
09:00 A RANDOMIZED CONTROLLED TRIAL OF EHEALTH PROGRAM FOLLOW-

UP BASED ON A 1-YEAR PREDICTION OF LONG-TERM GRAFT FAILURE
(KTFS) IN KIDNEY TRANSPLANTATION
Magali Giral – Nantes, France
09:10 RISK CLASSIFICATION MODELS FOR KIDNEY GRAFT FAILURE FROM A

LARGE GERMAN KIDNEY TRANSPLANT CENTRE
FISHBOWL
Update 04|08|2023 26
08:00 - 09:30 AI & I

Banquet Hall Chairs: Marlies Reinders – Rotterdam, The Netherlands
Colin White – Balbriggan, Ireland
Much has been said about the role of AI in the delivery of healthcare but is it really
ready for prime time in transplantation? How will it improve and streamline care?
Will it deliver personalised / precision care? Will it assist outpatient care? Will it be
precision medicine for the organ or the patient or both? What should we expect
from AI?
08:00 Introduction
08:05 AI: From Option To Imperative

08:25 Your virtual doctor will see you now

Shafi Ahmed – London, United Kingdom
08:45 Training in the metaverse

Igor Sauer – Berlin, Germany
09:05 AI and I - round table discussion

SOLUTION ROOM
08:00 - 09:30 Let’s talk about living donation: there’s an app for that
Mitropoulos Chairs: Klemens Budde – Berlin, Germany
Physicians and patients may employ technology-based interventions to increase

awareness of living kidney donation and also to link donors with transplant
candidates. This session will provide a guide on how to use Mobile apps and/or
Web pages to target the general population and ethnic minorities with the purpose
of increasing knowledge on living donation, including donor suitability and pre-
emptive transplantation, and also how to implement strategies to connect potential
donors to transplant candidates. Should risk calculators be used in communicating
the long-term risk of living donation? What are the ethical and legal challenges in
the use of technology-based interventions?
08:00 From home education to web education

Emma Massey – Rotterdam, The Netherlands
08:20 www.i_need_a_donor
Frank Dor - London United Kingdom
Update 04|08|2023 27
08:40 Ethical and legal issues in using social media for identifying donors
Katrina Bramstedt - Queensland, Australia; Greg Moorlock - Warwick, United
Kingdom
09:00 Risk calculators: friend or foe

Aisling Courtney – Belfast, United Kingdom
09:20 Discussion
BRIEF ORAL
08:00 - 09:30 Transplant Plus: Regenerative therapies and Xenotransplantation

Skalkotas Chairs: Jan Czogalla – Hamburg, Germany
08:00 THE (PRO)RENIN RECEPTOR IS INVOLVED IN KIDNEY ORGANOID

DEVELOPMENT
Martin Hoogduijn – Rotterdam, The Netherlands
08:06 ENGINEERING VASCULARIZED ENDOCRINE PANCREAS TO CURE TYPE 1

DIABETES
Kevin Bellofatto – Geneva, Switzerland
08:12 GENERATION OF VASCULARIZED ENDOCRINE CONSTRUCTS FOR TYPE 1

DIABETES
Laura Mar Fonseca – Geneva, Switzerland
08:18 ALLOGENEIC MESENCHYMAL STROMAL CELL THERAPY IN KIDNEY

TRANSPLANTATION: SHOULD REPEATED HLA MISMATCHES BE
AVOIDED?
Suzanne Bezstarosti – Leiden, The Netherlands
08:24 DEVELOPMENT OF AN ADVANCED PLATFORM FOR RAT LIVER

NORMOTHERMIC MACHINE PERFUSION EQUIPPED WITH A BIOREACTOR
SEEDED WITH MESENCHYMAL STEM CELLS
Caterina Lonati – Milan, Italy
08:30 THE CYTOPROTECTIVE EFFECTS OF EXTRACELLULAR VESICLES

DERIVED FROM HUMAN AMNIOTIC EPITHELIAL CELLS ON PANCREATIC
ISLETS
Reine Hanna – Geneva, Switzerland
08:36 INSULIN-INDEPENDENCE IN LARGE ANIMAL MODELS AFTER

PANCRERATECTOMY ANDAUTOTRANSPLANTATION OF 3D-BIOPRINTED
BIONIC PANCREATIC PETALS.
Michal Wszola – Warsaw, Poland
Update 04|08|2023 28
08:42 A MICROFLUIDIC BILE-DUCT-ON-A-CHIP PLATFORM FOR STUDYING

BILIARY EPITHELIUM IN A DISH
Jorke Willemse – Rotterdam, The Netherlands
08:48 THE EX VIVO REGENERATION OF ISCHEMICALLY DAMAGED HUMAN

KIDNEY ALLOGRAFTS
Lauren Brasile – Albany, United States
08:54 TACROLIMUS-LOADED MIXED THERMOSENSITIVE HYDROGEL FOR

IMPROVING THE OUTCOME OF SKIN AND VASCULARIZED COMPOSITE
ALLOTRANSPLANTATION
Madonna Rica Anggelia – Taoyuan, Taiwan
09:00 SINGLE CELL RNA SEQUENCING ANALYSIS OF HUMAN AMNIOTIC

EPITHELIAL CELLS TO DECIPHER THE MECHANISMS OF
IMMUNOMODULATION CONFERED TO PANCREATIC ISLETS
Juliette Bignard – Geneva, Switzerland
09:06 FEASIBILITY OF MANUFACTURE OF CHIMERIC ANTIGEN RECEPTOR

(CAR)-REGULATORY T CELLS (TREGS) FROM PATIENTS WITH END-STAGE
RENAL DISEASE (ESRD)
Hervé Bastian – Valbonne, France
09:12 AUXILIARY LIVER XENOTRANSPLANTATION TECHNIQUE IN A

TRANSGENIC PIG TO A NON-HUMAN PRIMATE MODEL
Kyo Won Lee - Seoul, Republic of South Korea
09:18 LONG-TERM (2 YEARS) SURVIVAL OF PORCINE TO NONHUMAN PRIMATE

LIFE-SUSTAINING KIDNEY XENOTRANSPLANTATION
Ahmad Karadagi – Boston, United States
FULL ORAL
08:00 - 09:30 Organ donation: clinical perspectives

MC 2 Chairs: John Forsythe – Bristol, United Kingdom
Marco Sacchi – Milan, Italy
08:00 PREDICTIVE RADIOLOGIC SIGNS TO EVOLVE TO BRAIN DEATH OR

CIRCULATORY DEATH
Nuria Masnou Burralló – Girona, Spain
08:10 FACTORS DETERMINING CONSENT FOR ORGAN DONATION AFTER BRAIN

DEATH IN FRANCE
Régis Bronchard - Saint Denis, France
Update 04|08|2023 29
08:20 MODULATORY EFFECT OF ALTEPLASE AND METHYLPREDNISOLONE

ASSOCIATION ON BRAIN DEATH DONOR
Lucas Ferreira da Anunciação - São Paulo, Brazil
08:30 ACTIVATION OF THE COMPLEMENT SYSTEM EARLY ON DURING BRAIN

DEATH MANAGEMENT
Laura Knijff – Leiden, The Netherlands
08:40 ANALYSIS OF RISK FACTORS FOR KIDNEY TRANSPLANTATION AFTER

CONTROLLED CIRCULATORY DEATH AND SYSTEMATIC USE OF
NORMOTHERMIC REGIONAL PERFUSION
Corinne Antoine - Paris, France
08:50 ‘SPREADING’ AGING WITH THE TRANSPLANTATION OF OLD ORGANS: AN

EXPERIMENTAL REALITY
Maximilian Roesel – Boston, United States
09:00 LONG-TERM MORTALITY OF LIVING KIDNEY DONORS: A NATION-BASED

COHORT STUDY
Jongman Kim - Seoul, Republic of South Korea
09:10 EXCELLENCE IN ORGAN UTILISATION – A QUANTITATIVE AND

QUALITATIVE EVIDENCE BASE FOR A NEW APPROACHES IN THE UK
Claire Williment - London, United Kingdom
DARE TO ASK
08:00 - 09:30 ESOT and IPTA joint session: Solutions to challenges in paediatric
Conference Suite 1 transplantation
Chairs: Nicos Kessaris – London, United Kingdom
We discuss current dilemmas and hot topics in paediatric transplantation focusing

on medical and surgical complexities. The session is delivered jointly by patients
and healthcare professionals. Delegates can bring complex cases for discussion
and get an expert opinion on them. The session is planned based on the feedback
received for the paediatric session at ESOT 2021.
08:00 I had HLA incompatible kidney transplantation in childhood. Patient story

Megan Carter – Dublin, Ireland
08:05 Is antibody incompatible transplantation justifiable for children?

Nizam Mamode – London, United Kingdom
08:20 Combined liver and kidney transplantation in children with congenital metabolic
abnormalities-is it worth doing?
Update 04|08|2023 30
08:35 Solutions for surgical challenges in liver transplantation

Carlos Esquivel – Stanford, United States
08:50 Solutions for surgical challenges in kidney transplantation

Nicos Kessaris – London, United Kingdom
09:05 Solutions for surgical challenges in heart transplantation

09:20 Panel Discussion
FOCUS GROUP
08:00 - 09:30 Living donation revolutions

MC 3.2 Chairs: Dieter Broering – Riyadh, Saudi Arabia
Mohamed Rela – Chennai, India
08:00 USEFULNESS OF LIVER VOLUMETRY BASED ON HEPATIC VENOUS

TERRITORY AS PREOPERATIVE EVALUATION FOR LIVING DONOR LIVER
TRANSPLANTATION
Woo Kyoung Jeong - Seoul, Republic of South Korea
08:10 RISK FACTORS ASSOCIATED WITH SURGICAL MORBIDITIES OF

LAPAROSCOPIC LIVING LIVER DONORS
Jinsoo Rhu - Seoul, Republic of South Korea
08:20 DUAL GRAFT LDLT HAS A ROLE IN AVOIDING SMALL-FOR-SIZE

SYNDROME
ChulSoo Ahn - Seoul, Republic of South Korea
08:50 REVOLUTIONIZING LIVER TRANSPLANT: THE JOURNEY FROM

LAPAROSCOPIC LDLT TO ROBOTIC LDLT
KW Lee Kwang-Woong Lee - Seoul, Republic of South Korea
09:00 POST-LIVER TRANSPLANT LONG-TERM SURVIVAL IN PATIENTS WITH

ACUTE-ON-CHRONIC LIVER FAILURE: LIVING-DONOR VERSUS
DECEASED-DONOR LIVER TRANSPLANTATION
Sang-Bin Han - Seoul, Republic of South Korea
09:10 *EFFECTIVENESS OF A DESENSITIZATION PROTOCOL ON ANTIBODY-

MEDIATED REJECTION IN LIVING DONOR LIVER TRANSPLANTATION: A
RETROSPECTIVE COHORT STUDY
YoungRok Choi - Seoul, Republic of South Korea
09:20 INTERNATIONAL LIVING DONOR LIVER TRANSPLANT REGISTRY –

LDLTREGISTRY.ORG
CHS Camila Hidalgo Salinas – Oxford, United Kingdom
Update 04|08|2023 31
FOCUS GROUP
08:00 - 09:30 Kidney machine perfusion and ischemia reperfusion injury

MC 3.4 Chairs: Maria Kaisar - Oxford United Kingdom
Georgios Katsanos - Thessaloniki Greece
08:00 TRANSPLANT OUTCOMES AFTER EXPOSURE OF DECEASED KIDNEY

DONORS TO CONTRAST MEDIUM
Kinita Chotkan – Leiden, The Netherlands
08:10 THE SETUP USED FOR EX VIVO RENAL NORMOTHERMIC PERFUSION

INFLUENCES A KIDNEY’S BEHAVIOR ON THE MACHINE
Veerle A. Lantinga – Groningen, The Netherlands
08:20 NORMOTHERMIC KIDNEY PERFUSION PHASE 1 – A CLINICAL TRIAL OF UP

TO 24-HOUR NORMOTHERMIC MACHINE PERFUSION PRIOR TO
TRANSPLANTATION
Richard Dumbill – Oxford, United Kingdom
08:30 MAGNETIC RESONANCE IMAGING ASSESSMENT OF FUNCTIONAL

DIFFERENCES BETWEEN KIDNEYS IN VIVO AND DURING EX VIVO
NORMOTHERMIC MACHINE PERFUSION
Tim L. Hamelink – Groningen, The Netherlands
08:40 KIDNEY TRANSCRIPTOME VARIES BETWEEN DONOR TYPES, WITH A

DIFFERENTIAL REPONSE TO ISCHEMIC PRECONDITIONING
Tiago Pinto Coelho – Liège, Belgium
08:50 FASTING PORCINE KIDNEYS DURING NORMOTHERMIC MACHINE

PERFUSION DOES NOT AFFECT MITOCHONDRIAL FUNCTION
L. Annick van Furth – Groningen, The Netherlands
09:00 RENAL ARTERY FUNCTIONS IN KIDNEYS AFTER THREE MONTHS

FOLLOWING RECONDITIONING IN PORCINE EXTENDED UDCD MODEL.
Galina Travnikova – Gothenburg, Sweden
09:10 REAL-TIME ASSESSMENT OF KIDNEY ALLOGRAFTS DURING HOPE USING

FLAVIN MONONUCLEOTIDE (FMN) - A PRECLINICAL STUDY.
Richard Sousa Da Silva – Zürich, Switzerland
TV-STUDIO
Update 04|08|2023 32
09:30 - 10:00 Work-life balance: how to recruit and retain transplant professionals of the
Muses Foyer future
Host: Jacqui Thornton – Winchester, United Kingdom
Guests: Pedro Miguel Baptista – Zaragoza, Spain

FULL ORAL
10:00 - 11:30 Risk of transmission of infectious disease and prevention

Lambrakis Chairs: Corinne Antoine - Paris, France
10:00 SHORT-TERM OUTCOME OF TRANSPLANT RECIPIENTS FROM SARS-COV-

2-POSITIVE ORGAN DONORS IN GERMANY
Ana Paula Barreiros – Mainz, Germany
10:10 KIDNEY TRANSPLANT RECIPIENTS BECOME LESS ADHERENT TO

PREVENTIVE MEASURES AFTER SARS-COV-2 VACCINATION AND AFTER
AWARENESS OF ANTIBODY RESPONSE
Sophie Frölke – Amsterdam, The Netherlands
10:20 VIROLOGICAL & CLINICAL OUTCOMES IN ORGAN RECIPIENTS FROM

SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
(SARS-COV-2) POSITIVE DECEASED ORGAN DONORS
Ines Ushiro-Lumb – London, United Kingdom
10:30 TWO-YEAR FOLLOW-UP OF LIVER GRAFTS FROM COVID-19 DONORS

Silvia Martini – Turin, Italy
10:40 CELLULAR HUMORAL MEMORY PROTECTS TRANSPLANT RECIPIENTS

FROM EMERGING SARS-COV-2 VARIANTS OF CONCERN THAT RESIST
CIRCULATING NEUTRALIZING ANTIBODIES
10:50 THE HUMORAL RESPONSE TO COVID-19 VACCINATION OF KIDNEY

TRANSPLANT RECIPIENTS IS PREDICTIVE OF SURVIVAL AFTER SARS-
COV-2 INFECTION
Markus Hovd – Oslo, Norway
11:00 SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY PREDICTS

SUCCESSFUL BOOSTER IMMUNIZATION AND SEVERE COVID-19 IN SOLID
ORGAN TRANSPLANT PATIENTS
Laura Donadeu – Barcelona, Spain
Update 04|08|2023 33
11:10 HEPATITIS E VIRUS (HEV) INFECTION IN DECEASED ORGAN DONORS –

OBSERVATIONS FROM THE FIRST 5 YEARS OF UNIVERSAL SCREENING
Ines Ushiro-Lumb – London, United Kingdom
SOLUTION ROOM
10:00 - 11:30 Technology to support global transplantation

Trianti Chairs: Muhammad Khurram – London, United Kingdom
How can technology can be utilised to support and develop organ transplantation
in low and middle income countries?
This session explores the potential role of technology in supporting the
development of organ transplantation programs in low and middle income
countries. The use of technology to facilitate remote training opportunities and
access to specialised expertise that may be unavailable in resource limited settings
will be discussed. The potential benefits and challenges inherent in providing
international support for program development and implementation will be
considered, [[+/- including potential ethical concerns about international outreach
activities]. Panelists and speakers from a range of settings will share their
experiences and perspectives, and audience members will be strongly encouraged
to share examples of effective practices and suggestions for future ESOT initiatives
in this domain.
10:00 Introduction – what technology can do for global patient care

10:10 The global transplant multi-disciplinary meeting

Chanaka Ruwan Abeyrathne – Colombo, Sri Lanka;
Chintana Galahitiyawa - Colombo, Sri Lanka; Abigail Lee London,United
Kingdom; Smaragdi Marinaki - Athens, Greece; Mireia Musquera - Barcelona,
Spain
10:40 Remote transplant learning
Mohamad Zaimi Abdul Wahab - Kuala Lumpur, Malaysia
10:55 How do you make it work in real world?

Sunil Schroff – Chennai, India
11:10 Discussion panel with audience
SOLUTION ROOM
Update 04|08|2023 34
10:00 - 11:30 Consent for research in donation and transplantation during the end of life
Banquet Hall period
Chairs: Jayme Locke – Birmingham, United States
Dominique Martin – Geelong, Australia
This multidisciplinary session explores some of the common challenges associated

with the conduct of transplant research involving potential deceased donors during
the end-of-life period, particularly with regard to ethical and legal aspects of
consent for participation in research. Each talk will comprise recommendations for
good practice that should also help to address potential barriers to the approval of
studies by research ethics committees. Attendees will have the opportunity to ask
questions and discuss strategies to address common barriers, such as those that
arise when seeking to conduct innovative trials or to involve the families of
deceased donors in research.
10:00 Introduction
Jayme Locke – Birmingham, United States; Dominique Martin – Geelong, Australia
10:05 Consent for participation in research and deceased donation - untangling the
legal frameworks
Shih-Ning Then – Brisbane, Australia
10:25 Making a decision about research in the context of donation - a family's

perspective
Julie O'Hara – Alabama, United States
10:35 Qualitative research involving families of potential deceased donors - addressing

the ethical concerns
Jessie Cooper - London United Kingdom; Zivarna Murphy - London United
Kingdom
10:55 Discussion
Gabriel Oniscu - Stockholm Sweden; Matthew Weiss - Montreal, Canada
BRIEF ORAL
10:00 - 11:30 Looking through the glass – fresh perspectives on ethicolegal and
Mitropoulos psychosocial aspects of donation and transplantation
Chairs: Frederike Ambagtsheer - Rotterdam, The Netherlands
Greg Moorlock – Warwick, United Kingdom
10:00 CLINICAL TRANSLATION AND IMPLEMENTATION OF A BIO-ARTIFICIAL

PANCREAS: A QUALITATIVE STUDY EXPLORING THE PERSPECTIVES OF
PATIENTS WITH TYPE 1 DIABETES
Dide de Jongh – Rotterdam, The Netherlands
Update 04|08|2023 35
10:06 PSYCHOLOGICAL SCREENING AND FOLLOW-UP CARE FOR LIVING LIVER

DONORS: 5-YEAR PROSPECTIVE COHORT DATA FROM A SINGLE
ACADEMIC CENTRE
Leonieke Kranenburg – Rotterdam, The Netherlands
10:12 PSYCHOSOCIAL EVALUATION OF LIVING KIDNEY DONORS IN QATAR –

PROCESS AND OUTCOMES OF THE COMMITTEE FOR OVERSIGHT OF
LIVING DONATION
Riadh Fadhil – Doha, Qatar
10:18 TRANSPLANT EXPERIENCES AND QUALITY OF LIFE IN PATIENTS WHO

UNDERWENT AN INCOMPATIBLE KIDNEY TRANSPLANT: A CROSS-
SECTIONAL PILOT SURVEY
10:24 ANXIETY AND DEPRESSIVE SYMPTOMS AMONG PATIENTS ON DIALYSIS,

KIDNEY AND KIDNEY-PANCREAS TRANSPLANT RECIPIENTS
Istvan Mucsi – Toronto, Canada
10:30 LONG TERM OUTCOMES OF CHILDREN OF FEMALE KIDNEY TRANSPLANT

RECIPIENTS – A RETROSPECTIVE REGISTRY STUDY
Goni Katz-Greenberg – Durham, United States
10:36 ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE IN THE LIVER

TRANSPLANT PATIENT CONDUCTED MORE THAN 10 YEARS AGO,
STATEWIDE STUDY
Fernando García Perez – Madrid, Spain
10:42 QUALITATIVE AND QUANTITATIVE RESEARCH ON ASSESSING THE

EXPERIENCE OF ONE'S BODY BY LIVING KIDNEY DONORS.
Mateusz Zatorski – Warsaw, Poland
10:48 DIFFERENCES BETWEEN PERCEIVED QUALITY OF LIFE AND MEDICAL

OUTCOMES IN PATIENTS WITH ADVANCED HEART FAILURE
Marco Valente – Bologna, Italy
10:54 PROFESSIONALS’ PERSPECTIVES ON REPORTING OF TRAVEL FOR

ORGAN TRANSPLANTATION: AN INTERNATIONAL CROSS SECTIONAL
STUDY.
Georgina Irish – Adelaide, Australia
11:00 THE ORGANIZATION OF THE HUMAN ORGAN TRADE: A COMPARATIVE

SCRIPT ANALYSIS BETWEEN LEGAL AND ILLEGAL KIDNEY TRANSPLANTS
Frederike Ambagtsheer - Rotterdam, The Netherlands
11:06 IMPLEMENTING A VALUES-DRIVEN POLICY IN A COMPLEX SYSTEM:

WHAT HAPPENED WHEN THE SOFT OPT-OUT SYSTEM OF ORGAN
DONATION WAS IMPLEMENTED IN ENGLAND?
Leah Mc Laughlin – Cardiff, United Kingdom
11:12 ANALYSIS OF JUDICIAL LITIGATION CONCERNING ORGAN

TRANSPLANTATION IN ONE OF THE LARGEST EUROPEAN UNIVERSITY
HOSPITALS
Francois Cauchy – Geneva, Switzerland
Update 04|08|2023 36
11:18 NATIONAL HEALTH INSURANCE COVERAGE OF ORGAN PERFUSION

MACHINES (PM) IMPROVES ACCESS TO TRANSPLANTATION.
Helene Logerot - Saint Denis, France
BRIEF ORAL
10:00 - 11:30 Complications and infections after kidney transplant

Skalkotas Chairs: Aisling Courtney - Belfast United, Kingdom
Evangelia Dounousi – Ioannina, Greece
10:00 PREDICTION OF KIDNEY GRAFT SURVIVAL AMONG DECEASED

TRANSPLANT RECIPIENTS IN THE UK: AN ARTIFICIAL INTELLIGENCE
APPROACH
Hatem Ali – Coventry, United Kingdom
10:06 REAL-LIFE IMPLEMENTATION OF A STRATEGY BASED ON CMV-SPECIFIC

CELL-MEDIATED IMMUNITY TO GUIDE CMV PREVENTIVE THERAPY IN
SOLID ORGAN TRANSPLANTATION
Delphine Kervella – Barcelona, Spain
10:12 MACHINE LEARNING MODELS IN RENAL TRANSPLANTATION: A

SYSTEMATIC REVIEW AND META-ANALYSIS OFPREDICTIVE
PERFORMANCE IN GRAFT SURVIVAL
Usman Haroon – London, United Kingdom
10:18 BURDEN OF REFRACTORY/RESISTANT CYTOMEGALOVIRUS OR

CYTOMEGALOVIRUS DRUG INTOLERANCE IN SOLID ORGAN
TRANSPLANT RECIPIENTS: EUROPEAN SUBGROUP ANALYSIS
Kimberly Davis – Lexington, United States
10:24 PREVALENCE OF CYTOMEGALOVIRUS ANTIVIRAL DRUG RESISTANCE IN

TRANSPLANT RECIPIENTS
Steve Kleiboeker - Lee's Summit, United States
10:30 THE RISK OF VENOUS THROMBOEMBOLISM IS ENHANCED AFTER A

CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENT
10:36 IMPACT OF PROTON PUMP INHIBITORS IN KIDNEY TRANSPLANT

RECIPIENTS
Update 04|08|2023 37
10:42 HYPERCHOLESTEROLEMIA IMPAIRED CAPILLARY VEGF AND NITRIC

OXIDE AND, IN TURN, DECREASED MICROVASCULAR DENSITY AND
TUBULAR VILLIN IN RENAL ALLOGRAFTS.
Binnaz Handan Ozdemir – Ankara, Turkey
10:48 ADVERSE OUTCOMES AFTER ALEMTUZUMAB THERAPY FOR KIDNEY

TRANSPLANT REJECTION
Lukas van Vugt – Rotterdam, The Netherlands
10:54 THE OUTCOME PREDICTION VALUE OF PROTEINURIA AND ALBUMINURIA

BY DIFFERENT WAYS OF MEASUREMENT IN KIDNEY TRANSPLANTATION
Qiang Zhang – Guangzhou, China
11:00 TUBULORETICULAR INCLUSIONS: A NEW PROGNOSTIC BIOMARKER IN

KIDNEY TRANSPLANTATION
Sarah Gleeson – London, United Kingdom
11:06 EARLY SURGICAL COMPLICATIONS IN EVEROLIMUS TREATED KIDNEY

TRANSPLANT RECIPIENTS: A CLAVIEN-DINDO CLASSIFICATION ANALYSIS
Patrizia Silvestri – Rome, Italy
11:12 RISK OF BLEEDING AFTER PERCUTANEOUS GRAFT KIDNEY BIOPSY IN

PATIENTS RECEIVING LOW DOSE ASPIRIN A SINGLE CENTER
RETROSPECTIVE STUDY
Francesco Fontana – Modena, Italy
11:18 IMPACT OF ALLOGRAFT CELLULAR INFLAMMATION ON THE IGA

NEPHROPATHY RECURRENCE AFTER KIDNEY TRANSPLANTATION.
Emilio Rodrigo – Santander, Spain
BRIEF ORAL
10:00 - 11:30 Molecular transplant immunology

MC 3 Chairs: Xavier Charmetant – Lyon, France
Maria Kaisar – Oxford, United Kingdom
10:06 SINGLE CELL RNA SEQUENCING OF DONOR-REACTIVE T CELLS

REVEALS ROLE OF APOPTOSIS IN DONOR-SPECIFIC
HYPORESPONSIVENESS OF KIDNEY TRANSPLANT RECIPIENTS
Nicolle Litjens – Rotterdam, The Netherlands
10:12 ELDERLY RENAL TRANSPLANT RECIPIENTS HAVE LESS

POLYFUNCTIONAL ALLOREACTIVE CD4 T CELLS PRE TRANSPLANT AND
LOWER IL-2 MEDIATED T CELL PROLIFERATION
Nicolle Litjens – Rotterdam, The Netherlands
Update 04|08|2023 38
10:24 RELEVANCE OF THE BANFF HUMAN ORGAN TRANSPLANT CONSENSUS

GENE PANEL FOR DETECTING ANTIBODY AND T-CELL MEDIATED
REJECTION OF KIDNEY ALLOGRAFTS
Alessia Giarraputo – Paris, France
10:30 DDPCR DETECTION OF MIRNAS FIBROSIS SIGNATURE IN URINE-EVS

FROM KIDNEY TRANSPLANTED PATIENTS: A NON-INVASIVE APPROACH
TO DETECT KIDNEY FIBROSIS
Marta Clos-Sansalvador – Badalona, Spain
10:36 MEK INHIBITION, A NEW THERAPEUTIC APPROACH IN ORGAN

TRANSPLANTATION
Gilles Blancho – Nantes, France
10:42 DECONVOLUTION ANALYSIS REVEALS CHANGES IN IMMUNE CELL

SUBSETS IN PERIPHERAL BLOOD FOR MULTIPLE REJECTION
PHENOTYPES FOLLOWING KIDNEY TRANSPLANT
Thomas Whisenant - La Jolla, United States
10:48 PRESENCE OF KIR2DL2/S2, KIR2DL5, AND KIR3DL1 MOLECULES IN LIVER

RECIPIENTS WITH ALCOHOLIC CIRRHOSIS COULD BE IMPLICATED IN
DEATH BY GRAFT FAILURE
Manuel Muro – Murcia, Spain
10:54 A NOVEL URINE-BASED LIQUID BIOPSY BIOMARKER FOR RENAL

FIBROSIS IN KIDNEY TRANSPLANT
Omar Enrique Taco Sánchez – Barcelona, Spain
11:00 NON-INVASIVE DETECTION OF REJECTION IN THE FIRST 2 WEEKS AFTER

KIDNEY TRANSPLANTATION USING URINARY CHEMOKINES
Karin Boer – Rotterdam, The Netherlands
11:06 ACTIVE IMMUNOLOGICAL PARTICIPATION AND METABOLIC SHUTDOWN

OF KIDNEY STRUCTURAL CELLS DURING KIDNEY TRANSPLANT
REJECTION
Elisabet Van Loon – Leuven, Belgium
11:12 DIRECT IMMUNOPHENOTYPING OF REGULATORY B CELLS AT 3 MONTHS

HAVE A PROGNOSTIC VALUE OF IMPROVED GRAFT OUTCOME AND
REJECTION RISK IN KIDNEY TRANSPLANT
Inés Perezpayá – Badalona, Spain
11:18 Γ/Δ T CELLS IN ANTIBODY-MEDIATED REJECTION: RINGLEADER OR MERE

EXECUTORS?
Xavier Charmetant – Lyon, France
JOINT SESSION
Update 04|08|2023 39
10:00 - 11:30 Advances in CMV diagnosis and treatment

MC 2
Chairs: Hannah Kaminski – Bordeaux, France
10:00 Update on diagnosis of CMV infection in SOT and HSCT recipients in the era of
new antivirals
Tiziana Lazzarotto – Bologna, Italy
10:15 Immunological monitoring of CMV infection

Hannah Kaminski – Bordeaux, France
10:30 CMV vaccine: have we reached the end?

Per Ljungman – Stockholm, Sweden
10:45 Refractory/resistant CMV infection: new options

Paolo Grossi – Varese, Italy
11:00 What is missing in the clinical applicability of CMV guidelines?

Hans Hirsch - Basel Switzerland
11:15 Q&A
SOLUTION ROOM
10:00 - 11:30 Let’s talk about: the strongest people who win battles we know nothing about
Library Chairs: Fabienne Dobbels – Leuven, Belgium
Ines Mega – Lisbon, Portugal
10:00 Why has nobody told me this before?

Liz Schick – Bern, Switzerland
10:20 You are not alone: Mental health challenges for HCP
10:40 How to address the unmet need? Solutions for patients and HCP
Martina de Zwaan – Hannover, Germany
11:00 Discussion panel with audience

Fabienne Dobbels – Leuven, Belgium; Stephen Potts - Edinburgh, United Kingdom
FISHBOWL
10:00 - 11:30 From the laparoscope to the robot
Update 04|08|2023 40
Conference Suite 1 Chairs: Silvio Nadalin – Tübingen, Germany

Khe Tran – Rotterdam, The Netherlands
Surgical techniques in transplantation have been static for many years with the
exception of laparoscopic approaches to donor-living donor surgery. Will the robot
make a difference? How far have we progressed, or will we remain in the realm of
open surgery?
10:00 Round one | Liver donor: laparoscopy

Ki-Hun Kim - Seoul, Republic of South Korea
10:10 Round one | Liver donor: robotic

Dieter Broering - Riyadh Saudi, Arabia
10:20 Round one | Rebuttal & Voting
10:30 Round two | Kidney donor: laparascopy

Lucrezia Furian - Padua Italy
10:40 Round two | Kidney donor: robotic

Giuliano Testa – Dallas, United States
10:50 Round two | Rebuttal & Voting
11:00 Round three | Kidney recipient: robotic

Karel Decaestecker – Gent, Belgium
11:10 Round three | Liver recipient: robotic

Dieter Broering – Riyadh, Saudi Arabia
11:20 Round three | Discussion
SCIENTIFIC SYMPOSIUM
10:00 - 11:30 Organised by the Vienna Comprehensive Transplant Center: Induction

MC 3.2 therapies in 2023 in SOT: Evidence and controversies
Chairs: Rainer Oberbauer – Vienna, Austria
TBC -
10:00 Overview
Thomas Wekerle – Vienna, Austria
10:10 Kidney
Klemens Budde – Berlin, Germany; Rainer Oberbauer – Vienna, Austria
10:20 Liver
Jacques Pirenne – Leuven, Belgium; Thomas Soliman - Vienna, Austria
Update 04|08|2023 41
10:30 Heart
Markus J. Barten – Hamburg, Germany; Andreas Zuckermann - Vienna, Austria
10:40 Lung
Andrew Fisher - Newcastle upon Tyne, United Kingdom; Peter Jaksch - Vienna,
Austria
10:50 Panel discussion with all speakers and Patrizia Burra (Padua) and
AnnemarieWeißenbacher (Innsbruck)
Markus J. Barten - Hamburg, Germany; Patrizia Burra - Padua, Italy; Klemens

Budde - Berlin, Germany; Andrew Fisher - Newcastle upon Tyne, United
Kingdom; Peter Jaksch - Vienna, Austria; Jacques Pirenne - Leuven, Belgium;
Thomas Soliman - Vienna, Austria; Annemarie Weissenbacher - Innsbruck,
Austria; Andreas Zuckermann - Vienna, Austria
FOCUS GROUP
10:00 - 11:30 Deceased donor kidney transplantation issues

MC 3.4 Chairs: Emin Baris Akin – Istanbul, Turkey
Chloe Balleste – Barcelona, Spain
10:00 FIVE-YEAR OUTCOMES OF KIDNEY TRANSPLANTATION FROM DONORS

AFTER CIRCULATORY DEATH OLDER THAN 65 YEARS OLD
Maria Ovidia Lopez Oliva – Madrid, Spain
10:10 KIDNEY OUTCOMES FROM UNCONTROLLED DONATION AFTER

CIRCULATORY DEATH: A LONGITUDINAL COHORT
Ana Pinho – Porto, Portugal
10:20 BIOLOGICAL INJURY ASSOCIATED WITH DECEASED DONOR

PATHWAYS REFLECT DIFFERENCES IN THE DONOR KIDNEY PROTEOME
AND CELLULAR STRESS RESPONSES
Rebecca Vaughan – Oxford, United Kingdom
10:30 RISK FACTORS OF ACUTE KIDNEY INJURY IN DECEASED KIDNEY

DONORS
Katarina Timkova – Prague, Czech Republic
10:40 DONOR CHARACTERISTICS ASSOCIATED WITH EARLY THROMBOTIC

MICROANGIOPATHY AFTER KIDNEY TRANSPLANTATION AND
OUTCOMES: A SINGLE-CENTER EXPERIENCE.
Peenida Skulratanasak – Bangkok, Thailand
10:50 NON-IMMUNOLOGICAL RISK FACTORS AND CLINICAL OUTCOME OF

SLOW GRAFT FUNCTION AFTER DECEASED DONOR KIDNEY
TRANSPLANTATION.
Chang-Kwon Oh - Suwon, Republic of South Korea
Update 04|08|2023 42
11:00 KIDNEY TRANSPLANT SURVIVAL ANALYSIS AND PROGNOSTIC FACTORS

AFTER 10 YEARS OF FOLLOW-UP.
Maria Ramos-Cebrián – Valencia, Spain
11:10 TRANSPLANT OUTCOME FROM OCTOGENARIAN DONORS: SINGLE

KIDNEY TRANSPLANT VERSUS DUAL KIDNEY TRANSPLANT
Arianna Vittori – Padua, Italy
HANDS-ON COURSE
10:00 - 11:30 Machine Perfusion in my hands: Virtual and interactive LIVER (Group 1)
Ground floor foyer -
Hands on course
6 machines for organ perfusion will be available in the wet lab setting. Guided by
tutors, participants will follow the steps of liver perfusion. Participants will rotate
around the machines/stations every 15 minutes. Additional registration for this
session is required. Please register via the Congress website
10:00 LifePort Liver Transporter - Organ Recovery Systems

10:15 VitaSmart - Bridge to life

Damiano Patrono – Turin, Italy
10:30 Metra - OrganOx

David Nasralla – London, United Kingdom
10:45 Aferetica
Vincent E. de Meijer – Groningen, The Netherlands
11:00 EBERS
Daniele Dondossola - Milan, Italy
11:15 Liver Assist - Xvivo

Davide Ghinolfi – Pisa, Italy
STATE OF THE ART

11:45 - 13:15 We are always the same age inside? The role of ageing in organ
Lambrakis transplantation
Chairs: Menna Clatworthy – Cambridge, United Kingdom
Diethard Monbaliu – Leuven, Belgium
Update 04|08|2023 43
In an effort to increase transplant numbers, we increasingly utilise organs from

older donors. Some function well, whilst others have less good outcomes. In
parallel, we are also considering older patients as transplant recipients, with
varying levels of frailty that might lead to a more difficult post-transplant course. In
this session, we will discuss the molecular features of organ ageing, and how
organs and transplant recipients might be assessed to assist with decision-making
on wait-listing and organ utilisation respectively. We will hear about how the
negative effects of ageing can be influenced by the microbiome, and potentially
reversed by targeting senescent cells within organs.
11:45 Organ-specific temporal changes in the molecular features of ageing

Menna Clatworthy – Cambridge, United Kingdom
12:05 The Gut microbiome and healthy ageing and longevity

Herbert Tilg – Innsbruck, Austria
12:25 Can we restore the regenerative capacity of old kidneys?

David Ferenbach – Edinburgh, United Kingdom
12:45 Age versus frailty in transplant recipients

Jasper Iske – Boston, United States
13:05 Discussion & Summary
STATE OF THE ART

11:45 - 13:15 Lost in transplantation: Impact of digitalisation of care

Trianti Chairs: Fabienne Dobbels – Leuven, Belgium
Rainer Oberbauer – Vienna, Austria
The use of electronic devices and modern electronic technologies (eHealth) can
undoubtedly improve clinical outcome of transplant recipients and reduce cost of
health care. What are hurdles in implementing eHealth in clinical practice? What
about patient preferences and required health care personnel technical skills to
support patient needs? eHealth applications generate large amounts of data,
which can be processed by methods of artificial intelligence (AI) to generate
automatic algorithms to support patient decisions. What is ready for prime time?
AI can provide automated analysis of digitalised slides of transplant pathology.
Where do we stand with automated pathology readings in solid organ
transplantation? Can AI overcome the problem of shortage of transplant
pathologists? Implementation of large-scale clinical research is increasingly
demanding nowadays, because of the logistic and financial burden. The recent
mandatory requirement that future clinical studies collect patient reported
outcomes (PROs) might make research a prohibitive task for Academia. How can
digital technology fix the problem?
11:45 Introduction
Update 04|08|2023 44
11:50 Digital solutions to traditional problems: technology, software and policy

Klemens Budde – Berlin, Germany
12:10 Moving AI empowered algorithms into telemedicine clinical practice

Carmen Lefaucheur – Paris, France
12:30 Gamification of healthcare - a winning strategy?

Rundgren Olli – Jyväskylä, Finland
12:50 Large-scale clinical research and PROs: digital solutions to make it easy
STATE OF THE ART

11:45 - 13:15 Making a difference with shared decision-making

Library Chairs: Pisana Ferrari – Udine, Italy
This session provides attendees with an overview of current best practices in

shared decision-making (SDM) and a series of talks exploring a range of ways in
which SDM can have a powerful impact and improve equity in access to
transplantation. Specifically, talks will explore the role of SDM and tools to support
risk evaluation and decision-making in donation and transplantation; the role of
SDM in empowering patient advocacy for transplant care; and the role of SDM in
supporting decision-making and inclusion of persons with disabilities in
transplantation.
11:45 Best practices in contemporary shared decision-making

Natalie Joseph-Williams - Cardiff , United Kingdom
12:05 Shared decision-making and risk evaluation - the role of decision-aids

Alessandra Grossi – Varese, Italy
12:25 Shared decision-making, empowerment and patient advocacy

Vivekanand Jha - New Delhi, India
12:45 Supported and shared decision-making in transplantation for people with

disabilities
Keren Ladin – Boston, United States
TV-STUDIO
Update 04|08|2023 45
13:15 - 13:45 X million Euros of EU investment – focus on four vital projects

Muses Foyer Host: Jacqui Thornton - Winchester United Kingdom
Guests: Ekaterine Berishvili – Geneva, Switzerland

Hannah Kaminski – Bordeaux, France
MODERATED EPOSTER SESSION

14:15 - 15:15 Moderated poster session on cardiac transplantation

MEP-1 Chair: Stephen Clark - Newcastle upon Tyne, United Kingdom
14:15 TRANSPLANT RECIPIENT OUTCOMES WITH EXTENDED CRITERIA

DONORS: AN ANALYSIS OF THE GUARDIAN HEART REGISTRY
14:15 VALIDATION OF THE 2014 CONSENSUS PRIMARY GRAFT DYSFUNCTION

DEFINITION USING THE GUARDIAN-HEART REGISTRY
Andrea Eixeres Esteve – Madrid, Spain
14:15 LOWER BASOPHIL COUNT AFTER ANTI-THYMOCYTE GLOBULIN

INDUCTION IS ASSOCIATED WITH A LOWER INCIDENCE OF CARDIAC
ALLOGRAFT REJECTION
Bosko Skoric – Zagreb, Croatia
14:15 HEART TRANSPLANTATION IN ADULTS WITH PERIPARTUM

CARDIOMYOPATHY
Nadegda Koloskova – Moscow, Russian Federation
14:15 INFLAMMATION IN BRAIN DEATH DONORS PROTECTS TO PRIMARY

GRAFT DYSFUNCTION IN HEART TRANSPLANTATION
Gabriel Moreno-Gonzalez – Barcelona, Spain
14:15 LOCAL LABORATORY-RUN DONOR-DERIVED CELL-FREE DNA TESTING IN

STABLE HEART TRANSPLANTATION: TWO-CENTRE EUROPEAN
FEASIBILITY STUDY
Tímea Teszák – Budapest, Hungary
14:15 CARDIORENAL PROTECTION WITH NEWER ANTIDIABETIC DRUGS IN

HEART TRANSPLANTATION: A CASE REPORT.
Walter Baronti – Grosseto, Italy
14:15 LIVER AFTER HEART AND COMBINED HEART LIVER TRANSPLANTATION

IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: A CROATIAN
EXPERIENCE
Maja Sremac – Zagreb, Croatia
Update 04|08|2023 46
14:15 LEFT VENTRICULAR ASSIST DEVICES AS BRIDGE-TO-TRANSPLANTATION

IN A LOW ORGAN DONOR ENVIRONMENT
Dimitris Miliopoulos – Kallithea, Greece
14:15 INITIAL EXPERIENCE WITH LOCAL LABORATORY RUN ASSAY TO DETECT

DONOR-DERIVED CELL FREE DNA FOR NONINVASIVE DIAGNOSIS OF
ACUTE MYOCARDIAL REJECTION
Stefania Manno – Bologna, Italy

14:15 - 15:15 Moderated poster session on infections complications in kidney

MEP-2 transplantation
Chair: Raj Thuraisingham – London, United Kingdom
14:15 BKEVER STUDY: BKV CLEARANCE IN KIDNEY TRANSPLANT RECIPIENTS

AFTER REPLACEMENT OF MMF BY EVEROLIMUS AND REDUCTION OF
IMMUNOSUPPRESSION
Sophie Caillard – Strasbourg, France
14:15 OUTCOME OF KIDNEY TRANSPLANTS FROM VIREMIC AND NON-VIREMIC

HEPATITIS C VIRUS POSITIVE DONORS INTO NEGATIVE RECIPIENTS:
RESULTS OF THE SPANISH REGISTRY
Antonio Franco – Alicante, Spain
14:15 LATE OPPORTUNISTIC INFECTIONS AFTER KIDNEY TRANSPLANTATION

IN THE ERA OF CONTEMPORARY IMMUNOSUPPRESSION: ROOM FOR
IMPROVEMENT
Marie Matignon – Creteil, France
14:15 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN KIDNEY

TRANSPLANT RECIPIENTS : A RETROSPECTIVE MULTICENTER
NATIONWIDE COHORT STUDY
Adelaide Sanson – Paris, France
14:15 LONG-TERM OUTCOMES OF LIVE KIDNEY DONORS WITH HEPATITIS B

VIRUS INFECTION: A PROPENSITY SCORE-MATCHED COHORT STUDY
Saifu Yin – Chengdu, China
14:15 COMPASSIONATE USE PROGRAMME OF MARIBAVIR FOR ADULT

PATIENTS WITH POST-TRANSPLANT REFRACTORY CMV INFECTION
Nassim Kamar – Toulouse, France
14:15 KIDNEY TRANSPLANTATION FROM DECEASED DONORS WITH

BACTEREMIA
Maria Darema – Athens, Greece
Update 04|08|2023 47
14:15 ADVANTAGES OF MONITORING CELLULAR IMMUNE RESPONSE AGAINST

CYTOMEGALOVIRUS IN RENAL TRANSPLANTATION.
Javier Arias-Alcalá – Cordoba, Spain
14:15 LONG-TERM IMMUNE DYSREGULATION AFTER RITUXIMAB INDUCTION IN

ABO INCOMPATIBLE LIVING-DONOR RENAL TRANSPLANTATION – IMPACT
ON CHRONIC BK VIRUS INFECTION
Rolf Weimer – Giessen, Germany

14:15 - 15:15 Moderated poster session on COVID-19

MEP-3 Chair: Corinne Antoine – Paris, France
14:15 SAFETY AND EFFICACY OF TIXAGEVIMAB/CILGAVIMAB FOR PRE-

EXPOSURE PROPHYLAXIS IN KIDNEY TRANSPLANT RECIPIENTS: A
MULTICENTER RETROSPECTIVE COHORT STUDY
Simona Simone – Bari, Italy
14:15 THE IMPACT OF MONOCLONAL ANTIBODY AGAINST SARS-COV2 AND

VACCINATION ON OUTCOMES IN KIDNEY TRANSPLANT RECIPIENTS WITH
COVID-19
Bruce Gelb - New York,United States
14:15 REPEATED COVID-19 VACCINATION OF IMMUNOCOMPROMISED KIDNEY

TRANSPLANT RECIPIENTS LEADS TO THE INDUCTION OF A FUNCTIONAL
T CELL SUBSET ASSOCIATED WITH ANTIBODY PRODUCTION
Yvette den Hartog – Rotterdam, The Netherlands
14:15 INCIDENCE AND SEVERITY OF COVID-19 IN RELATION TO ANTI-RBD IGG

ANTIBODY LEVEL AFTER COVID-19 VACCINATION IN KIDNEY
Céline Imhof – Groningen, The Netherlands
14:15 TH1-DOMINANT CYTOKINE RESPONSES IN KIDNEY PATIENTS AFTER

COVID-19 MRNA-1273 VACCINATION ARE ASSOCIATED WITH POOR
HUMORAL RESPONSES
Yvette den Hartog – Rotterdam, The Netherlands
14:15 REPEATED COVID-19 VACCINATION ENHANCES MEMORY T-CELL IL-21

AND MEMORY B-CELL RESPONSES IN IMMUNOCOMPROMISED KIDNEY
S.R.K. Reshwan Malahe – Rotterdam, The Netherlands
14:15 REAL-WORD EXPERIENCE OF SOTROVIMAB TO PREVENT SEVERE

COVID-19 IN KIDNEY TRANSPLANT RECIPIENTS: RESULTS FROM A
NATIONAL STUDY
Marie Matignon – CRETEIL, France
Update 04|08|2023 48
14:15 THE IMPACT OF EARLY THERAPIES FOR COVID IN A GROUP OF KIDNEY

TRANSPLANT PATIENTS
Elena Conto – Verona, Italy
14:15 SERONEGATIVE TRANSPLANT PATIENTS REMAIN AT SIGNIFICANT RISK

OF SARS-COV-2 INFECTION AND COMPLICATIONS; WE ARE NOT OUT OF
THE WOODS YET
Laszlo Szabo – Cardiff, United Kingdom
14:15 SARS-COV-2 ANTIBODIES RESPONSE AFTER VACCINATIONS IN KOREAN

KIDNEY TRANSPLANT RECIPIENTS
Kina Kim - Seoul, Republic of South Korea
PLENARY
15:00 - 16:30 Overcoming the organ shortage: Thinking outside the box
Lambrakis Chairs: Beatriz Dominguez-Gil – Madrid, Spain
Stefan Schneeberger – Innsbruck, Austria
This plenary session will address innovative strategies to fight organ shortage in
countries with developed organ donation programs from a multidisciplinary
perspective. The speakers will give insight into the role of algorithms and artificial
intelligence aiming to enhance the equitable answer to the patients urgently waiting
for an organ as well as the new solutions coming from regenerative medicine and
bioengineering promising to revolutionize the transplant field
15:00 Introduction: setting the scene for the session – current strategies
15:10 Can AI better address the gap between supply and demand?
Dorry Segev - New York, United States
15:30 Can bioengineering be a solution?

Pedro Miguel Baptista – Zaragoza, Spain
15:50 Reprogramming the blood group?

Sarah Hosgood – Cambridge, United Kingdom
16:10 Reconsidering the demand – one organ for life?

PLENARY
Monday, 18. September 2023
17:00 - 18:30 Leonardo Da Vinci
Update 04|08|2023 49
Lambrakis Chairs: Ekaterine Berishvili – Geneva, Switzerland

Menna Clatworthy – Cambridge, United Kingdom
Marta Crespo – Barcelona, Spain
Ina Jochmans – Leuven, Belgium
Jayme Locke – Birmingham, United States
Umberto Maggiore – Parma, Italy
Gabriel Oniscu – Stockholm, Sweden
17:00 BCL-6 INHIBITORS POTENTLY INHIBIT ALLOGENEIC T CELL ACTIVATION -

A NOVEL MECHANISM OF IMMUNOSUPPRESSION?
Louisa Steines – Regensburg, Germany
Challenged by Jury member Oriol Bestard - Barcelona, Spain
17:10 ENGINEERED T CELLS OVERCOMING REJECTION BY ANTIBODIES (CORA-

T CELLS): SELECTIVE TARGETING OF ALLOREACTIVE B CELLS IN SOLID
ORGAN TRANSPLANTATION
Anna Christina Dragon – Hannover, Germany
Challenged by Jury member Ekaterine Berishvili - Geneva, Switzerland
17:20 COMBINATION OF TCR-DEFICIENT CAR-TREGS AND ANTI-CD3

MONOCLONAL ANTIBODIES TO PROMOTE TRANSPLANT TOLERANCE
Julien Zuber – Paris, France
Challenged by Jury member Menna Clatworthy - Cambridge, United Kingdom
17:30 RECIPIENT FCΓR3A POLYMORPHISM INFLUENCES THE PROGNOSIS OF

AMR AND THE RESPONSE TO IVIG IN RENAL TRANSPLANTATION
Alice Koenig – Lyon, France
Challenged by Jury member Umberto Maggiore - Parma, Italy
17:40 CLINICAL VALIDATION OF AUTOMATED URINARY CHEMOKINE ASSAYS

FOR NON-INVASIVE DETECTION OF KIDNEY TRANSPLANT REJECTION: A
PROSPECTIVE COHORT STUDY
Challenged by Jury member Jayme Locke - Birmingham, United States
17:50 RACE-FREE EGFR EQUATION IN KIDNEY RECIPIENTS: A DEVELOPMENT

AND VALIDATION STUDY
Marc Raynaud – Paris, France
Challenged by Jury member Marta Crespo - Barcelona, Spain
18:00 DONOR-DERIVED CELL FREE DNA AS A SURVEILLANCE TOOL FOR

ACUTE CELLULAR REJECTION IN HEART TRANSPLANTATION: RESULTS
FROM THE FREE-DNA CAR STUDY
Marta Jimenez-Blanco – Madrid, Spain
Challenged by Jury member Luciano Potena - Bologna, Italy
Update 04|08|2023 50
18:10 LONG-TERM OUTCOMES AFTER HYPOTHERMIC OXYGENATED MACHINE

PERFUSION (HOPE) AND TRANSPLANTATION OF 1291 DONOR LIVERS
USING REAL-WORLD DATA
Janina Eden – Zürich, Switzerland
Challenged by Jury member Ina Jochmans -Leuven, Belgium
BRIEF ORAL
17:00 - 18:30 Kidney allograft immunopathology

Trianti Chairs: Olivier Aubert – Paris, France
Candice Roufosse – London, United Kingdom
17:00 HUMAN LEUKOCYTE ANTIGEN MISMATCHES AND GRAFT OUTCOMES IN

THE CONTEMPORARY ERA OF IMMUNOSUPPRESSION: A UK REGISTRY
ANALYSIS
Raja Rashid – Birmingham, United Kingdom
17:06 PATTERNS OF MAJOR-HISTOCOMPATIBILITY-COMPLEX (MHC) CLASS I–

RELATED CHAIN A (MICA) ALLOIMMUNE RESPONSES REVEALED BY
MACHINE LEARNING ALGORITHMS
Angeliki Vittoraki – ATHENS, Greece
17:12 EARLY SYSTEMIC SUBCLINICAL INFLAMMATION SCORES ARE

ASSOCIATED WITH SIGNIFICANT RISK FOR LONG-TERM KIDNEY GRAFT
FAILURE
Torbjørn Heldal – Oslo, Norway
17:18 EARLY SYSTEMIC VASCULAR INFLAMMATION SCORE IS ASSOCIATED

WITH I-IFTA IN BIOPSIES 6-WEEKS AND 1-YEAR AFTER KIDNEY
TRANSPLANTATION
Torbjørn Heldal – Oslo, Norway
17:24 CLINICAL AND MOLECULAR SPECTRUM OF V-LESION

Anna Buxeda – Barcelona, Spain
17:30 PRECISE COMPOSITION AND LOCALIZATION OF THE INFLAMMATORY

BURDEN OF 125 KIDNEY TRANSPLANT REJECTIONS: DETERMINANTS
AND PROGNOSIS IMPACT
Marion Rabant – Paris, France
17:36 HIGH REJECTION RATES WITH NO INDUCTION+RAPID STEROID

WITHDRAWAL IN WELL MATCHED LIVING DONOR KIDNEY TRANSPLANTS
WITH PREFORMED TCELL ALLOREACTIVITY
Maria Meneghini – Barcelona, Spain
Update 04|08|2023 51
17:42 EUROPEAN SURVEY ON CLINICAL PRACTICE OF DETECTING AND

TREATING T-CELL MEDIATED KIDNEY TRANSPLANT REJECTION
Priyanka Koshy – Leuven, Belgium
17:48 PROFILING THE IMMUNE CELL INFILTRATE OF KIDNEY ALLOGRAFTS IN

RELATION TO THE EXISTING BANFF HISTOLOGY
Thibaut Vaulet – Leuven, Belgium
17:54 OUTCOMES OF STANDARD VERSUS DELAYED INITIATION OF

TACROLIMUS IN RECIPIENTS OF DONATION AFTER
CARDIOCIRCULATORY DEATH KIDNEY
Lan Zhu – Wuhan, China
18:00 REAL-LIFE ASSESSMENT OF NON-INVASIVE MOLECULAR BIOMARKERS

FOR PREDICTING CLINICAL AND SUBCLINICAL HISTOLOGICAL LESIONS
IN KIDNEY TRANSPLANT RECIPIENTS
Joana Sellares – Barcelona, Spain
18:06 INHIBITION OF MTOR PATHWAY PREVENTS MISSING SELF-INDUCED NK

CELLS-MEDIATED REJECTION
18:12 THE INFLUENCE OF MYCOPHENOLATE MOFETIL ON TOP OF

TACROLIMUS ON BLOOD PRESSURE IN A RANDOMIZED COHORT OF
KIDNEY TRANSPLANT RECIPIENTS.
Zainab Al Fatly – Rotterdam, The Netherlands
18:18 A COMPREHENSIVE MONITORING OF MEDICATION ADHERENCE OVER

THE FIRST TWO YEARS AFTER RENAL TRANSPLANTATION - A
PROSPECTIVE, NON-INTERVENTIONAL STUDY.
Frederik Haupenthal – Vienna, Austria
DARE TO ASK
17:00 - 18:30 When the tension gets too intense- ethical and clinical challenges in the ICU
Mitropoulos in donation and transplantation.
Chairs: Željka Gavranović - Zagreb, Croatia
Eduardo Sousa - Coimbra Portugal
The aim of this session is to go in-depth into the role of ICU professionals in organ
donation. Major ethical and clinical challenges in the ICU context will be treated,
including their role in brain death donors DBD, Donors after cardiac death DCD,
pediatric DCD donors and donations included in end-of-life care ICOD. Thus it will
cover both ICU, donation and pediatric aspects. The session will point out the need
to bring the multi-professional team to the table to widen the perspective on
realistic care. DCD in the context of end-of-life care, with an emphasis on potential
perspectives/attitudes of HCP and families about decision-making
Update 04|08|2023 52
15:00 Introduction
Željka Gavranović Zagreb, Croatia; Eduardo Sousa – Coimbra, Portugal
15:05 Implementation of intensive care oriented to organ donation

Sara Alcántara Carmona – Madrid, Spain
15:20 Role and perceptions of ICU professionals on DCD

Matthieu Le Dorze – Paris, France
15:35 Paediatric perspective on DCD

Janet Mattsson – Stockholm, Sweden
15:50 Maximization of deceased donor detection in ICU through innovative digital tools
Marco Sacchi – Milan, Italy
16:05 Discussion Panel
FULL ORAL
17:00 - 18:30 Pediatric Transplantation around the world

Library Chairs: Silvio Nadalin – Tübingen, Germany
17:00 BELATACEPT OUTCOMES IN PEDIATRIC KIDNEY TRANSPLANTATION: AN

INTERNATIONAL MULTICENTER STUDY
Julien Hogan – Paris, France
17:10 LONGITUDINAL DYNAMICS OF SOLUBLE IMMUNE MEDIATORS IN

PAEDIATRIC LIVER TRANSPLANTATION IDENTIFIED SIGNATURES
ASSOCIATED WITH A FREEDOM OF REJECTION
Evgeny Chichelnitskiy – Hannover, Germany
17:20 MOLECULAR HLA MISMATCHING FOR PREDICTION OF PRIMARY

HUMORAL ALLOIMMUNITY AND GRAFT FUNCTION DETERIORATION IN
PAEDIATRIC KIDNEY TRANSPLANTATION.
Jon Jin Kim – Nottingham, United Kingdom
17:30 CAN HOPE MITIGATE ISCHEMIA-REPERFUSION INJURY IN EX-SITU SPLIT

GRAFTS? A COMPARATIVE STUDY WITH LIVING DONATION IN PEDIATRIC
LIVER TRANSPLANTATION
Guillaume Rossignol – Lyon, France
17:40 ‘UNIQUE’ STUDY - A 20 YEAR UK NATIONAL STUDY ON CLINICAL

OUTCOMES AND QUALITY OF LIFE IN CHILDREN WITH MULTI-ORGAN
TRANSPLANTS
Alicia Paessler – London, United Kingdom
Update 04|08|2023 53
17:50 MONITORING OF TORQUE-TENO VIRUS LOADS IN PEDIATRIC KIDNEY

TRANSPLANT RECIPIENTS MAY PREDICT OPPORTUNISTIC VIRAL
INFECTIONS DURING FOLLOW-UP
Fabian Eibensteiner – Vienna, Austria
18:00 NATIONAL LIVER ALLOCATION POLICIES FOR PEDIATRIC LIVER

TRANSPLANTATION ACHIEVE OPTIMAL OUTCOMES: INTENTION-TO-
TREAT ANALYSIS OF ITALIAN WAITING LIST
Silvia Trapani – Rome, Italy
18:10 PEDIATRIC KIDNEY TRANSPLANT PROGRAM IN WAR CONDITIONS

Oleg Godik – Kyiv, Ukraine
STORYTELLING
17:00 - 18:30 Patient storytelling

Conference Suite 1 Chairs: John Boletis – Athens, Greece
This session will give the stage to organ recipients (lung, heart, kidney and live) to
tell their stories. A panel discussion with members of the medical profession will
follow including a surgeon, specialist nurse, social worker and psychologist.
15:00 Introduction
John Boletis – Athens, Greece
15:05 My transplant life journey

Guðmundur Felix Grétarsson – Lyon, France
15:20 Dealing with unknown

TBC
15:35 Getting my life back

Pisana Ferrari – Udine, Italy
15:50 What it meant to save lives

Lisa Wilson – Hornchurch, United Kingdom
16:05 Panel discussion on patient experience, with moderator

Jacqui Thornton – Winchester, United Kingdom
BRIEF ORAL
Update 04|08|2023 54
17:00 - 18:30 Contemporary heart transplantation: scores, pumps, cells and much more
MC 3.2 Chairs: Marco Masetti – Bologna, Italy
17:00 IMAGING AND FUNCTIONAL EVALUATION OF THE EFFECT OF

TRANSPLANTATION OF MESENCHYMAL STEM CELLS IN EXPERIMENTAL
MODEL OF MYOCARDIAL INFARCTION.
Antonella Koutela – Athens, Greece
17:06 TRANSPLANTING PATIENTS WITH AMYLOIDOTIC CARDIOMYOPATHY: A

DREAM FOR FEW
Alessio Aloisio - Bologna Italy
17:12 THE FIRST IMPLANT OF A BIOARTIFICIAL TOTAL ARTIFICIAL HEART

IMPLANTATION IN A PATIENT WITH SEVERE PULMONARY
HYPERTENSION.
Lucrezia Palmieri – Naples, Italy
17:18 MULTIDRUG-RESISTANT ORGANISMS IN CRITICAL CARE AND 30-DAY

OUTCOMES OF HEART TRANSPLANT PATIENTS
Sophia Hatzianastasiou – Athens, Greece
17:24 OUTCOME OF HEART TRANSPLANT BRIDGED WITH VENO-ARTERIAL

EXTRACORPOREAL MEMBRANE OXYGENATION: A SINGLE CENTER
EXPERIENCE
Giacomo Ruzzenenti – Milan, Italy
17:30 HEART TRANSPLANT AFTER VENO-ARTERIAL EXTRACORPOREAL

MEMBRANE OXYGENATION SUPPORT: MID-TO LONG TERM OUTCOMES
FROM A THREE-CENTERS REGISTRY
Alessandra Francica – Verona, Italy
17:36 HEART TRANSPLANT SURVIVAL OUTCOMES: ROLE OF DONOR-

TRANSMITTED ATHEROSCLEROSIS
Stepan Sakhovskiy – Moscow, Russian Federation
17:42 POST-OPERATIVE INFECTIONS AND KIDNEY DYSFUNCTION IN HEART

TRANSPLANT RECIPIENTS: A DEADLY BOND
Maria Francesca Scuppa – Bologna, Italy
17:48 VALIDATION OF THE CLINICAL UTILITY OF MICRORNA AS NON-INVASIVE

BIOMARKERS OF CARDIAC REJECTION: A PROSPECTIVE LONGITUDINAL
MULTICENTER STUDY.
Guillaume Coutance – Paris, France
17:54 THE DIAGNOSTIC VALUE OF MIR-339 FOR CORONARY STENOSIS OF

CARDIAC ALLOGRAFT
Sofya Sharapchenko – Moscow, Russian Federation
18:00 THE IMPACT OF EXERCISE TRAININGS ON PHYSICAL CAPACITY AND

QUALITY OF LIFE AFTER HEART TRANSPLANTATION
Maria Simonenko - Saint-Petersburg, Russian Federation
Update 04|08|2023 55
18:06 MICRORNA-101 PLASMA LEVEL: DIAGNOSTIC AND PROGNOSTIC VALUE

FOR CARDIAC GRAFT ACUTE CELLULAR REJECTION
Sofya Sharapchenko – Moscow, Russian Federation
18:12 DEVELOPMENT AND VALIDATION OF SPECIFIC POST-TRANSPLANT RISK

SCORES ACCORDING TO THE TRANSPLANT ERA: A UNOS COHORT
ANALYSIS.
18:18 GRAFT REMODELING AFTER THORACIC TRANSPLANTATION: MIR-339

AND GALECTIN-3 IN THE DIAGNOSIS OF STRUCTURAL CHANGES
Sofya Sharapchenko - Moscow, Russian Federation
FOCUS GROUP
17:00 - 18:30 Access to transplantation & donation: is luck involved?

MC 3.4 Chairs: Fabienne Dobbels – Leuven, Belgium
17:00 THE KIDNEY DISTRIBUTION SYSTEM FOR TRANSPLANTATION IN CHILE

EXPLAINED ACCORDING TO GAME THEORY: HOW THEORETICAL
GENEROSITY TRANSFORMS INTO SELFISHNESS
17:10 IMPROVING THE ACCESS TO HEART TRANSPLANTATION FOR FOREIGN

PATIENTS OVER 10 YEAR PERIOD
Giada Giovannelli – Bologna, Italy
17:20 APOL1 GENETIC RISK FACTORS ELIMINATES POTENTIAL LIVING KIDNEY

DONORS
Bruce Gelb - New York, United States
17:30 GENDER DISPARITY TO ACCESS TO KIDNEY TRANSPLANTATION IN

TURKEY: 10-YEARS EVALUATION
Yaprak Sarıgöl Ordin - Izmir Turkey
17:40 LOW FEMALE ACCESS TO KIDNEY TRANSPLANTATION AND POST-

TRANSPLANT PREGNANCY
Patrizia Silvestri – Rome, Italy
17:50 EXCELLENCE IN ORGAN TRANSPLANTATION – A QUALITATIVE STUDY OF

GENDER SPECIFIC CARE NEEDS IN TRANSPLANTATION
Claire Williment – London, United Kingdom
Update 04|08|2023 56
18:00 LANGUAGE BARRIER AND LUNG TRANSPLANTATION: A DIFFICULT-TO-

TREAT CASE
Marco Valente – Bologna, Italy
18:10THE THE GRAPHIC NOVEL “THE NEW US” TO SUPPORT DOCTOR-PATIENTS

RELATIONSHIP IN TRANSPLANT PATIENT CARE-PATHWAY
Enrica Baraldi - Parma, Italy
HANDS-ON COURSE
17:00 - 18:30 Machine Perfusion in my hands: Virtual and interactive LIVER (Group 2)
Hands on course
tutors, participants will follow the steps of liver perfusion. Participants will rotate
around the machines/stations every 15 minutes.
Additional registration for this session is required. Please register via

the Congress website
17:00 LifePort Liver Transporter - Organ Recovery Systems


17:30 Metra - OrganOx

David Nasralla – London, United Kingdom
17:45 EBERS
Thamara Perera – Birmingham, United Kingdom
18:00 Aferetica
Daniele Dondossola - Milan, Italy
18:15 Liver Assist - Xvivo

Update 04|08|2023 57
Tuesday, 19. September 2023
FULL ORAL
Tuesday, 19 September 2023
08:00 - 09:30 Kidney immunology and HLA mismatch analysis

Lambrakis Chairs: Sebastiaan Heidt – Leiden, The Netherlands
08:00 ASSOCIATION OF PIRCHE-II SCORES WITH KIDNEY ALLOGRAFT

ANTIBODY-MEDIATED REJECTION: A POPULATION-BASED STUDY
08:10 NON-HLA RECIPIENT GENOTYPES ASSOCIATE WITH INCREASED RISK OF

ANTIBODY-MEDIATED KIDNEY GRAFT REJECTION
Sophie Limou – Nantes, France
08:20 IMPACT OF HLA EVOLUTIONARY DIVERGENCE AND EPLET MISMATCHES

ON KIDNEY ALLOGRAFT REJECTION AND OUTCOME: A POPULATION-
BASED STUDY
08:30 ALLOIMMUNE RISK STRATIFICATION IN KIDNEY TRANSPLANTATION -

DEVELOPMENT AND VALIDATION OF A NOVEL HLA MOLECULAR
MISMATCH ALGORITHM
Hannah Charlotte Copley – Cambridge, United Kingdom
08:40 NON-A1/NON-A1B TO B BLOOD GROUP DECEASED DONOR KIDNEY

TRANSPLANT: A LARGE AND SUCCESSFUL SINGLE CENTER EXPERIENCE
Hasan Khamash – Phoenix, United States
08:50 ANTI-HLA I IGG FC AGALACTOSYLATION DRIVES DIRECT ENDOTHELIAL

CELL ACTIVATION VIA IFNΑ PATHWAY
Anaïs BEYZE – Montpellier, France
09:00 MULTIPARAMETER MASS SPECTROMETRY DECIPHERS SPECIFIC

CIRCULATING NATURAL KILLER TCELL SUBSETS PROTECTING KIDNEY
TRANSPLANT PATIENTS FROM CMV INFECTION
Laura Donadeu – Barcelona, Spain
09:10 SPATIAL PROFILING OF THE KIDNEY ALLOGRAFT UNRAVELS A CENTRAL

ROLE OF FCYRIII+ INNATE IMMUNE CELLS IN REJECTION
Baptiste Lamarthée – Leuven, Belgium
Update 04|08|2023 58
FULL ORAL
08:00 - 09:30 Transplant Plus: Regenerative therapies and Xenotransplantation

Trianti Chairs: Nuria Montserrat – Barcelona, Spain
08:00 AUTOMATED DETECTION AND QUANTIFICATION OF IMMUNE CELL

INFILTRATES IN THE TWO FIRST SUCCESSFUL PIG-TO-HUMAN KIDNEY
XENOTRANSPLANTS
Erwan Morgand – Paris, France
08:10 MULTIMODAL DEEP PHENOTYPING OF GENETICALLY MODIFIED PIG

KIDNEY XENOGRAFTS TRANSPLANTED TO HUMAN RECIPIENTS REVEALS
ANTIBODY-MEDIATED REJECTION
08:20 HYDROGEL-BASED, PREVASCULARIZED, RETRIEVABLE ENDOCRINE

CONSTRUCT TO TREAT TYPE 1 DIABETES
Fanny Lebreton – Geneva, Switzerland
08:30 BIOENGINEERING OF VASCULARIZED INSULIN-SECRETING ORGANOIDS

FOR TYPE 1 DIABETES CELL THERAPY
Laura Mar Fonseca – Geneva, Switzerland
08:40 EXTRAHEPATIC BILE DUCT ORGANOIDS AS A MODEL TO STUDY

ISCHEMIA/REPERFUSION INJURY DURING LIVER TRANSPLANTATION
Henrik Junger – Regensburg, Germany
08:50 GENERATION OF ‘UNIVERSAL’ LOW-IMMUNOGENIC HUMAN PRIMARY

CHOLANGIOCYTE ORGANOIDS FOR TREATMENT OF BILE DUCT
DISORDERS
Sandra Petrus-Reurer – Cambridge, United Kingdom
09:00 MODELING KIDNEY FIBROSIS AND EXPLORING THE ANTI-FIBROTIC

ACTIVITY OF MEMBRANE PARTICLES GENERATED FROM MESENCHYMAL
STROMAL CELLS IN KIDNEY ORGANOIDS
Shengbing Li – Rotterdam, The Netherlands
09:10 HLA-DQ EPLET MISMATCH LOAD MAY IDENTIFY KIDNEY TRANSPLANT

PATIENTS ELIGIBLE FOR TACROLIMUS WITHDRAWAL WITHOUT DSA
FORMATION AFTER MSC THERAPY
Suzanne Bezstarosti – Leiden, The Netherlands
FOCUS GROUP
Update 04|08|2023 59
08:00 - 09:30 Oncology - it's time for wider access

Banquet Hall
Chairs: Umberto Cillo – Padua, Italy
Pal-Dag Line – Asker, Norway
08:00 ONCOLOGIC RESULTS AFTER TEN YEARS OF SYSTEMATIC APPLICATION

OF LOCO REGIONAL THERAPIES FOR HEPATOCELLULAR CARCINOMA
Enrico Prosperi – Bologna, Italy
08:10 LAPAROSCOPIC ABLATION AND SALVAGE TRANSPLANTATION FOR

PATIENTS WITH HEPATOCELLULAR CARCINOMA
Nicola Canitano – Padua, Italy
08:20 THE CLOUDED ZONE BEHIND THE SELECTION PROCESS FOR LIVER
TRANSPLANTATION IN COLORECTAL LIVER METASTASES PATIENTS: A
PROSPECTIVE ANALYSIS
Alessandra Bertacco – Padua, Italy
08:30 LIVER TRANSPLANTATION FOR HCC BEYOND MILAN CRITERIA AFTER

DOWN-STAGING WITH STEREOTACTIC RADIOTHERAPY OR
TRANSARTERIAL RADIOEMBOLIZATION
Alberto Calleri – Turin, Italy
08:40 EVALUATION OF A DELAYED LIVER TRANSPLANT STRATEGY FOR

PATIENTS LISTED FOR HCC TREATED WITH RESECTION OR THERMO-
ABLATION AS A BRIDGE TO LT
Catherine Lamarque – Créteil, France
08:50 LIVER TRANSPLANTATION SURVIVAL BENEFIT OVER RESECTION FOR

COLORECTAL METASTASIS IN PATIENTS WITH HIGH TUMOR LOAD:
MULTICENTER RETROSPECTIVE ANALYSIS
Jacopo Lanari – Padua, Italy
09:00 VON WILLEBRAND FACTOR ANTIGEN ALLOWS IMPROVED DECISION

MAKING IN HCC PATIENTS SUBJECTED TO SURGICAL TREATMENT
OPTIONS
David Pereyra – Vienna, Austria
09:10 DE NOVO CANCERS AFTER LIVER TRANSPLANTATION: A FRENCH

NATIONWIDE COHORT.
Ilias Kounis – Paris, France
SOLUTION ROOM
08:00 - 09:30 Let’s talk about DCD hearts – rewriting the rules of donation?
Mitropoulos Chairs: Nichon Jansen – Leiden, The Netherlands
Arezu Aliabadi-Zuckermann – Vienna, Austria
Update 04|08|2023 60
This session will focus on how to set up a DCD heart donation program, the
different types of DCD heart preservation, ethical issues concerning death
declaration and the effect of DCD heart donation on lung donation.
08:00 Heart preservation in DCD donation. The UK experience.

Marius Berman – Cambridge, United Kingdom
08:15 How to setup a DCD heart donation program in The The Netherlands TA NRP or
direct procurement ?
Niels van der Kaaij – Utrecht, The Netherlands
08:30 Ethical issues in DCD heart donation when faced with NRP programs
Antonio Rubino – Cambridge, United Kingdom
08:45 The US View

Jordan Hoffman – Denver, United States
09:00 Discussion
FULL ORAL
08:00 - 09:30 Managing myself after transplantatin- a fulltime job

Skalkotas Chairs: Martijn van den Hoogen – Rotterdam, The Netherlands
08:00 SYMPTOM BURDEN IN KIDNEY TRANSPLANT RECIPIENTS: A CROSS-

SECTIONAL STUDY
Niels Riemersma – Groningen, The Netherlands
08:10 THE LONGITUDINAL DEVELOPMENT OF TRANSPLANT SPECIFIC WELL-

BEING AND PROMINENT SYMPTOMS FROM PRE-TRANSPLANT TO FIVE
YEARS AFTER HEART TRANSPLANTATION.
Marita Dalvindt – Lund, Sweden
08:20 QUANTITATIVE FINDINGS FROM THE COMPASSIONATE MINDFUL

RESILIENCE PROGRAMME IN ADULT PATIENTS WITH CHRONIC KIDNEY
DISEASE (THE COSMIC STUDY)
Anna Wilson – Belfast, United Kingdom
08:30 MEDITERRANEAN DIET AND METABOLIC SYNDROME: A DIETARY

INTERVENTION STUDY TO REDUCE METABOLIC SYNDROME RISK AFTER
HEART TRANSPLANTATION.
Sandro Sponga – Udine, Italy
08:40 THE EFFECT OF SYSTEMCHANGE™ ON MEDICATION ADHERENCE IN

KIDNEY TRANSPLANT RECIPIENTS: A RANDOMIZED CLINICAL TRIAL
Yaprak Sarıgöl Ordin – Izmir, Turkey
Update 04|08|2023 61
08:50 NURSE-LED SELF-MANAGEMENT SUPPORT AFTER ORGAN

TRANSPLANTATION – A MULTICENTER, MULTI-ORGAN STEPPED WEDGE
RANDOMIZED CONTROLLED TRIAL
09:00 A RANDOMIZED CONTROLLED STUDY OF TELEMONITORING IN KIDNEY

TRANSPLANT RECIPIENTS : INTERIM RESULTS OF THE AP’TX TRIAL
Christophe Mariat - St. Priest en Jercy, France
09:10 UPTAKE OF HOME-MONITORING AFTER KIDNEY TRANSPLANTATION: A

RETROSPECTIVE ANALYSIS
Bartu Hezer – Rotterdam, The Netherlands
BRIEF ORAL
08:00 - 09:30 Transplantation outcomes and complications

MC 3 Chairs: Marina Berenguer – Valencia, Spain
Giacomo Germani – Padua, Italy
08:00 SPLIT-LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING

CHOLANGITIS IS ASSOCIATED WITH REDUCED GRAFT SURVIVAL DUE TO
HEPATIC ARTERY THROMBOSIS
Daniel Cox – Melbourne, Australia
08:06 IDENTIFICATION OF NOVEL LIVER TRANSPLANT BIOPSIES PHENOTYPES

ASSOCIATED WITH DISTINCT BIOLOGICAL PROFILES AND ALLOGRAFT
SURVIVAL
08:12 MACHINE PERFUSION TECHNIQUES FOR LIVER TRANSPLANTATION - A

META-ANALYSIS OF THE FIRST SEVEN RANDOMIZED CONTROLLED
TRIALS
Janina Eden – Zürich, Switzerland
08:18 ABSORBABLE SELF-EXPANDABLE BILIARY STENT AS APREVENTIVE

TREATMENT OF BILIARY COMPLICATIONS IN LIVER TRANSPLANT
Victor López-López – Murcia, Spain
08:24 THE ITALIAN EXPERIENCE ON LIVER TRANSPLANTATION FOR

UNRESECTABLE PERI-HILAR CHOLANGIOCARCINOMA: A NATIONAL
SURVEY AND FUTURE PERSPECTIVES
Alessandro Furlanetto – Padua, Italy
08:30 EARLY DIAGNOSIS OF LIVER GRAFT FIBROSIS AND STEATOSIS: ARE

NON-INVASIVE TESTS THE ANSWER?
Colin Dumont – Brussels, Belgium
08:36 IMPROVEMENT OF THE OUTCOMES OF LIVER TRANSPLANTATION AFTER

THE COVID-19 ERA: THE POSITIVE PROACTIVE EFFECT OF SARS-COV-2
Marco Pascale – Rome, Italy
Update 04|08|2023 62
08:42 RADIOLOGICAL CLASSIFICATION OF ISCHEMIC CHOLANGIOPATHY AFTER

DECEASED-DONOR LIVER TRANSPLANTATION
Midas van den Tweel – Rotterdam, The Netherlands
08:48 ADD-ON CONTRAST-ENHANCED US WITH DOPPLER US ON POD#1 CAN

REDUCE FALSE POSITIVES OF VASCULAR COMPLICATION AFTER LIVER
TRANSPLANTATION
Woo Kyoung Jeong - Seoul, Republic of South Korea
08:54 SURVIVAL OUTCOMES OF SALVAGE VS PRIMARY LIVER

TRANSPLANTATION FOR EARLY-STAGE HEPATOCELLULAR CANCERS:
SYSTEMATIC REVIEW AND META-ANALYSIS
Ahmed E Sherif – Edinburgh, United Kingdom
09:00 LIVER TRANSPLANTATION VERSUS LIVER RESECTION AND

HEPATOCELLULAR CARCINOMA: A SURVIVAL META-ANALYSIS OF META-
ANALYSIS
Francesca Cardella – Naples, Italy
09:06 SALVAGE LIVER TRANSPLANTATION FOLLOWING RESECTION OF

COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
Enrico Prosperi – Bologna, Italy
09:12 SAFETY AND EFFICACY OF GLP1-RAS AND ISGLT-2- COMPARED WITH

THE STANDARD OF CARE IN A COHORT OF LIVER TRANSPLANTED
PATIENTS: A RETROSPECTIVE STUDY
Aida Rebiha – Paris, France
09:18 MODIFYING TACROLIMUS RELATED TOXICITY AFTER LIVER

TRANSPLANTATION COMPARING ENVARSUS® AND ADVAGRAF®: A
MULTICENTER RANDOMIZED, CONTROLLED TRIAL
Midas Mulder – Rotterdam, The Netherlands
BRIEF ORAL
08:00 - 09:30 Innovations in surgical techniques

MC 2 Chairs: Hannah Maple – London, United Kingdom
Raj Prasad - Leeds, United Kingdom
08:00 TRANSITION FROM OPEN- TO ROBOT-ASSISTED DONOR RIGHT

HEPATECTOMY PROGRAM FOR ADULT TO ADULT LIVING LIVER
DONATION: EARLY OUTCOMES AND LESSONS LEARNED
Michele Finotti – Padua, Italy
08:06 REFINING AUXILIARY PARTIAL ORTHOTOPIC LIVER TRANSPLANTATION

(APOLT) FOR ACUTE LIVER FAILURE IN 48 ADULT PATIENTS
Riccardo Pravisani – Udine, Italy
Update 04|08|2023 63
08:12 ROBOTIC KIDNEY TRANSPLANTATION : A SINGLE INSTITUTIONAL

EXPERIENCE
Hyun-jeong Kim - Seoul, Republic of South Korea
08:18 IPSILATERAL SIMULTANEOUS NEPHRECTOMY WITH URETERO-

URETERAL ANASTOMOSIS IN KIDNEY TRANSPLANTATION FOR
POLYCYSTIC KIDNEY DISEASE
Silvio Nadalin – Tübingen, Germany
08:24 LAPDOCTOR: TELL ME HOW DIFFICULT WILL BE MY

DONOR. MULTICENTRIC VADITATION OF A NEW SCORING SYSTEM THAT
ANTICIPATES DIFFICULTY OF LDN.
Gionata Spagnoletti – Rome, Italy
08:30 HAND ASSISTED RETROPERITONEOSCOPIC DONOR NEPHRECTOMY

(HARP-DN); LESSONS LEARNED FROM 1001 CASES
Emin Baris Akin – Istanbul, Turkey
08:36 MINIMALLY INVASIVE APPROACH FOR RAPID LIVER TRANSPLANTATION:

ARE WE READY FOR PRIME TIME? EXPERIENCE WITH LAPAROSCOPIC
SECOND STEP APPROACH.
Alessandra Bertacco – Padua, Italy
08:42 FULL-LEFT/FULL-RIGHT LIVER SPLITTING WITH MIDDLE HEPATIC VEIN

AND CAVAL PARTITION DURING DUAL HYPOTHERMIC OXYGENATED
MACHINE PERFUSION
Alessandro Furlanetto – Padua, Italy
08:48 CLAMSHELL VERSUS BILATERAL ANTEROLATERAL THORACOTOMY FOR

DOUBLE LUNG TRANSPLANTATION: IMPACT ONFUNCTIONAL AND
CLINICAL OUTCOMES
Alessandro Palleschi – Milan, Italy
08:54 A SINGLE CELL AND SPATIAL TRANSCRIPTOMICS APPROACH TO

ELUCIDATING CD8 T CELLS IN VASCULARIZED COMPOSITE
ALLOTRANSPLANTATION REJECTION
09:00 HAND TRANSPLANTATION AT A TERTIARY CARE CENTRE IN INDIA

George Kurian – Kochi, India
09:06 DISCORDANT HISTOLOGICAL FINDINGS DURING ACUTE REJECTION IN A

COMBINED FACE AND HAND TRANSPLANT RECIPIENT
09:12 DEVELOPMENT OF A SHARED DECISION MAKING CONVERSATION AID

FOR VCA
Sheila Jowsey-Gregoire – Rochester, United States
09:18 MULTI-LEVEL ANALYSIS OF THE NEOVASCULARIZATION AND

INTEGRATION PROCESS OF A NON-VASCULARIZED RECTUS FASCIA
FOLLOWING INTESTINAL TRANSPLANTATION
Laurens J. Ceulemans – Leuven, Belgium
Update 04|08|2023 64
SOLUTION ROOM
08:00 - 09:30 Health democracy in organ transplantation

Library Chairs: George Papatheodoridis – Athens, Greece
The session will explore the concept of shared decision-making (SDM) from a
range of perspectives, engaging with misconceptions and assumptions about the
role of SDM in donation and transplantation. Participants will learn about potential
barriers - both real and imagined- to meaningful SDM and discuss examples of
effective strategies to address common barriers. Following three talks featuring
patient, clinician and organizational perspectives, a multidisciplinary panel will
draw on their personal and professional experiences to discuss the culture(s) of
SDM in a range of settings.
08:00 Introduction
08:06 How can patients shape delivery of transplantation?

08:24 Implementing patient centricity in clinics

Caroline Whitworth – Edinburgh, United Kingdom
08:42 Going patient-centric in clinical trial design and endpoints (early involvement of
patients)
Aimee Sundberg – Lexington, United States
09:00 Discussion Panel with audience

Keren Ladin – Boston, United States; Georgios Tsoulfas - Thessaloniki, Greece
FISHBOWL
08:00 - 09:30 Orchestrating clinical translation of regenerative therapies

Conference Suite 1 Chairs: Patrizia Burra – Padua, Italy
John Forsythe – Bristol, United Kingdom
The transition from pre-clinical to clinical studies is a unique process that is

impacted by the developed therapy product and the complexity of the
manufacturing process. This session will discuss the potential challenges and tips
for preparing a smooth translation of RM product.
08:00 Introduction
Patrizia Burra - Padua, Italy; John Forsythe - Bristol United Kingdom
08:10 The scientist’s view

Ying Kai Chan – Boston, United States
Update 04|08|2023 65
08:25 The clinician’s view

Eelco de Koning – Leiden, The Netherlands
08:40 The commercial view

Panos Kefalas – London, United Kingdom
08:55 The patient view

Liz Schick – Bern, Switzerland

Patrizia Burra - Padua, Italy; John Forsythe - Bristol United Kingdom
FOCUS GROUP
08:00 - 09:30 Biomarkers and monitoring kidney health

MC 3.2 Chairs: Asimina Fylaktou – Thessaloniki, Greece
Claire Tinel – Paris, France
08:00 EVOLUTION OF DDCFDNA DURING THE FIRST WEEK AFTER SURGERY

PREDICTS MEDIUM TO LONG-TERM RENAL OUTCOMES
David Cucchiari – Barcelona, Spain
08:10 MAGNETIC RESONANCE IMAGING TEXTURE ANALYSIS TO ASSESS

GRAFT INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY IN PATIENTS
WITH TRANSPLANTED KIDNEYS
Francesco Fontana – Modena, Italy
08:20 VALIDATION OF THE INTERNATIONAL IGA NEPHROPATHY PREDICTION

TOOL IN KIDNEY TRANSPLANT RECIPIENTS WITH IGA NEPHROPATHY
RECURRENCE
Emilio Rodrigo – Santander, Spain
08:30 CORTICAL IRON DEPOSITION ASSESSED BY MAGNETIC RESONANCE

IMAGE IS ASSOCIATED WITH FIBROSIS
Anna Manonelles – Barcelona, Spain
08:40 INTRA-GRAFT TEMRA CD8+ T CELLS: AN INDEPENDENT PREDICTOR OF

KIDNEY ALLOGRAFT FAILURE INDEPENDENT OF REJECTION
CATEGORIES
08:50 LONGITUDINAL MONITORING OF TORQUE TENO VIRUS DNAEMIA IN

RENAL TRANSPLANT RECIPIENTS PREDICTS LONG-TERM
COMPLICATIONS OF INADEQUATE IMMUNOSUPPRESSION
Update 04|08|2023 66
09:00 TORQUE TENO VIRUS PLASMA CONCENTRATION TRENDS IN KIDNEY

TRANSPLANT RECIPIENTS BEFORE PATHOGENIC INFECTIONS AND
ALLOGRAFT REJECTION
Steve Kleiboeker - Lee's Summit, United States
09:10 TORQUE TENO VIRUS VIRAL LOAD PREDICTS SARS-COV-2 VACCINE

RESPONSE IN KIDNEY TRANSPLANT RECIPIENTS
Morgane Solis – Strasbourg, France
FOCUS GROUP
08:00 - 09:30 Insights on IRI and PGD in cardiothoracic transplantation

MC 3.4 Chairs: Irene Bello – Barcelona, Spain
Stephan Ensminger – Lübeck, Germany
08:00 POSITIVE LONG-TERM EFFECTS OF 17Β-ESTRADIOL AND

METHYLPREDNISOLONE ASSOCIATION ON LUNG INFLAMMATION
TRIGGERED BY BRAIN DEATH IN FEMALE RATS
Marina Vidal-dos-Santos - São Paulo, Brazil
08:10 MITOCHONDRIAL DAMAGE COMPARISON BETWEEN BRAIN DEATH

DONORS AND DONORS AFTER CIRCULATORY DEATH IN LUNG
TRANSPLANTATION: PROSPECTIVE MULTICENTER STUDY
Irene Bello – Barcelona, Spain
08:20 A NOVEL WHOLE-BODY COOLING SYSTEM PROTECTS DONOR LUNGS

FROM ISCHEMIA REPERFUSION INJURY:TARGETING UNCONTROLLED
DONATION AFTER CIRCULATORY DEATH DONORS
Hiromichi Niikawa – Sendai, Japan
08:30 NOT TOO WARM, NOT TOO COLD: REAL-WORLD MULTI-CENTER

OUTCOMES WITH ELEVATED HYPOTHERMIC PRESERVATION OF DONOR
LUNGS
John Haney – Durham, United States
08:40 SINGLE-CENTER SHORT TO INTERMEDIATE TERM OUTCOMES AFTER 100

DONOR HEART PROCUREMENTS WITH A NON-PERFUSING
HYPOTHERMIC STORAGE SYSTEM
Iuliana Coti – Vienna, Austria
08:50 CUSTODIOL-N VERSUS CUSTODIOL: RESULTS FROM A PROSPECTIVE

RANDOMISED SINGLE BLIND MULTICETNER PHASE III TRIAL IN PATIENTS
UNDERGOING HEART TRANSPLANTATION
09:00 EFFECTS OF TRIIODOTHYRONINE AND PRECONDITIONING ON EX VIVO

RAT HEARTS SUBJECTED TO NORMOTHERMIC PERFUSION.
IMPLICATIONS FOR DONOR HEART PRESERVATION
Iordanis Mourouzis – Athens, Greece
Update 04|08|2023 67
09:10 EARLY ECMO OVERCOMES PRIMARY GRAFT DYSFUNCTION AFTER

HEART TRANSPLANT.
ANGELIKI GKOUZIOUTA – Kallithea, Greece
TV-STUDIO
09:30 - 10:00 Spotlight on ESOT Congress 2025

Muses Foyer Chairs: Jacqui Thornton – Winchester, United Kingdom
Guest: Olivier Thaunat – Lyon, France
BRIEF ORAL
10:00 - 11:30 Management and selection of kidney transplant candidates

Lambrakis Chairs: Maria Darema – Athens, Greece
Umberto Maggiore – Parma, Italy
10:00 REPEAT HLA CLASS 2 MISMATCHES REMAIN ASSOCIATED WITH GRAFT

LOSS OF THE SECOND KIDNEY TRANSPLANT : A COLLABORATIVE
TRANSPLANT STUDY REGISTRY ANALYSIS
Lissa Pipeleers – Brussels, Belgium
10:06 SENSITIVE HLA ANTIBODY DETECTION AND THE RISK OF ANTIBODY-

MEDIATED REJECTION AND GRAFT FAILURE
Jasper Callemeyn - Korbeek-Lo, Belgium
10:12 DEVELOPMENT AND VALIDATION OF A MULTIDIMENSIONAL

PROGNOSTICATION SYSTEM FOR KIDNEY TRANSPLANT PATIENT
SURVIVAL: THE MORTALITY MBOX
Charlotte Debiais-Deschamps – Paris, France
10:18 OUTCOMES OF RENAL TRANSPLANTATION USING DONOR AFTER

CARDIOCIRCULATORY DEATH FOR HIGHLY SENSITIZED PATIENTS IN
SPANISH AND CATALAN PROGRAMS
Edoardo Melilli – Barcelona, Spain
10:24 DIETARY OXALIC ACID INTAKE AND PLASMA OXALIC ACID

CONCENTRATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Joke Roodnat – Rotterdam, The Netherlands
Update 04|08|2023 68
10:30 CIRCULATING TNF-Α LEVELS IN DECEASED DONORS ASSOCIATE WITH

POSTTRANSPLANT FUNCTION IN KIDNEY TRANSPLANTATION
Sarah Fawaz – Oxford, United Kingdom
10:36 UTILITY OF RAMP TEST TIME IN PATIENTS UNDERGOING ASSESSMENT

FOR RENAL TRANSPLANTATION
Rebecca Smith – London, United Kingdom
10:42 ASSOCIATION BETWEEN ABDOMINAL CT MEASUREMENTS OF BODY

COMPOSITION AND WAITLIST MORTALITY IN KIDNEY TRANSPLANT
CANDIDATES
Evelien Quint – Groningen, The Netherlands
10:48 EMPLOYMENT BEFORE, AT OR AFTER KIDNEY TRANSPLANTATION IN

DENMARK – A NATIONAL CASE-CONTROL STUDY
Rasmus Carlsen – Oslo, Norway
10:54 DOES TYPE OF DIALYSIS MODALITY INFLUENCE POST-

TRANSPLANTATION OUTCOMES? A POPULATION-COHORT ANALYSIS
USING REGISTRY DATA
Asra Karim – Birmingham, United Kingdom
11:00 CHARACTERISTICS OF PRE-TRANSPLANT HOSPITALIZATIONS ARE

ASSOCIATED WITH ELDERLY PATIENT SURVIVAL AFTER KIDNEY
TRANSPLANTATION
Renaud Snanoudj - Le Kremlin-Bicêtre, France
11:06 SARCOPENIA OF KIDNEY TRANSPLANT RECIPIENTS AS A PREDICTIVE

MARKER FOR REDUCED GRAFT FUNCTION AND GRAFT SURVIVAL AFTER
KIDNEY TRANSPLANTATION
Hristos Karakizlis – Giessen, Germany
11:12 EFFECTS OF SOCIAL DEPRIVATION ON REGISTRATION ON THE RENAL

TRANSPLANTATION WAITING-LIST THROUGH MARKERS OF
NEPHROLOGICAL CARE: A MEDIATION ANALYSIS.
Eve Calvar – Caen, France
11:18 THE PATIENT'S WISH IS A MAJOR REASON FOR REMOVAL FROM THE
EUROPEAN SENIOR PROGRAMME WAITING LIST
SOLUTION ROOM
10:00 - 11:30 Personalization starts before transplantation: choosing the best organ for
Trianti long-term success
Chairs: Carmen Lefaucheur – Paris, France
Maarten Naesens – Leuven, Belgium
Update 04|08|2023 69
In this session, we will discuss the recent advancements in the immunologic risk
stratification, as well as insights into the role of donor characteristics (e.g. Older
DCD kidneys), and how the immunological risks add to the organ quality risks. We
can also discuss which algorithms and tools exist to improve this risk stratification,
and how this could be implemented into realistic allocation systems, better than it
is done currently.
10:00 Optimising patient selection (risk stratification)

Sebastiaan Heidt – Voorburg, The Netherlands
10:20 Combining donor and recipient characteristics for optimal risk stratifications at the
time of transplantation in different solid organ transplantation
10:40 Survey on practices on dealing with highly sensitized patients

Lionel Rostaing – Grenoble, France
11:00 Engage 1, 2, 3
11:20 Discussion panel
BRIEF ORAL
10:00 - 11:30 Organ preservation and ischemia reperfusion

Banquet Hall Chairs: Amelia Hessheimer – Madrid, Spain
Diethard Monbaliu – Leuven, Belgium
10:00 REMOVAL OF CHROMATIN-ASSOCIATED-MOLECULAR-PATTERNS

(CAMPS) REDUCES EX-SITU REPERFUSION INJURY IN PORCINE DCD
LIVERS PRESERVED WITH NMP.
Fungai Dengu – Oxford, United Kingdom
10:06 IN SITU AND EX SITU DYNAMIC PRESERVATION VERSUS COLD STORAGE

IN LIVER TRANSPLANTATION FROM OLDER DONATION AFTER
CIRCULATORY DEATH DONORS
Ivo Schurink – Rotterdam, The Netherlands
10:12 MAXIMUM LIVER FUNCTION CAPACITY TEST (LIMAX) DURING ABDOMINAL

NORMOTHERMIC REGIONAL PERFUSION AS PREDICTOR OF GRAFT
FUNCTION AFTER TRANSPLANTATION
Femke de Goeij – Rotterdam, The Netherlands
10:18 MITOCHONDRIAL INTEGRITY AND FUNCTION PARTIALLY RECOVER

DURING LONG-TERM NORMOTHERMIC PERFUSION OF THE LIVER
Christina Bogensperger – Innsbruck, Austria
Update 04|08|2023 70
10:24 OUTCOMES OF LIVERS WITH PROLONGED DURATION OF EX SITU

NORMOTHERMIC PERFUSION: CAN LIVER TRANSPLANTATION BE A
DAYTIME ACTIVITY?
Harry Spiers – Cambridge, United Kingdom
10:30 GRAFT VIABILITY AND LIVER TRANSPLANT RECOVERY ASSESSMENT

USING INDOCYANINE GREEN CLEARANCE TEST: PRELIMINARY ANALYSIS
OF A PROSPECTIVE STUDY.
Gabriele Spoletini – Rome, Italy
10:36 OBSERVATIONS DURING IMPLEMENTATION OF AN EX-SITU

NORMOTHERMIC LIVER MACHINE PERFUSION PROGRAMME
10:42 MARKERS OF COAGULATION AND FIBRINOLYSIS DURING

NORMOTHERMIC LIVER PERFUSION MIGHT REFLECT ON VASCULAR
INTEGRITY AND PRESERVATION INJURY
Jule Dingfelder – Vienna, Austria
10:48 PILOT, RANDOMIZED TRIAL FOR THE COMPARISON OF HYPOTHERMIC

VERSUS NORMOTHERMIC EX-SITU LIVER PRESERVATION IN DCD LIVER
TRANSPLANTATION (DCDNET TRIAL)
10:54 NORMOTHERMIC MECHANICAL PERFUSION (NMP) REDUCES THE RISK

OF ISCHEMIC CHOLANGIOPATHY IN RECIPIENTS OF DCD LIVER
TRANSPLANTS
Kunam Reddy – Phoenix, United States
11:00 THE ROLE OF COLD ISCHEMIA TIME AND HYPOTHERMIC PERFUSION IN

PREDICTING EARLY HEPATOCELLULAR CARCINOMA RECURRENCES
AFTER LIVER TRANSPLANTATION
Gerti Dajti – Bologna, Italy
11:06 THE EFFECT OF CONTINUOUS LIVER NORMOTHERMIC MACHINE

PERFUSION ON THE SEVERITY OF HISTOLOGICAL BILE DUCT INJURY.
Nicholas Gilbo – Leuven, Belgium
11:12 THE IMPACT OF DONOR TIME TO DEATH AND FUNCTIONAL WARM

ISCHAEMIA TIME ON RECIPIENT OUTCOME FOLLOWING DCD LIVER
TRANSPLANTATION
Abdullah Malik - Newcastle upon Tyne, United Kingdom
11:18 HOPE REDUCES DURATION OF GLYCOCALYX SHEDDING – ITS DAMAGE

MARKER SYNDECAN-1 CAN PREDICT EARLY ALLOGRAFT DYSFUNCTION
Laurin Rauter – Vienna, Austria
FULL ORAL
10:00 - 11:30 Improving outcomes of end-stage heart failure: from MCS to the long-term
Update 04|08|2023 71
Mitropoulos Chairs: Cristiano Amarelli – Naples, Italy

Stephen Clark - Newcastle upon Tyne, United Kingdom
10:00 5-YEAR OUTCOME AFTER CONTINUOUS FLOW LVAD WITH FULL-

MAGNETIC VS HYBRID LEVITATION SYSTEM:RESULTS OF AN ALL-
COMERS MULTICENTER REGISTRY
Alessandra Francica – Verona, Italy
10:10 IMPACT OF THE 2018 FRENCH ALLOCATION SCHEME ON THE PROFILE

OF HEART TRANSPLANTATION CANDIDATES AND RECIPIENTS: INSIGHTS
FROM A HIGH-VOLUME CENTER.
10:20 RESULTS FROM OVER 800 TRANSPLANT RECIPIENTS ENROLLED IN THE

GUARDIAN-HEART REGISTRY: CHALLENGING THE STANDARD OF CARE
10:30 HEART TRANSPLANTATION FROM CONTROLLED DONATION AFTER THE

CIRCULATORY DETERMINATION OF DEATH: OUR EXPERIENCE.
María del Mar Martín Magán - El Palmar, Spain
10:40 MOLECULAR DIAGNOSTIC CLASSIFICATION OF HEART ALLOGRAFT

REJECTION BASED ON THE TARGETED BANFF HUMAN ORGAN
TRANSPLANT GENE EXPRESSION PANEL
10:50 BANFF HUMAN ORGAN TRANSPLANT CONSENSUS GENE PANEL FOR

DETECTING ANTIBODY MEDIATED REJECTION IN HEART ALLOGRAFT
BIOPSIES
11:00 PREGNANCY AFTER HEART TRANSPLANT

Lisa Coscia – Philadelphia, United States
11:10 LONG-TERM OUTCOMES OF COMPLEMENT INHIBITION FOR PREVENTION

OF ANTIBODY-MEDIATED REJECTION IN IMMUNOLOGICALLY HIGH-RISK
HEART TRANSPLANTATION
SOLUTION ROOM
10:00 - 11:30 What if HCP listen to patients? Non-adherence after transplantation
Skalkotas Chairs: Anna Brantmark – Gothenburg, Sweden
Keren Ladin – Boston, United States
Various aspects of non-adherence will be discussed from the perspectives of

health care professionals and more importantly patients. This session will
challenge the conventional thinking around this topic and suggest a more person-
focused approach to addressing this issue. It will address the link between health
care beliefs and adherence and also how the side effect burden affects this
Update 04|08|2023 72
issue. The session will end with a brainstorming segment with patients, panel
members and the audience looking for solutions to this complex issue
10:00 The realities of post-transplant medication - the patient perspective

Emma Dalman – Stockholm, Sweden
10:10 Clinicians’ approach to fixing the problem

Janette Ribaut – Basel, Switzerland
10:20 The impact of health care beliefs on adherence

Rob Horne – London, United Kingdom
10:40 How strong is the link between symptom burden and adherence
11:00 Panel Discussion and debate with the audience - the way forward
Anna Brantmark - Gothenburg, Sweden; Emma Dalman - Stockholm, Sweden;
Anna Forsberg - Lund Sweden; Rob Horne - London, United Kingdom; Keren Ladin
- Boston, United States
BRIEF ORAL
10:00 - 11:30 Translational transplant immunology

MC 3 Chairs: Marta Crespo – Barcelona, Spain
Thomas Resch – Innsbruck, Austria
10:00 CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THYMIC

FUNCTION AT THE TIME OF KIDNEY TRANSPLANTATION.
Ioannis Katerinis – Paris, France
10:06 DOES RECEPTOR-MEDIATED INTERNALISATION OF HYALURONAN (HA)

MATRIX IN THE RENAL CORTEX EXPLAIN THE PROTECTION CONFERRED
BY ISCHAEMIC PRE-CONDITIONING?
Aeliya Zaidi – Cardiff, United Kingdom
10:12 DIFFERENTIAL KINETICS OF HLA CLASS II ANTIGENS EXPRESSION ON

PRIMARY HUMAN GLOMERULAR ENDOTHELIAL CELLS
Maria Meneghini – Barcelona, Spain
10:18 A PRO-INFLAMMATORY IMMUNE STATE IS INFLUENCED BY

PERTURBATIONS OF MICROBIAL METABOLITES IN RENAL
TRANSPLANTATION
Fernando Yuen Chang – London, United Kingdom
10:24 UNREPRESENTED HUMAN LEUKOCYTE ANTIGEN ALLELES ON SINGLE

ANTIGEN BEAD ASSAYS: A COMPARISON AMONGST DIFFERENT TEST
KITS
Shan-Yeu Carolyn Tien – Singapore, Singapore
Update 04|08|2023 73
10:30 EVALUATION OF METHODS FOR THE TISSUE-OF-ORIGIN

DECONVOLUTION OF PLASMA AND URINARY CELL-FREE DNA IN
ALLOGRAFT RECIPIENTS AND HEALTHY VOLUNTEERS
Nicholas Kueng – Bern, Switzerland
10:36 HUMAN REGULATORY B CELLS PREVENT EFFECTOR CD4+CD25- T CELL

PROLIFERATION THROUGH A MECHANISM DEPENDENT FROM
GRANZYME B AND LYMPHOTOXIN ALPHA.
Nicolas Sailliet – Nantes, France
10:42 THE INFLUENCE OF VIRUS-SPECIFIC IMMUNOGLOBULINES AS

MODULATORS OF ANTIGEN-SPECIFIC T-CELL EXPANSION
Amina Abu-Omar – Homburg, Germany
10:48 GAMMA-DELTA T CELL THERAPY FOR POST-TRANSPLANT

CYTOMEGALOVIRUS INFECTION: PROOF OF CONCEPT
Lionel Couzi – Bordeaux, France
10:54 THE DISTINCT INNATE IMMUNE RESPONSE OF DONATION AFTER

CIRCULATORY DEATH LIVERS DURING NORMOTHERMIC MACHINE
PERFUSION
Joris Blondeel – Leuven, Belgium
11:00 EX SITU PORCINE LIVER MACHINE PERFUSION ACTIVATES THE

COMPLEMENT SYSTEM AND INCREASES CYTOKINES INDEPENDENT OF
PRE-INDUCED LIVER INJURY
Ida Færden – Oslo, Norway
11:06 TETRAHYDRO-BENZOTHIOPHENE ROR GAMMA T INVERSE AGONISTS TO

TARGET TH17 IN SENSITIZED SKIN ALLOGRAFT MOUSE MODEL
Ahmed Fouda - Montreal Canada
11:12 CD8+CD3- CELLS ARE CRITICAL FOR TREG MEDIATED HUMORAL

TOLERANCE
Romy Steiner – Vienna, Austria
11:18 RESEARCH FOR NOVEL MECHANISM OF IMMUNOSUPPRESSION

THROUGH PD-1/PD-L1 PATHWAY
Sunghyo An - Seoul, Republic of South Korea
FOCUS GROUP
10:00 - 11:30 Digital Health for personalised care

MC 2 Chairs: Klemens Budde – Berlin, Germany
Update 04|08|2023 74
10:00 DEVELOPMENT AND VALIDATION OF ANTIBODY-MEDIATED REJECTION

PREDICTION MODEL ON AUGMENTED DATA USING GENERATIVE MODEL
IN KIDNEY TRANSPLANT PATIENTS
Daniel Yoo – Paris, France
10:10 DEEP LEARNING MODELS OF REAL-TIME NON-INVASIVE IMAGING

DURING WARM PERFUSION OF EXPANDED CRITERIA DONOR KIDNEYS
POTENTIALLY PREDICT ACUTE REJECTION
Iacopo Cristoferi – Rotterdam, The Netherlands
10:20 PANCREATIC STEATOSIS AND TRANSPLANT SUITABILITY ASSESSMENT

WITH IMAGE BASED MACHINE LEARNING MODELS
Georgios Kourounis - Newcastle upon Tyne, United Kingdom
10:30 THE IMPACT OF DEATH IN PREDICTING KIDNEY-ALLOGRAFT FAILURE: A

COMPETING RISK ANALYSIS STUDY (NCT03474003)
Agathe Truchot – Paris, France
10:40 PREDICTORS OF OUTCOMES OF DCD VERSUS DBD KIDNEY

TRANSPLANTATION FROM SUPRA MARGINAL DONORS ( D4). A MACHINE
LEARNING ANALYSIS OF NHSBT REGISTRY DATA
Sanjay Mehra – Liverpool, United Kingdom
10:50 MEASUREMENT FREQUENCY OF BLOOD PRESSURE IN NEWLY KIDNEY

TRANSPLANTED PATIENTS DROPS OVER TIME IN REGULAR
TELEMEDICINE SURVEILLANCE
Verena Graf – Berlin, Germany
11:00 EXPECTATIONS, CONCERNS, AND WILLINGNESS TOWARD THE USE OF

MHEALTH TOOLS IN LIVER AND KIDNEY TRANSPLANT RECIPIENTS: A
PILOT SURVEY STUDY.
Justyna Gołębiewska – Gdańsk, Poland
11:10 BLOOD PRESSURE MEASUREMENTS IN A REGULAR TELEMEDICINE

SERVICE AFTER RENAL TRANSPLANTATION IN DIFFERENT AGE GROUPS
Matthias Pfefferkorn – Berlin, Germany
SOLUTION ROOM
10:00 - 11:30 Let’s talk about transition: can we ever get it right?
Library Chairs: Jelena Stojanovic – London, United Kingdom
Stella Stabouli – Thessaloniki, Greece
Based on ESOT 2021 delegate feedback that more discussions are needed on
transition, this session addresses systems where the transition process is poor
flagging its challenges, followed by a summary of a very successful transition
Update 04|08|2023 75
programme. Session is opened by a patient who had heart and kidney transplant
as a child and shares her experiences on good and bad transition process and
effects it had on her lives. We expand on the role of MDT in transition and close
the session with an open discussion between delegates and panellists on future
collaborations on guideline setting.
10:00 Patient story- off to a flying start

Cecilia Adamou - Cobham, United Kingdom
10:10 Challenges in setting up a transition programme

Fernanda Ortiz – Helsinki, Finland
10:30 Multidisciplinary team and its role in transition

Claire Gaymer - London, United Kingdom; Nicos Kessaris – London, United
Kingdom
10:55 Successful transition - one way to do it

Paul Harden – Oxford, United Kingdom
11:10 Guideline proposal discussion

Paul Harden - Oxford, United Kingdom; Jelena Stojanovic – London, United
Kingdom; Nicos Kessaris - London, United Kingdom; Fernanda Ortiz - Helsinki,
Finland
FISHBOWL
10:00 - 11:30 Digital interface with patients – outpatients in the 22nd century
Conference Suite 1 Chairs: Marita Dalvindt – Lund, Sweden
Colin White – Balbriggan, Ireland
The move to increased digitalisation offers huge advantages but also warrants
major changes in the way health systems function for both patients, their families
and healthcare workers. Successful implementation requires investment and
overcoming change resistance. This session will focus on how to do this
successfully and the potential cost savings along with a discussion on how such
technology reduces the carbon footprint of healthcare.
10:00 Telemedicine 2.0: Outpatient telemedicine clinics - implementation, advantages

and pitfalls
Conor Byrne – London, United Kingdom
10:20 Measuring Return of investment in digital healthcare interventions

10:40 The environmental impact of telemedicine

Dorry Segev - New York, United States

John Nosta – Mendham, United States; Raj Thuraisingham - London, United
Kingdom
Update 04|08|2023 76
FOCUS GROUP
10:00 - 11:30 The clinical spectrum of kidney transplant rejection

MC 3.2 Chairs: Caroline Dudreuilh – London, United Kingdom
10:00 MICROVASCULAR INJURY, EITHER IN DSA POSITIVE OR NEGATIVE

ANTIBODY-MEDIATED REJECTION (ABMR), DETERMINES THE
PROGNOSIS IN RENAL ALLOGRAFTS
Binnaz Handan Ozdemir – Ankara, Turkey
10:10 NEXT GENERATION SEQUENCING: ANTIBODY-MEDIATED REJECTION

MOLECULAR SIGNATURE AND MACHINE LEARNING CLASSIFIER
Esteban Cortes Garcia – Paris, France
10:20 PROTOCOL BIOPSIES IN PATIENTS WITH SUBCLINICAL DE NOVO DSA

AFTER KIDNEY TRANSPLANTATION: LONG TERM DEATH CENSORED
GRAFT SURVIVAL.
Dominique Bertrand – Rouen, France
10:30 IMPACT OF PREFORMED DONOR-SPECIFIC HLA-CW AND HLA-DP

ANTIBODIES ON ACUTE ANTIBODY MEDIATED REJECTION IN KIDNEY
TRANSPLANTATION.
10:40 CLINICAL UTILITY ASSESSMENT OF ANNUAL SYSTEMATIC SCREENING

OF POST KIDNEY TRANSPLANT DE NOVO DONOR SPECIFIC ANTIBODIES
Sofiane Salhi – Toulouse, France
10:50 DEVELOPMENT OF DE NOVO DONOR-SPECIFIC HLA ANTIBODIES AND

ABMR IN RENAL TRANSPLANT PATIENTS DEPENDS ON CYP3A5
GENOTYPE
Justa Friebus-Kardash – Essen, Germany
11:00 DISTINCT EFFECTOR CD28-CD8 T CELL POPULATIONS DIFFERENTIALLY

CONTRIBUTE TO KIDNEY ALLOGRAFT REJECTION
Kevin Louis – Paris, France
11:10 SUBCLINICAL REJECTION-FREE DIAGNOSTIC AFTER KIDNEY

TRANSPLANTATION USING BLOOD GENE EXPRESSION
Richard Danger – Nantes, France
BRIEF ORAL
Update 04|08|2023 77
10:00 - 11:30 Treatable traits lead the way towards better outcomes in lung transplantation
MC 3.4 Chairs: Antoine Roux – Paris, France
Andrea Zajacova – Prague, Czech Republic
10:54 EVALUATION OF LONG-LASTING LUNG INFLAMMATION IN CIRCULATORY

DEATH RAT DONORS USING TISSUE CULTURE AND NORMOTHERMIC
REGIONAL PERFUSION
Mayara Munhoz de Assis Ramos - Sao Paulo, Brazil
11:18 EVEROLIMUS IN LUNG TRANSPLANT RECIPIENTS FOR CLAD

PREVENTION: A REAL LIFE EXPERIENCE
Letizia Corinna Morlacchi – Milan, Italy
10:42 FUNGAL INFECTION WITHIN THE FIRST YEAR AFTER LUNG

TRANSPLANTATION DOES NOT AFFECT LONG TERM SURVIVAL
Embla Bodén – Lund, Sweden
10:30 DIAGNOSTIC YELD AND SAFETY OF CRYOBIOPSY VERSUS FORCEPS

BIOPSY IN LUNG ALLOGRAFT RECIPIENTS: A SINGLE-CENTER
RETROSPECTIVE ANALYSIS
Alessandro Palleschi – Milan, Italy
11:06 IDENTIFYING TREATABLE TRAITS IN RESTRICTIVE ALLOGRAFT

SYNDROME: A NESTED CASE-CONTROL STUDY
Hanne Beeckmans – Leuven, Belgium
10:18 CLINICAL RELEVANCE OF CELL-FREE DNA QUANTIFICATION AND

QUALIFICATION DURING THE FIRST MONTH AFTER LUNG
TRANSPLANTATION
Silvia Casas – Brisbane, United States
10:36 INFLUENCE OF THE RESPIRATORY TRACT'S MICROBIOLOGICAL

SPECTRUM ON THE OUTCOME AFTER LUNG TRANSPLANTATION
Maximilian Vorstandlechner – Munich, Germany
10:24 COMPARISON OF PLASMA DONOR-DERIVED CELL-FREE DNA WITH

LASHA SCORING SYSTEM IN LUNG TRANSPLANTATION: A SINGLE
CENTRE EXPERIENCE
Federica Pezzuto – Padua, Italy
11:12 EXTRACORPOREAL PHOTOPHORESIS IN CHRONIC LUNG ALLOGRAFT

DYSFUNCTION. SINGLE CENTER EXPERIENCE
Juan Pablo Reig Mezquida – Valencia, Spain
10:48 POLIOMAVIRUS BK REPLICATION IN URINE DETERMINES A RAPID

DECLINE IN KIDNEY FUNCTION AFTER LUNG TRANSPLANTATION.
Javier Arias-Alcalá – Cordoba, Spain
11:00 EFFECT OF DONOR AGE ON LUNG TRANSPLANT SURVIVAL: A

MULTICENTER RETROSPECTIVE STUDY FROM THE COLT DATABASE.
Berenice Reucherand – Nantes, France
Update 04|08|2023 78
10:12 INCREASED TOTAL CELL-FREE DNA EARLY AFTER LUNG

TRANSPLANTATION IS ASSOCIATED WITH BASELINE LUNG ALLOGRAFT
DYSFUNCTION
Andrea Zajacova – Prague, Czech Republic
HANDS-ON COURSE
10:00 - 11:30 Machine Perfusion in my hands: Virtual and interactive KIDNEY (Group 1)
Hands on course
tutors, participants will follow the steps of kidney perfusion. Participants will rotate
Additional registration for this session is required. Please register via the Congress
website
10:00 LifePort Kidney Transporter - Organ Recovery Systems


Colin Wilson - Newcastle upon Tyne, United Kingdom
10:30 Kidney Assist Transport - Xvivo

Henri Leuvenink – Groningen, The Netherlands
10:45 Kidney Assist - Xvivo

Cyril Moers – Groningen, The Netherlands
11:00 EBERS
Annemarie Weissenbacher – Innsbruck, Austria
11:00 Aferetica
Lionel Badet - Lyon, France
STATE OF THE ART

11:45 - 13:15 Charting the Future - Bioartificial Organs Approaching the Bedside?!
Lambrakis Chairs: Cristiano Amarelli – Naples, Italy
Regenerative medicine requires orchestrated interdisciplinary approach to achieve

an overarching goal - repair, replace, and regenerate damaged organs and
tissues. This session will address the state of the art, and key lessons from, organ
Update 04|08|2023 79
decellularization, organoids generation technology, 3D printing and artificial organ

creation, proposing a path forward towards safe translation.
11:45 Advancements towards artificial organs

Cecile Legallais –Paris, France
12:05 Small organs large aspirations: Next generation organoids

Nuria Montserrat – Barcelona, Spain
12:25 Lung bioengineering and regeneration

12:45 Bioprinting
Burcin Ekser – Indianapolis, United States
STATE OF THE ART

11:45 - 13:15 Caring in times of crisis

Trianti Chairs: Luciano Potena – Bologna, Italy
This state-of-the-art session addresses the practical and ethical implications of

providing transplant and donation care in times of crisis. Three speakers will
provide a current overview of factors that may disrupt healthcare systems and
undermine standards of care in a range of settings as well as recommendations to
minimise disruptions to care and protect potential and actual organ donors and
transplant recipients. They will explore the provision of care to refugees fleeing
conflict who are transplant candidates and recipients; migrants' vulnerabilities to
organ trafficking; and maintenance of donation and transplantation programs in the
setting of pandemics.
11:45 Are we prepared for the next crisis?

Matthew Weiss – Montreal, Canada
12:05 Transplant care in times of conflict

Mehmet Sever – Istanbul, Turkey
12:25 Migration and organ trade: kidney sales as a gateway to Europe

Frederike Ambagtsheer – Rotterdam, The Netherlands
12:45 Is there enough Resilience in the system?

Raymond Vanholder – Ghent, Belgium

Update 04|08|2023 80
STATE OF THE ART

11:45 - 13:15 From meaning to measurement- how to value what matters in transplantation
Library care
Chairs: Micaela Hamrin – Stockholm, Sweden
Patient-reported outcome measures (PROMs) and Patient Reported Experience

Measures (PREMs) are necessary to determine if health services also lead to
better health from patients’ perspectives. There is a demand for increased use of
such instruments in clinical routines as well as in national quality registers for
transplantation. There are inherent challenges when using PREMs as satisfaction
with care might be influenced by expectations, personality traits and previous care
experiences. One way to minimize the impact of these factors is to ask about
specific experiences, e.g., the care in relation to transplantation. It has been shown
that systematic use of patient-reported measures improves and facilitates the
communication and relationship between patients and health care professionals.
Health problems are identified and dealt with in a more proactive way. PREMs
focus on aspects of the humanity of care, such as being treated with dignity or not
kept waiting while PROMs focus more on outcomes of importance e.g. HRQoL,
functional status, and symptom distress. This session will outline, what to measure,
why and how. Why is it increasingly important to evaluate the patients' perspective
of the transplantation process and care?
11:45 What matters to me

Micaela Hamrin – Stockholm, Sweden
11:50 Measuring what matters for patients

K.M. Karin Vermeulen – Groningen, The Netherlands
12:10 Will PROMS and PREMs drive change in transplant practice?

Fabienne Dobbels – Leuven, Belgium
12:30 Measuring cost-effectiveness in transplant care

Lorenzo Mantovani – Milan, Italy
12:50 Striving to become patient centric in life sciences research

Claudio Procaccianti – Milan, Italy
13:10 Time to measure together

Micaela Hamrin – Stockholm, Sweden
TV-STUDIO
Update 04|08|2023 81
13:30 - 14:00 Diversity, collaboration and equity – the TI way.

Muses Foyer Host: Jacqui Thornton - Winchester United Kingdom
Guests: Saskia Bos - Newcastle upon Tyne, United Kingdom

Nazia Selzner – Toronto, Canada
Thierry Berney – Geneva, Switzerland

14:15 - 15:15 Moderated poster session on pancreas and islet transplantation

MEP-1 Chair: Ekaterine Berishvili – Geneva, Switzerland
14:15 CONTINUOUS VS DISCONTINUOUS HUMAN ISLET PURIFICATION: A

MATCHED DONOR COMPARISON.
Antoine Buemi – Brussels, Belgium
14:15 NORMOTHERMIC EX SITU PANCREAS PERFUSION FOR THE

PRESERVATION OF PORCINE PANCREAS GRAFTS
Laura Mazilescu – Essen, Germany
14:15 EFFECT OF RECIPIENT BODY MASS INDEX ON OUTCOME OF PANCREAS

TRANSPLANTATION: A SINGLE-CENTER 20-YEAR EXPERIENCE
Samrat Ray – Toronto, Canada
14:15 USING DIABETES TECHNOLOGY TO MANAGE HYPERGLYCAEMIA IN

PEOPLE WITH TYPE 1 DIABETES AND FAILING PANCREAS TRANSPLANT
Thomas Johnston – London, United Kingdom
14:15 EARLY RELAPAROTOMY NEED AND RISK FACTORS AFTER

SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION
Bruno Fraga Dias – Porto, Portugal
14:15 40TH ANNIVERSARY OF PANCREAS TRANSPLANTATION IN SPAIN.

LESSONS LEARNED AFTER MORE THAN 650 CASES IN A SINGLE CENTER
14:15 RETRANSPLANTATION AFTER PANCREAS GRAFT FAILURE IS IT A VIABLE

OPTION FOR SELECTED CANDIDATES?
Barbara Franchin – Padua, Italy
14:15 EVALUATION OF THE EFFICACY OF ANTI-INFLAMMATORY PULMONARY

ENTERAL FORMULA IN THE TREATMENT OF PANCREATIC AND LUNG
INJURY DUE TO OBSTRUCTIVE JAUNDICE
Sanem Cimen – Ankara, Turkey
Update 04|08|2023 82
14:15 ISLET ISOLATION AFTER NORMOTHERMIC MACHINE PERFUSION OF

DISCARDED HUMAN PANCREAS. A PROOF OF CONCEPT STUDY.
Catherine Parmentier – Toronto, Canada
14:15 SHORT-TERM RESULTS OF ALEMTUZUMAB INDUCTION PROTOCOL

CHANGE IN SIMULTANEOUS PANCREAS KIDNEY TRANSPLANTATION
FOLLOWING THE COVID-19 PANDEMIC
Vikrant Thakur – Manchester, United Kingdom

14:15 - 15:15 Moderated poster session on liver transplantation

MEP-2 Chair: Hermien Hartog – Groningen, The Netherlands
14:15 LIVER TRANSPLANTATION DURING COVID-19 PANDEMIC WITH INFECTED

DONOR: A RISK WORTH TAKING
Davide Chiappori - L'Aquila, Italy
14:15 INDIVIDUALIZED HBIG WITHDRAWAL IN AN HISTORICAL COHORT OF

LIVER TRANSPLANT RECIPIENTS IN ITALY.
Raffaella Vigano – Milan, Italy
14:15 DO DONOR LIVER BLOOD TESTS PREDICT LIVER TRANSPLANT

OUTCOMES? UK NATIONAL COHORT STUDY
14:15 OUTCOMES OF RE-REFERRALS FOR PATIENTS WITH ALCOHOL-RELATED

LIVER DISEASE WHO WERE PREVIOUSLY DECLINED FOR LIVER
TRANSPLANTATION
Benjamin Cox – Toronto, Canada
14:15 THE MORBIDITY BURDEN AFTER LIVER TRANSPLANTATION – A

TREATMENT-BASED ANALYSIS
Joris Couillerot – Lyon, France
14:15 EVALUATION THE SIX MONTH ABSTINENCE RULE PRIOR TO LIVER

TRANSPLANT: A CLINICAL PRACTICE GUIDELINE
C Joanna Dionne – Hamilton, Canada
14:15 IMPACT OF DUAL HYPOTHERMIC OXYGENATED MACHINE PERFUSION (D-

HOPE) ON HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER
TRANSPLANTATION
Update 04|08|2023 83
14:15 LIVER TRANSPLANT RECIPIENTS WITH AUTOIMMUNE HEPATITIS IN THE

SWISS TRANSPLANT COHORT STUDY HAVE A HIGHER RISK OF GRAFT
LOSS AND VASCULAR COMPLICATIONS
Julien Vionnet – Lausanne, Switzerland
14:15 GOOD OUTCOMES AFTER PEDIATRIC LIVER-RETRANSPLANTATIONS: THE

ETHICAL DISCUSSION SHOULD BE ENDED
Markus Götz – Regensburg, Germany
14:15 IS REMNANT LIVER VOLUME RATIO LESS THAN 30% STILL

CONTRAINDICATION TO RIGHT HEPATECTOMY FOR LIVING LIVER
DONORS?
Joodong Kim - Daegu, Republic of South Korea

14:15 - 15:15 Moderated poster session on kidney transplants in children and young
MEP-3 people
Chair: Miriam Cortes Cerisuelo – London, United Kingdom
14:15 DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) AS A NON-INVASIVE

BIOMARKER OF KIDNEY ALLOGRAFT REJECTION IN PEDIATRIC KIDNEY
TRANSPLANTATION.
14:15 RENAL ALLOGRAFT SURVIVAL FOR (RE)TRANSPLANTED CHILDREN IN

ADULTHOOD; AN ERA REGISTRY STUDY FROM 1978 TO 2019.
Evgenia Preka – London, United Kingdom
14:15 REGIONAL OUTCOMES OF PAEDIATRIC RENAL TRANSPLANTATION IN

THE UK. A MACHINE LEARNING ANALYSIS
Georgios Koufopoulos – Liverpool, United Kingdom
14:15 KIDNEY TRANSPLANTATION IN CHILDREN WEIGHING 10 KG OR LESS: IS

IT A CHALLENGE?
Ozlem Unlugedik – Istanbul, Turkey
14:15 THE EFFECT OF HLA MISMATCHES ON POST-TRANSPLANT OUTCOMES IN

PAEDIATRIC RENAL TRANSPLANTATION
Angela Benson – London, United Kingdom
14:15 BASILIXIMAB VS ANTI-THYMOCYTE/ANTI-LYMPHOCYTE GLOBULINS IN

PEDIATRIC KIDNEY TRANSPLANTS: A SYSTEMATIC REVIEW AND META-
ANALYSIS
Mikhail Nozdrin – London, United Kingdom
Update 04|08|2023 84
14:15 EFFECT OF DONOR TYPE ON GRAFT AND PATIENT SURVIVAL IN

PAEDIATRIC RECIPIENTS OF KIDNEY AND LIVER TRANSPLANTATION.
Maria Selyanina – London, United Kingdom
14:15 STEROID-BASED VS STEROID-FREE IMMUNOSUPPRESSION IN

PAEDIATRIC KIDNEY TRANSPLANTS: A SYSTEMATIC REVIEW AND META-
ANALYSIS
Kavyesh Vivek - London, United Kingdom
14:15 COMPARISON OF OUTCOMES BETWEEN BASILIXIMAB AND

THYMOGLOBULIN IN LOW-RISK PEDIATRIC KIDNEY TRANSPLANT
RECIPIENTS FROM PEDIATRIC DECEASED DONORS
Qiang Zhang – Guangzhou, China
14:15 SYSTEMATIC DIGITAL ASSESSMENT OF PATIENT-REPORTED OUTCOMES

IN CLINICAL FOLLOW-UP OF PEDIATRIC KIDNEY TRANSPLANTATION
PATIENTS: A PILOT STUDY.
Fabian Eibensteiner – Vienna, Austria
TV-STUDIO
14:30 - 15:00 Xenotransplantation – are we ready for clinical trials in humans?

Guests: Frederike Ambagtsheer – Rotterdam, The Netherlands

PLENARY
15:15 - 16:45 Resolving the Shumway Paradox: Xenotransplantation in the spotlight

Lambrakis Chairs: Umberto Cillo – Padua, Italy
Ekaterine Berishvili – Geneva, Switzerland
The session will review the scientific advances that laid the first pig-to-human heart
transplant, one of the most exciting breakthroughs in transplantation medicine of
the century. Featured experts will discuss the future for xenotransplantation
including clinical potential, challenges, ethical considerations.
15:15 Introduction & Opening
Update 04|08|2023 85
15:20 Xenotransplantation: From zero to hero?

Where do we come from? Where are we going?
15:40 CRISPR then nature – Generation of the genetically modified pigs: techniques
and choice of the target genes
David Ayares – Blacksburg, United States
16:00 Building the bridge to clinic

Main challenges on the path to success, international standards and regulatory
issues for xenotransplantation
Eckhard Wolf – Munich, Germany
FULL ORAL
17:00 - 18:30 Innovations in kidney immunosuppression

Lambrakis Chairs: Georg Böhmig – Vienna, Austria
17:00 IMPACT OF DESENSITIZATION THERAPY WITH ISATUXIMAB ON HLA-

SPECIFIC MEMORY B CELLS AND PLASMA CELLS IN HIGHLY SENSITIZED
PATIENTS
Alba Torija - Hospitalet de Llobregat, Spain
17:10 DARATUMUMAB DESENSITIZATION BEFORE KIDNEY TRANSPLANTATION

– A PILOT STUDY
Marie Matignon – Creteil, France
17:20 EARLY RESULTS OF ATTAIN (ITN090ST): DARATUMUMAB & BELATACEPT

FOR HLA DESENSITIZATION IN KIDNEY TRANSPLANT CANDIDATES WITH
100% CPRA
Flavio Vincenti - San Francisco, United States
17:30 A PILOT STUDY EVALUATING DUAL CO-STIMULATION BLOCKADE WITH

DAZODALIBEP (HZN4920) AND BELATACEPT FOR PROPHYLAXIS OF
KIDNEY ALLOGRAFT REJECTION
Flavio Vincenti - San Francisco, United States
17:40 A PHASE I/IIA TRIAL OF AUTOLOGOUS REGULATORY T CELL THERAPY

TOGETHER WITH DONOR BONE MARROW INFUSION IN KIDNEY
TRANSPLANTATION
Thomas Wekerle – Vienna, Austria
Update 04|08|2023 86
17:50 LONG-TERM OUTCOMES AFTER CONVERSION TO A BELATACEPT-BASED

IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT: A MATCHED COHORT
STUDY
Gillian Divard – Paris, France
18:00 EFFECTIVENESS OF THE TREATMENT OF ANTIBODY MEDIATED

REJECTION: A REAL-WORLD EVIDENCE STUDY
18:10 RESULTS OF THE TRIBUTE RADOMIZED TRIAL: TREATMENT WITH

BORTEZOMIB OF LATE ANTIBODY-MEDIATED REJECTION DUE TO DE
NOVO DSA
Renaud Snanoudj - Le Kremlin-Bicêtre, France
FULL ORAL
17:00 - 18:30 Basic science immunology

Trianti
Chairs: Martin Hoogduijn – Rotterdam, The Netherlands

17:00 A NOVEL BI-SPECIFIC FUSION PROTEIN WITH CTLA4IG/PDL2 AS A NOVEL

IMMUNOSUPPRESSANT MOLECULE MODULATING ALLOIMMUNE
RESPONSES
Delphine Kervella – Barcelona, Spain
17:10 VISUALIZING THE EFFECT OF BCL6 INHIBITION ON B AND T

LYMPHOCYTES BY THE SMALL MOLECULE COMPOUND 79-6 BY MEANS
OF IMAGING FLOW CYTOMETRY
Rens Kraaijeveld – Rotterdam, The Netherlands
17:20 PROTECTIVE EFFECT OF RECOMBINANT THROMBOMODULIN ALPHA

AGAINST LONG COLD ISCHEMIA REPERFUSION INJURY IN A RAT KIDNEY
TRANSPLANT MODEL
Kazunobu Shinoda – Kawasaki, Japan
17:30 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITION AS A

NOVEL TREATMENT TARGET IN ALLOGRAFT REJECTION
Bernhard Texler – Innsbruck, Austria
17:40 NK-MEDIATED INNATE ALLORECOGNITION CONTROLS THE EARLY

PRODUCTION OF DONOR SPECIFIC ANTIBODIES BY THE INVERTED
DIRECT PATHWAY
Xavier Charmetant – Lyon, France
Update 04|08|2023 87
17:50 ALLOREACTIVE T CELL REPERTOIRES DISPLAY BIASED VARIABLE

SEGMENT USAGE AND FINE-TUNING OF PEPTIDE SPECIFICITY BY
COMPLEMENTARITY-DETERMINING REGION 3Β.
Alexandra Sharland – Sydney, Australia
18:00 MAPPING THE CELLULAR AND MOLECULAR LANDSCAPE OF ADAPTIVE

IMMUNE RESPONSES IN KIDNEY ALLOGRAFT REJECTION
Kevin Louis – Paris, France
18:10 SINGLE CELL TRANSCRIPTOME OF ALLOREACTIVE CD8 T CELLS

SUPPORTS ROLES FOR BOTH DELETION AND EXHAUSTION IN
TOLERANCE INDUCTION.
Alexandra Sharland – Sydney, Australia
STORYTELLING
17:00 - 18:30 I did it my way. How did I get here?

Mitropoulos Chairs: Hannah Esser – Innsbruck, Austria
Hannah Valantine – Stanford, United States
This motivational session will highlight the highs and lows of the career =>
motivation for the young generation.
17:00 Aspirations and inspirations

Camillo Ricordi – Miami, United States
17:15 How do you turn obstacles into opportunities/ challenges

Hannah Valantine – Stanford, United States
17:30 Changing the preservation paradigm

Peter Friend – Oxford, United Kingdom
17:45 Breaking down barriers

Elmi Müller - Cape Town, South Africa
18:00 Panel Discussion

Hannah Esser – Innsbruck, Austria; Hannah Valantine - Stanford, United States
BRIEF ORAL
17:00 - 18:30 Cardiovascular and metabolic complications after kidney transplant - old
Library challenges, new solutions
Update 04|08|2023 88
Chairs: Maria Koukoulaki - Athens, Greece

Adnan Sharif – Birmingham, United Kingdom
17:00 IS A BLOOD PRESSURE BELOW 130/80 MM HG A UNIVERSAL GOAL FOR

ALL RENAL TRANSPLANT RECIPIENTS? AN ANALYSIS OF THE
COLLABORATIVE TRANSPLANT STUDY
Thuong Hien Tran – Heidelberg, Germany
17:06 COMPARISON OF OFFICE, HOME AND AMBULATORY BLOOD PRESSURE

IN KIDNEY TRANSPLANT RECIPIENTS WITH AND WITHOUT TELEMEDICINE
MONITORING
Georgios Eleftheriadis – Berlin, Germany
17:12 PREDICTION OF MACE AND MORTALITY AMONG KIDNEY TRANSPLANT

CANDIDATES USING RISK FACTORS, CORONARY ARTERY CALCIUM
SCORE AND CORONARY CT ANGIOGRAPHY
Marie Nielsen – Aarhus, Denmark
17:18 INFLUENCE OF LOW- AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL

ON GRAFT FUNCTION IN RENAL TRANSPLANT RECIPIENTS - A
COLLABORATIVE TRANSPLANT STUDY REPORT
Thuong Hien Tran – Heidelberg, Germany
17:24 GLIFLOZIN IN RENAL TRANSPLANTATION: A MULTICENTER

OBSERVATIONAL STUDY (GREAT-ASTRE)
Lucie Maigret – Tours, France
17:30 RISK FACTORS OF DE NOVO POST TRANSPLANTATION DIABETES

MELLITUS MORE THAN 8 WEEKS AFTER KIDNEY TRANSPLANTATION - A
NATIONAL COHORT STUDY
Rasmus Carlsen – Oslo, Norway
17:36 POST-TRANSPLANT DIABETES MELLITUS IN DIFFERENT

IMMUNOSUPPRESSION TREATMENTS: A META-ANALYSIS
Laia Oliveras - L'Hospitalet de Llobregat, Spain
17:42 DEVELOPMENT AND VALIDATION OF A NEW SCORE TO ASSESS THE

RISK OF POST-TRANSPLANTATION DIABETES MELLITUS IN KIDNEY
Maria Carolina Isaza-Lopez – Medellin, Colombia
17:48 A PROSPECTIVE COHORT STUDY OF SODIUM/GLUCOSE

COTRANSPORTER 2 INHIBITOR-TREATED DIABETIC KIDNEY TRANSPLANT
PATIENTS
Jin min Kong - Busan, Republic of South Korea
17:54 FIRST USE OF DEEP LONG SHORT-TERM MEMORY NEURAL NETWORK IN

PREDICTING KIDNEY GRAFT FUNCTION
Vesna Furic Cunko – Zagreb, Croatia
18:00 IMPACT OF FULL CORRECTION OF HEMOGLOBIN AMONG POST-

TRANSPLANT ANEMIC KIDNEY TRANSPLANT RECIPIENTS: PROSPECTIVE
RANDOMIZED CONTROLLED TRIAL
Hasaneen Aboatya – Kuwait, Kuwait
Update 04|08|2023 89
18:06 ERECTILE DYSFUNCTION AFTER KIDNEY TRANSPLANTATION IN MALES

WITH END-STAGE KIDNEY DISEASE: A META-ANALYSIS
Adelina Miron – Iasi, Romania
18:12 OUTCOMES FOLLOWING ARTERIO-VENOUS FISTULA LIGATION

FOLLOWING KIDNEY TRANSPLANTATION
18:18 PROSPECTIVE RANDOMIZED CONTROLLED TRIAL ANALYZING THE

EFFECTS OF DENOSUMAB ON BONE MINERAL DENSITY AND BONE
METABOLISM IN RENAL ALLOGRAFT TRANSPLANTS.
Amit Sharma – Chandigarh, India
FOCUS GROUP
17:00 - 18:30 Public perception in organ donation : multi-stakeholder vision and work team
Conference Suite 1 Chairs: Corinne Antoine – Paris, France
17:00 ORGAN DONATION AFTER BRAIN-DEATH - FAMILY DYNAMICS, FACTORS

FOR CONSENT AND ATTACHMENT OF MEANING AS A WAY TO PROCESS
LOSS
Isidora Skourli – Athens, Greece
17:10 RELATIVES’ DECISION PROCESSES AND PERCEPTIONS IN THE CONTEXT

OF INTENSIVE CARE FOR ORGAN DONATION: RESULTS OF A
QUALITATIVE STUDY
Rubén García-Sánchez – Madrid, Spain
17:20 OUTCOME TO DEVELOPING EDUCATION PROGRAMS TO ADVANCE

ORGAN DONATION ACTIVITY IN THE ORGAN PROCUREMENT
ORGANIZATION: A SIX YEAR DATA
Maria Theresa Bad-Ang - Davao City, Philippines
17:30 ICU STAFF’S SELF-REPORTED NEED FOR SUPPORT AND EDUCATION IN

ORGAN DONATION
Kathe Meyer – Oslo, Norway
17:40 IMPROVING DECEASED DONATION THROUGH AN INTERNATIONAL

COOPERATION TRAINING FOR HEALTH PROFESSIONALS
17:50 MASS MEDIA CAMPAIGNS SENSITIZE BUT FAIL TO INCREASE ACTUAL

ORGAN DONATION RATE
Update 04|08|2023 90
18:00 BARRIERS AND FACILITATORS TOWARD THE MAKING OF DECEASED

ORGAN DONATION AMONG STAKEHOLDERS FROM TWO DIVERSE
REGIONS IN INDIA.
Britzer Paul Vincent – Luton, United Kingdom
18:10 OLDER LIVING LIVER DONORS CAN ENLARGE THE DONOR POOL: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Hayo ter Burg – Rotterdam, The Netherlands
BRIEF ORAL
17:00 - 18:30 Pediatric Transplantation - Stronger Together

MC 3.2 Chairs: Miriam Cortes Cerisuelo – London, United Kingdom
Nicos Kessaris – London, United Kingdom
17:00 LANDSCAPE OF SUBCLINICAL REJECTION IN A LARGE INTERNATIONAL

COHORT OF PEDIATRIC KIDNEY TRANSPLANT (KTX) RECIPIENTS.
Julien HOGAN – Paris, France
17:06 DETERMINATION OF SHORT AND LONG TERM RESULTS OF LIVER

TRANSPLANTED PATIENTS WITH THE DIAGNOSIS OF INBORN ERRORS
OF METABOLISM
Figen Ozcay – Ankara, Turkey
17:12 THE UK KIDNEY DONOR RISK INDEX POORLY PREDICTS LONG-TERM

TRANSPLANT SURVIVAL IN PAEDIATRIC KIDNEY TRANSPLANT
RECIPIENTS.
Jon Jin Kim – Nottingham, United Kingdom
17:18 IMPACT OF ANTI-ENDOTHELIN-1 RECEPTOR TYPE A ANTIBODIES IN

PEDIATRIC RENAL TRANSPLANTATION
Emanuele Cozzi – Padua, Italy
17:24 SIMULTANEOUS TOTAL INTERNAL BILIARY DIVERSION IN LIVER

TRANSPLANTATION FOR PROGRESSIVE FAMILIAL INTRAHEPATIC
CHOLESTASIS TYPE 1: A STANDARD OF CARE?
Jagadeesh Menon – Chennai, India
17:30 HYPOTHERMIC OXYGENATED MACHINE PERFUSION IN PEDIATRIC

KIDNEY TRANSPLANTATION: A PRELIMINARY SINGLE CENTER
EXPERIENCE.
Gionata Spagnoletti – Rome, Italy
17:36 LIVER RETRANSPLANTATION IN CHILDREN.

Agnieszka Kwiecińska – Warsaw, Poland
Update 04|08|2023 91
17:42 KIDNEY TRANSPLANTATION IN PEDIATRIC PATIENTS WITH SEVERE

LOWER URINARY TRACT DYSFUNCTION. IS ILEAL CONDUIT M.BRICKER
AS GOOD AS NORMAL BLADDER?
Dorota Broniszczak-Czyszek – Warsaw, Poland
17:54 KIDNEY GRAFT OUTCOMES FOLLOWING KIDNEY VERSUS

SIMULTANEOUS LIVER-KIDNEY TRANSPLANTATION IN CHILDREN –
ANALYSIS OF THE UNOS DATABASE
Ioannis D. Kostakis – London, United Kingdom
18:00 KIDNEY GRAFT OUTCOMES FOLLOWING PAEDIATRIC BLOOD GROUP

INCOMPATIBLE TRANSPLANTATION – ANALYSIS OF THE UNOS
DATABASE
Ioannis D. Kostakis – London, United Kingdom
18:06 VALIDATION OF A PREDICTION SYSTEM FOR RISK OF ALLOGRAFT LOSS

(IBOX) IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
18:12 BRIDGING THE RENAL TRANSPLANT GAP IN PEDIATRIC PATIENTS IN

GREECE: A 3-YEAR EXPERIENCE OF A PEDIATRIC TRANSPLANT
PROGRAM IN AN ADULT TRANSPLANT CENTER
Eleni Kapsia – Athens, Greece
18:18 FIRST REPORT ON THE USE OF A TRANSPLANTED RECTUS SHEATH

FASCIA FOR A COMBINED LIVER AND KIDNEY TRANSPLANT IN A
PAEDIATRIC PATIENT WITH MMA
Alicia Paessler – London, United Kingdom
FULL ORAL
17:00 - 18:30 Defining risk and optimizing selection

MC 3.4 Chairs: Luca Belli – Milan, Italy
Nazia Selzner – Toronto, Canada
17:00 WHERE TO DRAW THE LINE IN EX-SITU SPLIT LIVER TRANSPLANTATION

FOR ADULT RECIPIENTS? A BENCHMARKING ANALYSIS
Xavier Muller – Lyon, France
17:10 LIVER TRANSPLANTATION IN THE ELDERLY: PROPOSAL FOR AN

INNOVATIVE PATIENT SELECTION PROTOCOL
Nicola Canitano – Padua, Italy
17:20 AGE AND LIVER GRAFT: A SYSTEMATIC REVIEW WITH METAREGRESSION

Ilaria Neri – Rome, Italy
Update 04|08|2023 92
17:30 DEVELOPMENT OF A ‘LIVER ATLAS’ USING OVER 1,000 CONSECUTIVE

DECEASED DONOR LIVERS TO IDENTIFY HEPATIC STEATOSIS PRIOR TO
RETRIEVAL
Hussain Abbas – Oxford, United Kingdom
17:40 PREDICTING POST-TREATMENT (SURGICAL, ABLATIVE, LIVER

TRANSPLANT) RECURRENCE IN EARLY-STAGE HEPATOCELLULAR
CARCINOMA USING DEEP MACHINE LEARNING
Ramesh Batra - New Haven, United States
17:50 DOES NATIVE HEPATECTOMY TECHNIQUE HAVE ANY IMPACT ON

ONCOLOGIC OUTCOMES OF LIVER TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA?
Riccardo Pravisani – Udine, Italy
18:00 PREDICTION AND DIAGNOSIS OF REJECTION IN LIVER

TRANSPLANTATION USING A BIOMARKER MODEL BASED ON CXCL-10
AND MICRORNAS 155-5P AND 181A-5P
Pablo Ruiz – Barcelona, Spain
18:10 WORLDWIDE DATA FROM THE IMPROVEMENT LIVER TRANSPLANT

STUDY: AN INTERIM ANALYSIS OF DONOR AND RECIPIENT PROFILES.
Alfonso Avolio – Rome, Italy
HANDS-ON COURSE
17:00 - 18:30 Machine Perfusion in my hands: Virtual and interactive KIDNEY (Group 2)
Hands on course
tutors, participants will follow the steps of kidney perfusion. Participants will rotate
website
17:00 LifePort Kidney Transporter - Organ Recovery Systems


17:30 Kidney Assist Transport - Xvivo

Henri Leuvenink – Groningen, The Netherlands
17:45 Kidney Assist - Xvivo

Update 04|08|2023 93
18:00 EBERS
18:15 Aferetica
Lionel Badet – Lyon, France
HANDS-ON COURSE
17:00 - 18:00 Machine Perfusion in my hands: Virtual and interactive LUNG/HEART

Hands on course
tutors, participants will follow the steps of heart and lung perfusion. Participants will
rotate around the machines/stations every 25 minutes.
website
17:00 XPS - Xvivo

17:25 Heart technology - Xvivo

Cristiano Amarelli – Naples, Italy
STATE OF THE ART

20:00 - 21:00 Xenotransplantation: Navigating Ethical Frontiers and Societal Impact

Atrium Chair: Jacqui Thornton - Winchester United Kingdom
20:00 Discussion Panel
David Ayares - Blacksburg, United States; Efstratios Chatzixiros - Geneva,

Switzerland; Penilla Gunther - Stockholm, Sweden; Matthias Kaiser - Bergen,
Norway; Jayme Locke - Birmingham, United States; Eckhard Wolf - Munich,
Germany;
Update 04|08|2023 94
Wednesday, 20 September 2023
STATE OF THE ART

08:00 - 09:30 ABMR across organs

Lambrakis Chairs: Marlies Reinders – Rotterdam, The Netherlands
Robin Vos – Leuven, Belgium
Antibody-mediated rejection is recognised as a major threat to transplant success,

for all solid organs. Although the existence of antibody-mediated rejection is widely
recognised, the phenotypic diversity of the disease presents clinical dilemmas in
its classification, with implications for the outcome. In this session, new insights
into the pathobiology of antibody-mediated rejection and phenotypes of
microvascular inflammation will be discussed, as well as their relation to clinical
diagnostics and therapeutic options. Finally, guidelines for monitoring and
prevention of antibody-mediated rejection will be critically evaluated.
08:00 New picture of ABMR: The phenotype and importance of ABMR

08:20 Monitoring ABMR in organ transplantation

Marta Crespo – Barcelona, Spain
08:40 Prevention and treatment of ABMR

Carmen Lefaucheur – Paris, France
09:00 ABMR without anti-HLA Donor specific antibodies: New targets and activation
mechanisms
09:20 Q&A
STATE OF THE ART

08:00 - 09:30 Machine Perfusion - what next?

Trianti
Chairs: Ina Jochmans – Leuven, Belgium
As Machine Perfusion is making a significant impact on the delivery of

transplantation, a new set of questions is being asked: what next after organ
perfusion? How do we blend Machine Perfusion with regenerative medicine? How
Update 04|08|2023 95
do we deliver this service and make it available without introducing new barriers to
access?
08:00 Introduction
Ina Jochmans – Leuven, Belgium
08:05 In-situ, ex-situ or both?

08:25 Treat & Repair is the new aim

Paulo Martins - Boston, United States
08:45 From Preservation to Organ banking

Marcelo Cypel – Toronto, Canada
09:05 Make or break: achieving sustainability

09:25 Session wrap-up
STATE OF THE ART

08:00 - 09:30 Policy making, driving change in Europe

Banquet Hall Chairs: Efstratios Chatzixiros – Geneva, Switzerland
Pisana Ferrari – Udine, Italy
This state-of-the-art session aims to share the initiatives driven in policy-making to

homogenise clinical practices ensuring legal and ethical framework in Europe.
Different stakeholders involved in organ donation and transplantation activities,
(public/international institutions, patients, and professionals) will present projects
driven in this regard. The main topics and challenges that will be discussed are the
risk of overlapping initiatives; the role of the stakeholders shaping policies in the
EU; the possibility to extend the EU experience to other territories; and the policy
implementation.
08:00 Transplant Eurovision

Emanuele Cozzi – Padua, Italy
08:20 From aspiration to implementation

Stefaan van der Spiegel – Brussels, Belgium
08:40 Can patients’ associations shape policy in the EU?

09:00 Making donation usual in Europe

09:20 Discussion
Update 04|08|2023 96
TV-STUDIO
09:30 - 10:00 Transplantation- a public health issue? Ensuring equal access.

Guests: Chloe Balleste – Barcelona, Spain

Umberto Cillo – Padua, Italy
SOLUTION ROOM
10:00 - 11:30 A new dawn? Molecular microscope for real time patient care
Lambrakis Chairs: Menna Clatworthy - Cambridge United Kingdom
Michael Mengel - Alberta Canada
This solution room session will present novel insight into molecular diagnosis for
real-time patient care. The Banff point of view, the medical point of view and the
next steps into moving to real-time molecular diagnosis in solid organ
transplantation will be discussed. Is histology old fashion?
10:00 Molecular Diagnosis: Building the molecular diagnosis system (why?)

Alexandre Loupy – Paris, France
10:15 Molecular Diagnosis: moving to real time diagnosis (how do we move?)

10:30 Is histology really overrated?

10:45 Rejection in liver transplantation

Chris Bellamy – Edinburgh, United Kingdom
10:55 Rejection in lung transplantation

Antoine Roux – Paris, France
11:05 Meet the experts, Histology vs molecular diagnosis. Is histology old fashion these
days?
Olivier Aubert - Paris, France; Chris Bellamy - Edinburgh, United Kingdom;
Alexandre Loupy - Paris France; Michael Mengel - Alberta, Canada; Candice
Roufosse - London, United Kingdom; Antoine Roux - Paris, France
Update 04|08|2023 97
DARE TO ASK
10:00 - 11:30 How can I bring machine perfusion into my clinical practice?
Trianti Chairs: Cristiano Amarelli – Naples, Italy
How to implement technology in routine clinical practice?

How does machine perfusion change KPIs in transplants?
How to get MP reimbursed?
10:00 Introduction
Cristiano Amarelli - Naples, Italy; Sarah Hosgood – Cambridge, United Kingdom
10:05 Do I need a liver perfusion programme?

10:20 Lung programme establishment

10:35 More hearts but at what cost?

Arezu Aliabadi-Zuckermann – Vienna, Austria
10:50 Where to go with kidney perfusion?

11:05 Q&As from audience: Building a sustainable perfusion programme?
FULL ORAL
10:00 - 11:30 Kidney biomarkers to the rescue

Banquet Hall Chairs: Umberto Maggiore – Parma, Italy
10:00 ASSESSMENT OF DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) IN

KIDNEY TRANSPLANT RECIPIENTS WITH INDICATION BIOPSY
Louise Benning – Heidelberg, Germany
10:10 MULTIDIMENSIONAL RISK ASSESSMENT OF KIDNEY ALLOGRAFT

REJECTION USING DONOR DERIVED CELL-FREE DNA
Cindy Ursule-Dufait – Paris, France
Update 04|08|2023 98
10:20 DETECTION OF KIDNEY ALLOGRAFT REJECTION USING BLOOD

BIOMARKERS: RESULTS OF THE EUROPEAN MULTICENTER
PROSPECTIVE EU-TRAIN TRIAL (NCT03652402)
10:30 DSA-NEGATIVE MICROVASCULAR INFLAMMATION IN KIDNEY

TRANSPLANT BIOPSIES: GENE EXPRESSION COMPARISON WITH NATIVE
AND TRANSPLANT KIDNEY CONTROLS
Anna Buxeda – Barcelona, Spain
10:40 AGE-MODULATED PROTEOMIC SIGNATURES OF DONOR KIDNEY

BIOPSIES ASSOCIATE WITH BELOW-MEDIAN 12 MONTH OUTCOMES
Philip Charles – Oxford, United Kingdom
10:50 OVERALL ACTIVITY AND CHRONICITY INDICES OF KIDNEY TRANSPLANT

BIOPSIES: VALIDATION ON NEW DATA.
11:00 ASSESSING REJECTION WITH MACHINE LEARNING BASED ON BIOPSY

ELEMENTARY LESIONS AND CLINICAL INFORMATION
Marc Labriffe – Limoges, France
11:10 KIDNEY COLOR: ARTIFICIAL INTELLIGENCE IMAGE PROCESSING TO

IMPROVE KIDNEY TRANSPLANT OUTCOMES PREDICTION
Enric Miret Alomar – Barcelona, Spain
FULL ORAL
10:00 - 11:30 Organ preservation and ischemia reperfusion

Mitropoulos Chairs: Umberto Cillo – Padua, Italy
Thamara Perera – Birmingham, United Kingdom
10:00 PROLONGED HYPOTHERMIC MACHINE PERFUSION TO ENABLE DAYTIME

LIVER TRANSPLANTATION – A RANDOMIZED CLINICAL TRIAL
Vincent E. de Meijer – Groningen, The Netherlands
10:10 WHAT IS THE OPTIMAL PRESERVATION STRATEGY FOR MARGINAL LIVER

GRAFTS USING HYPOTHERMIC OXYGENATED PERFUSION? A
PRECLINICAL STUDY
10:20 HYPOTHERMIC OXYGENATED PERFUSION AFTER NORMOTHERMIC

REGIONAL PERFUSION TO EXTEND SELECTION CRITERIA IN CDCD LIVER
TRANSPLANTATION
Update 04|08|2023 99
10:30 DUAL HYPOTHERMIC OXYGENATED MACHINE PERFUSION IS

ASSOCIATED WITH IMPROVED RECOVERY OF ACUTE KIDNEY INJURY
AFTER DCD LIVER TRANSPLANTATION
Femke de Goeij – Rotterdam, The Netherlands
10:40 LACTATE DYNAMICS DURING THE FIRST 6 HOURS OF LIVER

NORMOTHERMIC MACHINE PERFUSION PREDICTS CLINICAL OUTCOME –
A MULTICENTER STUDY
Julia Hofmann – Innsbruck, Austria
10:50 BLOCKADE OF REGULATED CELL DEATH ABROGATES EFFECTOR T-CELL

INFILTRATION AND MINIMIZES HEPATIC ISCHEMIA REPERFUSION
DAMAGE
Elke Eggenhofer – Regensburg, Germany
11:00 THE USE OF A CYTOKINES ADSORPTION CARTRIDGE DURING EX-SITU

HYPO AND NORMOTHERMIC MACHINE PERFUSION IN LIVER
TRANSPLANTATION: A PILOT RANDOMIZED STUDY
11:10 HYPOXIA INDUCIBLE FACTOR MODULATION DURING NORMOTHERMIC

MACHINE PERFUSION (NMP) ACCELERATES REDUCTION IN HEPATIC
STEATOSIS
Hussain Abbas – Oxford, United Kingdom
BRIEF ORAL
10:00 - 11:30 Kidney rejection, function and survival

Skalkotas Chairs: Muhammad Khurram – London, United Kingdom
Stathis Tsiakas – Athens, Greece
10:00 LANDSCAPE OF T-CELL MEDIATED REJECTION RESPONSE TO

TREATMENT AFTER KIDNEY TRANSPLANTATION.
10:06V OPERABILITY OF THE BANFF “V” LESION SCORE IN DSA POSITIVE MIXED
REJECTION
Karolien Wellekens – Leuven, Belgium
10:12 CALLING INTO QUESTION THE ADDED VALUE OF THE ‘PTC RULE’ IN
CLASSIFYING KIDNEY TRANSPLANT REJECTION
Karolien Wellekens – Leuven, Belgium
10:18 COMPARISON OF CLINICAL AND PATHOLOGICAL FEATURES OF

REJECTION IN ABO-IMCOMPATIBLE AND ABO-COMPATIBLE KIDNEY
TRANSPLANTATION
Hyun-jeong Kim – Seoul, Republic of South Korea
Update 04|08|2023 100

10:24 ACUTE REJECTION AFTER CONVERSION TO BELATACEPT IN KIDNEY

TRANSPLANTATION
Dominique Bertrand – Rouen, France
10:32 SUBCLINICAL ANTIBODY-MEDIATED REJECTION DETECTED BY EARLY

(TWO WEEKS) PROTOCOL BIOPSIES IN HIGHLY IMMUNIZED TRANSPLANT
RECIPIENTS
Carolt Arana – Barcelona, Spain
10:38 A NOVEL TWO STAGE REJECTION PREDICTION MODEL IN KIDNEY

ALLOGRAFT USING SERIAL GENE EXPRESSION PROFILE AND DONOR-
DERIVED CELL-FREE DNA
Sook Park – Chicago, United States
10:44 SURVIVAL OUTCOMES COMPARING OLDER LIVING DONOR VERSUS

STANDARD CRITERIA DONOR KIDNEY TRANSPLANTATION VERSUS NOT
BEING TRANSPLANTED
Kamlesh Patel – Morden, United Kingdom
10:50 PREDICTION OF GRAFT SURVIVAL PRIOR TO ACCEPTING AN OFFER FOR

LIVING DONOR KIDNEY TRANSPLANT: AN ARTIFICIAL INTELLIGENCE
APPROACH
10:56 PREDICTION OF KIDNEY FAILURE AND DEVELOPMENT OF

HYPERTENSION AMONG POTENTIAL LIVING DONORS: AN ARTIFICIAL
INTELLEGENCE APPROACH
11:02 DECEASED DONOR KIDNEY TRANSPLANTATION IN PRESENSITIZED

RECIPIENTS WITHOUT PRIOR DESENSITIZATION THERAPY: A SINGLE-
CENTER EXPERIENCE
Lan Zhu – Wuhan, China
11:08 IMPACT OF INDIVIDUAL EPLETS TO ACUTE REJECTION STUDIED BY

MACHINE LEARNING METHOD: ANALYSIS OF KOREAN ORGAN
TRANSPLANTATION REGISTRY
Jong Cheol Jeong - Seongnam, Republic of South Korea
11:14 CLINICAL EVOLUTION OF PATIENTS WITH DE NOVO DONOR-SPECIFIC

HLA ANTIBODIES AFTER KIDNEY TRANSPLANTATION
Covadonga López del Moral – Berlin, Germany
11:20 USE OF TOCILIZUMAB IN CHRONIC ACTIVE ANTIBODY-MEDIATED

REJECTION IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
Maria Sangermano – Padua, Italy
STORYTELLING
Update 04|08|2023 101

10:00 - 11:30 Equality, diversity and inclusion: where do we go from here?

Library Chairs: Dominique Martin – Geelong, Australia
David Paredes-Zapata – Barcelona, Spain
This session will focus on equality, diversity, and inclusion within ESOT and in the
wider context of scientific research and clinical practice. The first part of the session
will include a presentation of the results of the ESOT survey on equality, diversity,
and inclusion, covering the community's thoughts about the present status of the
Society and the field of transplantation as well as their proposals to improve such
status. Potential areas of intervention will be presented to the audience for a
discussion of practical actions to be taken in different contexts to take ESOT into
a more inclusive future. The second part of the session will provide the audience
with insights on implicit bias, one of the key factors at the basis of human beings’
perceptions about social groups, which affects our knowledge and behaviours.
10:00 Welcome and introduction

Dominique Martin - Geelong, Australia; David Paredes-Zapata – Barcelona, Spain
10:05 ESOT Survey on Equality, Diversity, and Inclusion: Results overview

Anna Forsberg - Lund Sweden; Liset Pengel - Rotterdam, The Netherlands
10:25 Implicit bias
Simona Capisani – Durham, United Kingdom
10:45 Discussion
10:45 Taking ESOT into the future

Anna Forsberg - Lund Sweden; Liset Pengel - Rotterdam, The Netherlands
11:15 Wrap up and conclusion

Dominique Martin - Geelong, Australia; David Paredes-Zapata – Barcelona, Spain
PLENARY
11:45 - 13:45 Closing Plenary: The future of transplant health and healthcare
Lambrakis
Chairs: Fiona Loud – Alton, United Kingdom
With an extraordinary array of exciting developments in transplantation, we are

looking at an exciting future. However, there is still much to do in enhancing life
after transplantation, defining, and improving the outcomes that matter to patients
and placing transplantation at the top of political agendas and at the core of
European healthcare. In this session we will explore solutions to improve the future
of transplant health, taking a moonshot towards a unified transplant healthcare in
Europe to reduce variation in care and improve access to innovative therapies. We
will also explore how we should shape transplant care so that patients,
professionals and policy makers are equal partners willing to embrace this
evolution and redefine the vision for the future of our field.
Update 04|08|2023 102

11:45 Introduction
12:10 Moon shot to a unified transplant healthcare

Efstratios Chatzixiros – Geneva, Switzerland
11:50 The future of transplant health - Enhancing life after transplantation

Maarten Naesens – Leuven, Belgium
12:30 One + one = three

Fiona Loud – Alton, United Kingdom
12:50 LDV winners presentation and award ceremony

13:10 Legacy Award Ceremony in honour of Maria Rosa Costanzo and Michael
Nicholson
Vassilios Papalois – London, United Kingdom

13:30 Presidential Address

Update 04|08|2023 103

ESOT Congress 2023 ScientificProgramme

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

ESOT Congress 2023 ScientificProgramme

Uploaded by

Copyright:

Available Formats

Scientific Programme

Saturday, 16 September 2023

ESOT SCIENCE DAY

09:20 Translational and clinical cell therapy in VCA

09:40 Monitoring: How can we identify tolerant patients?

10:00 Panel discussion

11:00 - 12:30 ESOT Science Day: Cheating death

11:00 Supercooling / hybernation

11:20 Cell derived EV as a replacement of living cell therapy

11:40 Mitochondria in the spotlight

12:00 Panel discussion

13:30 - 15:00 ESOT Science Day: Spatial Omics

13:30 A practical guide to start tomorrow

15:30 Bile duct repair (on the pump)

ESOT EDUCATION COURSE

09:20 - 10:30 ESOT Education Course: Immunosuppression: a critical step in the

09:20 Welcome and Introduction

09:30 A refresher on the basic mechanisms underlying rejection(s)

09:45 Pharmacodynamic of the main immunosuppressive drugs

10:00 Emerging concepts in transplant immunology: innate rejection

11:00 - 12:30 ESOT Education Course: Immunosuppression: a critical step in the

11:00 Kidney and pancreas

11:15 Heart and lung

11:30 Liver and intestine

11:45 Management of immunosuppression in paediatric patients

13:30 - 15:00 ESOT Education Course: Immunosuppression: a critical step in the

13:30 Prophylaxis and treatment of post-transplant infections: CMV and other

13:45 Prevention and management of anti-microbial resistance

14:00 Long-term adverse effects of immunosuppression: renal insufficiency and

14:15 Infections and immune monitoring: quantiferon, TTV et al.

14:30 Q&A and group discussion

15:30 - 17:00 ESOT Education Course: Immunosuppression: a critical step in the

15:30 Risk management of peculiar immunological conditions

15:45 Fertility and pregnancy while on immunosuppression

16:30 Integrating the patient perspective: patient-reported outcomes

17:10 - 18:00 ESOT Education Course: Immunosuppression: a critical step in the

Sunday, 17 September 2023

SPECIALTY UPDATE SYMPOSIA

09:40 Histopathological analysis of pre-implantation donor kidney biopsy: Redefining

10:00 Novel antidiabetic treatments in kidney transplant recipients

11:00 - 12:30 EKITA SUS: Comorbidities management post- kidney transplantation:

11:55 Complexities of pediatric kidney transplantation in the 21st century

Once a contraindication to liver transplantation, now even candidates with

09:00 New insights of Pathophysiology of Portal Vein Thrombosis (PVT)

09:10 Evaluation and classification of PVT in Liver Transplant (LT) candidates

09:25 Update on medical management of PVT on cirrhotics and LT candidates

09:35 Outcomes and limitations of TIPS and portal recanalization in LT candidates

10:00 Management of complex PVT: technical considerations during LT

10:10 Management of complex PVT: when to consider multivisceral transplantation?

10:20 Update on RP4LT Collaborative Study

11:00 Active drinkers in urgent need of a liver transplant

11:45 Cardiovascular risk assessment of liver transplant candidates

12:00 Frailty and liver transplantation: a practical approach

12:15 Discussion and wrap-up

09:00 Welcome and introduction

09:05 My journey to new hands

09:20 Early days of Unspecified Kidney Donation in the UK

09:35 DCD Heart Transplantation in Children

09:50 Deceased Donor family experience

10:05 Panel discussion

09:00 Some like it hot: Normothermic, Subnormothermic or Cold?

09:15 In-situ evaluation of DCD heart donors: the value of NRP